,PageNo,Text
0,page_0,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 S t . Jude OSTPDL1 In i t ia l ve rs ion , da ted : 07-29-2016 . Resubm i t ted to CT-SRC 09-27-2016 . Resubm i t ted to IRB 10-21-2016 and 11-16-2016 ( IRB app roved : 12-13-2016 ) Ac t iva ted : Janua ry 3 , 2017 Amendmen t 1 .0 , da ted : 04-06-2017 ( IRB app roved : 05-09-2017 ) Ac t iva ted : June 16 , 2017 Rev is ion 1 .1 , da ted 01-19-2018 ( IRB app roved : 01-26-2018 ) Ac t iva ted : A PHASE I I TR IAL OF AVELUMAB , A FULLY HUMAN ANT IBODY THAT TARGETS CELLS EXPRESS ING PD-L1 IN PAT IENTS W ITH RECURRENT OR PROGRESS IVE OSTEOSARCOMA IND# 132 ,874 (sponso r : S t . Jude ) P r inc ipa l Inves t iga to r M ichae l W . B ishop , MD , MS Depa r tmen t o f Onco logy So l id Tumo r D iv is ion S t . Jude Sub- Inves t iga to rs A lbe r to S . Pappo , MD Depa r tmen t o f Onco logy So l id Tumo r D iv is ion Deo Kuma r S r ivas tava , PhD Guo l ian Kang , PhD Zhaohua Lu , PhD Depa r tmen t o f B ios ta t is t ics Jenn i fe r L . Ha rman , PhD Depa r tmen t o f Psycho logy Pau l Thomas , PhD Ben jam in Youngb lood , PhD Depa r tmen t o f Immuno logy Sue Kas te , DO M ichae l Doub rov in , MD , PhD Depa r tmen t o f D iagnos t ic Imag ing S t . Jude Ch i ld ren 's Resea rch Hosp i ta l 262 Danny Thomas P lace Memph is , Tennessee 38105-3678 Te lephone : (901 ) 595-3300 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
1,page_1,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Con ten ts o f th is documen t may no t be ex t rac ted w i thou t pe rm iss ion f rom the P r inc ipa l Inves t iga to r S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
2,page_2,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 L is t o f Co l labo ra t ing Inves t iga to rs/ Ins t i tu t ions Con tac t In fo rma t ion Leo Masca renhas , MD , MS Lee J . He lman , M .D . Keck Schoo l o f Med ic ine Un ive rs i ty o f Sou the rn Ca l i fo rn ia Ch i ld ren 's Hosp i ta l Los Ange les 4650 Sunse t B lvd Ma i l S top 57 Los Ange les , CA 90027 Ph : 323-361-6058 lmasca renhas@ch la .usc .edu lhe lman@ch la .usc .edu James L . Gu l ley , M .D . , Ph .D . Cen te r fo r Cance r Resea rch Na t iona l Cance r Ins t i tu te Bu i ld ing 10 , Room 12N226 Be thesda , MD 20892-1750 Ph : 301-435-2956 gu l ley j@ma i l .n ih .gov Je f f rey Sch lom , PhD Ca ro l ine Jochems , MD , PhD Renee Donahue , PhD Labo ra to ry o f Tumo r Immuno logy and B io logy Cen te r fo r Cance r Resea rch Na t iona l Cance r Ins t i tu te Bu i ld ing 10 , Room 8B09 Be thesda , MD 20892-1750 Ph : 301-496-4343 js141@n ih .gov Sa rah B . Wh i t t le , MD L isa L . Wang , MD N ino Ra inusso , MD Texas Ch i ld ren ’s Cance r Cen te r Bay lo r Co l lege o f Med ic ine 1102 Ba tes S t ree t , Su i te 1240 .12 Hous ton , TX Ph : 832-824-4822 sbwh i t t l@ txch .o rg l lwang@ txch .o rg nc ra inuss@ txch .o rg F i lemon De la C ruz , MD Pau l A . Meye rs , MD A lexande r J Chou , MD Memo r ia l S loan Ke t te r ing Cance r Cen te r 1275 Yo rk Ave #1408 New Yo rk , NY 10065 212-639-5952 de lac r f1@mskcc .o rg meye rsp@mskcc .o rg choua@mskcc .o rg S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
3,page_3,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 PROTOCOL SUMMARY OSTPDL1 , A Phase I I T r ia l o f Ave lumab , a Fu l ly Human An t ibody tha t Ta rge ts Ce l ls Exp ress ing PDL1 in Pa t ien ts w i th Recu r ren t o r P rog ress ive Os teosa rcoma P r inc ipa l Inves t iga to r : M ichae l W . B ishop , MD , MS IND ho lde r : S t . Jude Ch i ld ren ’s Resea rch Hosp i ta l , IND# 132 ,874 . B r ie f backg round and ove rv iew o f s tudy : Pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma have a poo r ove ra l l su rv iva l ra te and a re un l ike ly to ach ieve cu re w i thou t comp le te su rg ica l rem iss ion . The in t roduc t ion o f new cy to tox ic and b io log ic agen ts has fa i led to show e f f icacy in th is popu la t ion . Immuno the rapy w i th checkpo in t inh ib i to rs has demons t ra ted d rama t ic changes in ou tcomes in seve ra l adu l t cance rs and may p rov ide g rea te r bene f i t fo r tumo rs w i th h igh mu ta t iona l load . The pu rpose o f th is phase I I s tudy is to assess the e f f icacy o f ave lumab fo r the t rea tmen t o f pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma who have measu rab le res idua l d isease . In te rven t ion : S ing le agen t ave lumab . B r ie f ou t l ine o f t rea tmen t p lan : Pa t ien ts w i l l rece ive ave lumab eve ry 2 weeks in cyc les o f 28 days fo r up to 24 mon ths , o r 26 cyc les . P rog ress ion f ree su rv iva l and response to the rapy a f te r 4 cyc les o f t rea tmen t w i l l be assessed . In add i t ion , the tox ic i ty p ro f i le o f ave lumab in th is popu la t ion w i l l be c lose ly mon i to red . S tudy des ign : Mu l t i-cen te r phase I I s tudy . Samp le s ize : 32 eva luab le pa t ien ts ; 40 to ta l pa t ien ts . Da ta managemen t : Da ta managemen t and s ta t is t ica l ana lys is w i l l be p rov ided loca l ly by the Comp rehens ive Cance r Cen te r Deve lopmen ta l B io logy So l id Tumo rs P rog ram , and B ios ta t is t ics Depa r tmen t a t S t . Jude Ch i ld ren ’s Resea rch Hosp i ta l . Human sub jec ts : The ma in r isk to resea rch pa r t ic ipan ts w i l l be the po ten t ia l tox ic i t ies assoc ia ted w i th the use o f the inves t iga t iona l agen t , ave lumab . Resea rch pa r t ic ipan ts w i l l be in fo rmed o f tox ic i t ies wh ich have been assoc ia ted w i th the s tudy d rug and po ten t ia l s ide e f fec ts o f p rocedu res recommended in th is s tudy . Adve rse even ts w i l l be mon i to red , t rea ted , and repo r ted fo l low ing ins t i tu t iona l and fede ra l gu ide l ines and regu la t ions . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
4,page_4,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 EXPER IMENTAL DES IGN SCHEMA *Ave lumab w i l l be g iven on Days 1 & 15 o f each 28 day cyc le Un resec ted recu r ren t o r p rog ress ive os teosa rcoma S tudy en t ry Cyc le 1-2 Ave lumab Cyc le 3-4 Ave lumab Ave lumab * Con t inue eve ry 2 weeks fo r up to 24 mon ths , o r 26 cyc les Eva lua t ion eve ry 3 mon ths End p ro toco l the rapy Eva lua t ion Eva lua t ion P rog ress ive d isease o r unaccep tab le tox ic i ty (a t any t ime ) O f f p ro toco l the rapy P rog ress ive d isease o r unaccep tab le tox ic i ty O f f p ro toco l the rapy S tab le o r respon se S tab le o r respon se S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
5,page_5,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 TABLE OF CONTENTS 1 .0 OB JECT IVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 1 .1 P r ima ry Ob jec t ives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 1 .2 Seconda ry Ob jec t ive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 1 .3 Exp lo ra to ry Ob jec t ives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 2 .0BACKGROUND AND RAT IONALE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 2 .1 Backg round . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 2 .2 P rec l in ica l S tud ies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 2 .3 C l in ica l S tud ies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6 2 .4 Ra t iona le fo r th is S tudy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 2 .5 Ove rv iew o f P roposed S tudy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 2 .6 Ra t iona le fo r Co r re la t ive B io logy S tud ies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 2 .7 Ra t iona le fo r Qua l i ty o f L i fe S tud ies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 3 .0EL IG IB IL ITY CR ITER IA AND STUDY ENROLLMENT . . . . . . . . . . . . . . . . . . . . . . . .14 3 .1 Inc lus ion C r i te r ia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 3 .2 Exc lus ion C r i te r ia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 3 .3 Rec ru i tmen t and Sc reen ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 3 .4 En ro l lmen t a t S t . Jude . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 3 .5 En ro l lmen t a t Co l labo ra t ing S i tes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 4 .0TREATMEN T PLAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 4 .1 Ove rv iew o f T rea tmen t P lan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 4 .2 T rea tmen t Du r ing Cyc le 1 and Subsequen t Cyc les. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 5 .0DOSE MOD IF ICAT IONS FOR TOX IC IT IES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 5 .1 Adve rse D rug Reac t ions Requ i r ing Ave lumab D iscon t inua t ion o r Mod i f ica t ion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 5 .2 T rea tmen t Mod i f ica t ion fo r Symp toms o f In fus ion-Re la ted Reac t ions.21 5 .3 Managemen t o f Immune-Med ia ted Adve rse Reac t ions . . . . . . . . . . . . . . . . . . . . . . . .22 5 .4 Au to immune o r Immune Sys tem D iso rde rs A f fec t ing O the r O rgan Sys tems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 5 .5 Cen t ra l Venous Ca the te r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 5 .6 Concom i tan t The rapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 6 .0DRUG INFORMAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 6 .1 Ave lumab (MSB0010718C , an t i-PD-L1 ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28 7 .0REQU IRED EVALUAT IONS , TESTS , AND OBSERVAT IONS . . . . . . . . . . . . . .29 7 .1 Eva lua t ions Be fo re and Du r ing The rapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 7 .2 Ex tended Sa fe ty Fo l low-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 8 .0CORRELAT IVE RESEARCH STUD IES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 8 .1 Tumo r T issue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 8 .2 Immuno log ic Resea rch – NC I Tes t ing Ba t te ry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 8 .3 Immuno log ic Resea rch – S t . Jude Tes t ing Ba t te ry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35 9 .0EVALUAT ION CR ITER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 9 .1 Response De f in i t ions and C r i te r ia fo r So l id Tumo rs . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 9 .2 Response C r i te r ia fo r Pa t ien ts w i th So l id Tumo r and Measu rab le D isease 40 9 .3 Response C r i te r ia fo r Eva luab le D isease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 9 .4 Bes t Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41 9 .5 Du ra t ion o f Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
6,page_6,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 9 .6 Tox ic i ty Eva lua t ion C r i te r ia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 10 .0OFF TREATMENT AND OFF STUDY CR ITER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 10 .1 O f f T rea tmen t C r i te r ia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 10 .2 O f f S tudy C r i te r ia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 11 .0SAFETY AND ADVERSE EVENT REPORT ING REQU IREMENTS . . . . . . . .44 11 .1Repo r t ing Adve rse Expe r iences and Dea ths to S t . Jude IRB . . . . . . . . . . . . . . . . . .44 11 .2Repo r t ing to S t Jude IRB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46 11 .3Repo r t ing f rom S t . Jude to P f ize r (D rug Manu fac tu re r ). . . . . . . . . . . . . . . . . . . . . . . .46 11 .4Repo r t ing to S t . Jude Regu la to ry A f fa i rs O f f ice and FDA . . . . . . . . . . . . . . . . . . . . . .47 11 .5Reco rd ing Adve rse Even ts and Se r ious Adve rse Even ts. . . . . . . . . . . . . . . . . . . . . . .47 11 .6P rocess fo r Repo r t ing Adve rse Even ts f rom and to Co l labo ra t ing S i tes 48 12 .0DATA COLLECT ION , MON ITOR ING AND CONF IDENT IAL ITY . . . . . . . .49 12 .1 Da ta Co l lec t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49 12 .2S tudy Mon i to r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49 12 .3Con f iden t ia l i ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50 13 .0STAT IST ICAL CONS IDERAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50 13 .1S tudy Des ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50 13 .2Seconda ry Ob jec t ives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52 13 .3Exp lo ra to ry Ob jec t ives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52 13 .4An t ic ipa ted Comp le t ion Da tes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54 14 .0OBTA IN ING INFORMED CONSENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54 14 .1Consen t P r io r to Resea rch In te rven t ions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54 14 .2Consen t a t En ro l lmen t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54 14 .3Consen t a t Age o f Ma jo r i ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55 14 .4Consen t When Eng l ish is No t the P r ima ry Language . . . . . . . . . . . . . . . . . . . . . . . . . . . .55 14 .5Co l lec t ion o f Co l labo ra t ing Ins t i tu t ion Consen t Fo rms . . . . . . . . . . . . . . . . . . . . . . . .55 15 .0REFE RENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56 APPEND ICES Append ix I :Pe r fo rmance S ta tus Sca les/Sco res Append ix I I :New Yo rk Hea r t Assoc ia t ion Func t iona l C lass i f ica t ion Append ix I I I : Ins t ruc t ions fo r Co l lec t ion and Sh ipp ing o f Resea rch B lood Samp les to NC I S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
7,page_7,"OSTPDL1 Page 1 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 1 .0 OB JECT IVES 1 .1 P r ima ry Ob jec t ives 1 .1 .1To es t ima te the response ra te to 4 cyc les o f ave lumab in pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma . 1 .1 .2To es t ima te the 16-week p rog ress ion f ree su rv iva l o f pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma a f te r t rea tmen t w i th ave lumab . 1 .2 Seconda ry Ob jec t ive 1 .2 .1To desc r ibe the tox ic i t ies assoc ia ted w i th the adm in is t ra t ion o f ave lumab in pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma . 1 .3 Exp lo ra to ry Ob jec t ives 1 .3 .1To exp lo re fac to rs assoc ia ted w i th response in pa t ien ts t rea ted w i th ave lumab a f te r recu r ren t o r p rog ress ive os teosa rcoma (e .g . tumo r PD-L1 exp ress ion ) . 1 .3 .2To measu re pa rame te rs o f immune ac t iva t ion inc lud ing subse ts o f pe r iphe ra l b lood mononuc lea r ce l ls (PBMCs ) and se rum ma rke rs o f immune ac t iva t ion . 1 .3 .3To eva lua te the ro le o f T-ce l ls in immune checkpo in t b lockade v ia measu res o f ce l l p ro l i fe ra t ion , co- inh ib i to ry recep to r exp ress ion on CD8 T ce l ls , T ce l l repe r to i re , and ep igene t ic p rog ramm ing . 1 .3 .4To assess the qua l i ty o f l i fe o f pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma unde rgo ing t rea tmen t w i th ave lumab , and to exp lo re re la t ionsh ips be tween c l in ica l fac to rs and pa t ien t- repo r ted HRQOL ou tcomes . 2 .0 BACKGROUND AND RAT IONALE 2 .1 Backg round Os teosa rcoma is the mos t common bone tumo r in ch i ld ren and ado lescen ts . I t is es t ima ted the re a re app rox ima te ly 400 new cases o f ped ia t r ic os teosa rcoma d iagnosed in the Un i ted S ta tes each yea r . 1 Nea r ly 70% o f ch i ld ren who a re t rea ted w i th os teosa rcoma w i th cu r ren t the rap ies tha t inc lude mu l t imoda l chemo the rapy w i th h igh dose me tho t rexa te , doxo rub ic in , and c isp la t in (MAP ) and su rge ry can be cu red f rom the i r d isease . 2 Howeve r , pa t ien ts who p resen t w i th me tas ta t ic d isease o r re lapse con t inue to fa re poo r ly w i th es t ima ted su rv iva l ra tes tha t do no t S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
8,page_8,"OSTPDL1 Page 2 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 exceed 30% . 3-6 Fu r the rmo re , fo r pa t ien ts who re lapse , cu re is a lmos t imposs ib le i f they canno t be deemed su rg ica l ly f ree o f d isease . 3 Th is obse rva t ion suppo r ts the need fo r iden t i f ica t ion o f ac t ive agen ts tha t can fac i l i ta te remova l o f a l l g ross tumo r in the even t o f a re lapse . In a s tudy by the Ge rman Coope ra t ive Os teosa rcoma S tudy G roup , the ove ra l l 5- yea r su rv iva l a f te r a f i rs t re lapse o f os teosa rcoma was 23% and the su rv iva l fo r pa t ien ts who d id no t have a second su rg ica l comp le te response was 0% . 3 In a repo r t f rom the same g roup , f ive yea r ove ra l l and even t f ree su rv iva l ra tes fo r pa t ien ts who expe r ienced a second o r subsequen t re lapses we re on ly 32% and 18% a t the t ime o f second recu r rence and 25% and 0% fo r those who expe r ienced a th i rd recu r rence . 7 O the r s tud ies have shown s im i la r resu l ts . Fo r examp le , in a repo r t o f 235 pa t ien ts t rea ted a t the R izzo l i Ins t i tu te , 5 yea r pos t- re lapse even t- f ree and ove ra l l su rv iva l we re 27% and 28% , respec t ive ly . 8 S t ra teg ies to imp rove the ou tcome o f pa t ien ts w i th me tas ta t ic d isease and recu r ren t d isease have been la rge ly ine f fec t ive . In a s tudy o f 43 pa t ien ts w i th os teosa rcoma who expe r ienced a f i rs t pu lmona ry recu r rence and who we re t rea ted w i th inha led GM-CSF , the 3-yea r even t f ree and ove ra l l su rv iva l we re 7 .8 and 35 .4% respec t ive ly . 9 In ano the r s tudy tha t u t i l ized R1507 , a monoc lona l an t ibody aga ins t the insu l in- l ike g row th fac to r-1 recep to r , on ly 2 o f 38 pa t ien ts w i th os teosa rcoma expe r ienced an ob jec t ive response and the med ian t ime to p rog ress ion was 5 .7 weeks . 10 Recen t ly , an ana lys is was conduc ted to assess the ou tcomes fo r ch i ld ren w i th recu r ren t o r re f rac to ry os teosa rcoma who we re en ro l led in a se r ies o f phase I I s tud ies w i th in the Ch i ld ren ’s Onco logy G roup (COG ) f rom 1997 to 2007 . These s tud ies inc luded the agen ts topo tecan , ima t in ib , oxa l ip la t in , ixabep i lone , doce taxe l , i r ino tecan and rebeccamyc in . Rad iog raph ic responses we re seen in on ly 3 t r ia ls w i th the h ighes t response ra te be ing 11% in pa t ien ts who we re t rea ted w i th topo tecan . When poo led ac ross a l l 7 s tud ies , even t f ree su rv iva l fo r 96 os teosa rcoma sub jec ts w i th measu rab le d isease was 12% a t 4 mon ths (95% C I 6 .0%-19% ) . 11 Th is va lue is now be ing used to de f ine a benchma rk fo r ac t iv i ty o f new compounds in the COG and is be ing inco rpo ra ted in to the des ign o f phase I I t r ia ls fo r recu r ren t os teosa rcoma . Us ing th is new ly adop ted endpo in t , the COG recen t ly conduc ted a s tudy o f the ha l ichond r in B ana log e r ibu l in mesy la te fo r pa t ien ts w i th me tas ta t ic and recu r ren t os teosa rcoma . Th is agen t was se lec ted as a resu l t o f p rec l in ica l obse rva t ions o f the Ped ia t r ic P rec l in ica l Tes t ing P rog ram o f the Na t iona l Cance r Ins t i tu te (NC I ) . 12 Desp i te ve ry rap id acc rua l o f 19 pa t ien ts ove r a 4 mon th pe r iod , the e f f icacy endpo in t desc r ibed above was no t me t and the s tudy is c los ing . Howeve r , the rap id en ro l lmen t o f pa t ien ts w i th recu r ren t os teosa rcoma re f lec t the u rgen t need to deve lop nove l the rap ies tha t cou ld be inco rpo ra ted no t on ly in the re lapsed se t t ing bu t in pa t ien ts w i th me tas ta t ic o r new ly d iagnosed d isease , and the w i l l ingness o f these pa t ien ts and fam i l ies to pa r t ic ipa te in inves t iga t ions o f nove l agen ts . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
9,page_9,"OSTPDL1 Page 3 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 O the r s t ra teg ies a imed a t imp rov ing ou tcome o f pa t ien ts w i th os teosa rcoma based on h is to log ic response pa rame te rs have a lso been la rge ly unsuccess fu l . I t is we l l known tha t the deg ree o f tumo r nec ros is fo l low ing neoad juvan t chemo the rapy is a p red ic to r o f c l in ica l ou tcome in ch i ldhood os teosa rcoma . Thus th is pa rame te r has been used as an ind i rec t measu re o f c l in ica l ou tcome and has been exp lo i ted in an a t temp t to imp rove su rv iva l o f these pa t ien ts , v ia augmen ta t ion o f pos t- ope ra t ive chemo the rapy fo r pa t ien ts whose tumo rs demons t ra te an inadequa te response to p re-ope ra t ive t rea tmen t . Th is was one o f the key ob jec t ives o f the recen t EURAMOS t r ia l , an in te rna t iona l p rospec t ive c l in ica l t r ia l encompass ing Ame r ican and Eu ropean co l labo ra t ive onco logy g roups , in wh ich pa t ien ts we re s t ra t i f ied a f te r su rge ry to rece ive s tanda rd o r mod i f ied the rapy based on h is to log ic response to up f ron t t rea tmen t w i th MAP chemo the rapy . Un fo r tuna te ly , the resu l ts fa i led to show any s ign i f ican t imp rovemen t in the ou tcome o f pa t ien ts who we re t rea ted w i th in te r fe ron a f te r they ach ieved a favo rab le h is to log ic response to MAP chemo the rapy , o r we re g iven add i t iona l cou rses o f chemo the rapy w i th i fos fam ide and e topos ide i f they expe r ienced a poo r h is to log ic response . 13 , 14 Genom ic ana lys is o f os teosa rcoma has demons t ra ted tha t th is tumo r is genom ica l ly comp lex w i th a la rge numbe r o f soma t ic non-s i len t mu ta t ions ave rag ing 25-32 mu ta t ions pe r case and 1 .2 mu ta t ions pe r megabase . 15 , 16 In add i t ion , os teosa rcoma has a h igh numbe r o f s t ruc tu ra l va r ia t ions tha t exceeds the numbe r seen in o the r ped ia t r ic tumo rs such as emb ryona l rhabdomyosa rcoma . 15 The ma jo r i ty o f os teosa rcomas ca r ry an abe r ra t ion in the TP53 pa thway , and 50% have hype rmu tab le reg ions known as ka taeg is . 15 Add i t iona l recu r ren t gene a l te ra t ions found in two s tud ies o f os teosa rcoma inc lude RB1 , DLG2 , and ATRX . A l though app rox ima te ly 24% o f os teosa rcoma have a l te ra t ions in the P I3K/mTOR pa thway cha rac te r ized by va r iab le a l te ra t ions o f PTEN , o r mu ta t ions in TSC2 , NF1 , P I3KCA , AKT , o r PDPK1 , 16 no c l in ica l s tud ies ta rge t ing th is pa thway in os teosa rcoma a re cu r ren t ly ac t ive . The use o f immuno the rapy to t rea t ma l ignan t d iseases has been advanced in recen t yea rs w i th the use o f checkpo in t inh ib i to rs , pa r t icu la r ly w i th the adven t o f monoc lona l an t ibod ies d i rec ted aga ins t cy to tox ic T- lymphocy te-assoc ia ted p ro te in 4 (CTLA-4 ) and p rog rammed ce l l dea th p ro te in 1 (PD-1 ) , bo th immunomodu la to ry recep to rs exp ressed on T ce l ls , 17 as we l l as the l igand fo r PD-1 (PD-L1 ) tha t has been iden t i f ied on a numbe r o f tumo r types . D rama t ic responses and long te rm cu res have been documen ted in pa t ien ts w i th va r ious adu l t ma l ignanc ies inc lud ing me lanoma , non-sma l l ce l l lung cance r , Hodgk in lymphoma , rena l ce l l ca rc inoma , and co lo rec ta l ca rc inoma . 18-23 S tud ies us ing checkpo in t inh ib i to rs sugges t tha t the response to these agen ts m igh t be in pa r t re la ted to the exp ress ion o f PD-L1 in tumo r t issue ; howeve r , the comb ined use o f CTLA-4 and PD-1 inh ib i to rs may ove rcome the lowe r S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
10,page_10,"OSTPDL1 Page 4 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 response ra tes seen in pa t ien ts whose tumo rs had nega t ive PD-L1 exp ress ion and we re t rea ted w i th s ing le agen t n ivo lumab , 24 sugges t ing tha t PD-L1 m igh t no t be an op t ima l su r roga te b ioma rke r o f response to these agen ts . In add i t ion , i t is l ike ly tha t induc ib le PD-L1 exp ress ion appea rs to be mo re s t r ingen t ly co r re la ted w i th PD-1 b lockade response as a resu l t o f adap t ive immune res is tance . 25 Mo re recen t ly , tumo r spec i f ic non-synonymous mu ta t ions have been iden t i f ied as be ing immunogen ic ; the ma jo r i ty o f th is “mu tanome ” is recogn ized by CD4+ T ce l ls . To th is e f fec t , inc reased mu ta t iona l bu rden in me lanoma has been assoc ia ted w i th responses to CTLA-4 b lockade ; howeve r , inc reased mu ta t iona l load a lone may no t exp la in the bene f i t seen in these pa t ien ts . The p resence o f spec i f ic un ique neoep i tope s igna tu res tha t con fe r h ighe r ra tes o f MHC I c lass b ind ing appea rs to be essen t ia l fo r ach ievemen t o f c l in ica l response . 26 , 27 The d rama t ic response to checkpo in t inh ib i to rs in pa t ien ts w i th mu ta t ions in m isma tch repa i r de f ic ien t co lo rec ta l cance r suppo r ts the obse rva t ion tha t a h igh mu ta t iona l load is assoc ia ted w i th the numbe r o f mu ta t ion-assoc ia ted an t igens tha t can t r igge r an immune response aga ins t the tumo r . 19 The h igh mu ta t iona l load in os teosa rcoma makes th is tumo r an a t t rac t ive ta rge t fo r immuno the rapy . Recen t wo rk has demons t ra ted tha t human me tas ta t ic os teosa rcoma ce l ls exp ress PD-L1 ; popu la t ions o f PD-L1 pos i t ive ce l ls we re obse rved in 12 o f 16 me tas ta t ic tumo rs by immuno f luo rescence . The p resence o f PD-L1 may dec rease the ac t iv i ty o f cy to tox ic T lymphocy tes (CTLs ) exp ress ing PD-1 ; b lockade o f PD-1/PD- L1 imp roved CTL func t ion in v i t ro and in v ivo . In a K7M2 mouse mode l o f os teosa rcoma th is resu l ted in dec reased tumo r bu rden and p ro longed su rv iva l . 28 In add i t ion , in an imp lan tab le mode l o f me tas ta t ic os teosa rcoma , T ce l ls in f i l t ra t ing PD-L1 an t ibody- res is tan t tumo rs up- regu la te add i t iona l inh ib i to ry recep to rs , no tab ly CTLA-4 , wh ich impa i rs the i r ab i l i ty to med ia te tumo r re jec t ion . Comb ina t ions o f α-CTLA-4 and α-PD-L1 an t ibody b lockade in the K7M2 mouse mode l o f me tas ta t ic os teosa rcoma p roduces comp le te con t ro l o f tumo rs in a ma jo r i ty o f m ice as we l l as immun i ty to fu r the r tumo r inocu la t ion . 29 In ano the r s tudy an RNA-based assay to de te rm ine PDL1 exp ress ion leve ls showed 32 o f 38 os teosa rcoma tumo rs exp ressed PDL1 ; h igh leve ls (3 log o r mo re ) o f PDL1 we re exp ressed in 9 tumo r samp les . PDL1 exp ress ion was pos i t ive ly co r re la ted w i th tumo r in f i l t ra t ing lymphocy tes (T ILs ) . 30 Wh i le da ta is l im i ted on the c l in ica l ac t iv i ty o f PD-1 o r PD-L1 inh ib i t ion in pa t ien ts w i th os teosa rcoma , a recen t repo r t f rom a c l in ica l t r ia l u t i l iz ing the Me rck PD- 1 inh ib i to r pemb ro l izumab in pa t ien ts w i th advanced bone and so f t t issue sa rcomas demons t ra ted a pa r t ia l response in 1 o f 19 en ro l led os teosa rcoma sub jec ts a t 8 weeks ; l im i ted da ta on p rog ress ion f ree su rv iva l was ava i lab le . 31 2 .2 P rec l in ica l S tud ies S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
11,page_11,"OSTPDL1 Page 5 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 2 .2 .1Ave lumab Ave lumab (a lso re fe r red to as MSB0010718C ) is a fu l ly human IgG-1 an t ibody wh ich is d i rec ted aga ins t PD-L1 . Ave lumab b inds PD-L1 and b locks the in te rac t ion be tween PD-L1 and i ts recep to rs PD-1 and B7-1 . The in te rac t ion be tween PD-L1 and PD-1/B7-1 s ign i f ican t ly inh ib i ts ac t iv i ty o f T ce l ls . Wh i le PD-L1 can be de tec ted on res t ing and ac t iva ted T ce l ls , B ce l ls , mac rophages , dend r i t ic ce l ls and mas t ce l ls , tumo r ce l ls may a lso exp ress h igh leve ls o f PD-L1 on the i r su r face compa red w i th no rma l t issues . 32 H igh leve ls o f PD-L1 exp ress ion have been found to be assoc ia ted w i th d isease p rog ress ion , inc reased me tas tas is , poo r response to t rea tmen t , and dec reased su rv iva l in a numbe r o f human cance rs . 33 B lockade o f PD-L1 removes the supp ress ive e f fec ts o f PD-L1 on an t i- tumo r CD8+ T ce l ls , resu l t ing in the res to ra t ion o f cy to tox ic T ce l l response and e l im ina t ion o f tumo r ce l ls . Fu r the rmo re , as a fu l ly human IgG1 monoc lona l an t ibody , ave lumab has the po ten t ia l to fac i l i ta te tumo r ce l l k i l l ing v ia tumo r-d i rec ted an t ibody d r iven ce l lu la r cy to tox ic i ty (ADCC ) . 2 .2 .2P rec l in ica l Pha rmaco logy S tud ies Ave lumab func t iona l ly enhances T ce l l ac t iva t ion in v i t ro and s ign i f ican t ly inh ib i ts the g row th o f PD-L1 exp ress ing tumo rs in v ivo . Ave lumab b inds to human PD-L1 w i th a h igh a f f in i ty o f 0 .7 nM and compe t i t ive ly b locks the in te rac t ion o f PD-L1 w i th PD-1 . In v i t ro s tudy resu l ts showed tha t by b ind ing to PD-L1 , ave lumab e f fec t ive ly enhances T ce l l ac t iva t ion as measu red by in te r leuk in-2 ( IL-2 ) o r in te r fe ron-gamma ( IFN-γ ) p roduc t ion . As a mono the rapy , ave lumab demons t ra ted an t i- tumo r ac t iv i ty aga ins t mu r ine MC38 co lon ca rc inoma tumo rs cha rac te r ized by h igh leve l o f PD-L1 exp ress ion w i th an obse rved dose-dependen t t rend when g iven eve ry th i rd day fo r a to ta l o f 3 doses . Dos ing was de te rm ined to be 400 µg , app rox ima t ing to 20 mg/kg . In v ivo an t i- tumo r e f fec ts we re p r ima r i ly med ia ted by CD8+ T ce l ls as ev idenced by obse rva t ion tha t in v ivo dep le t ion o f CD8+ T ce l ls ab roga ted an t i- tumo r e f f icacy . The con t r ibu t ion o f ADCC as a mechan ism o f an t i- tumo r ac t iv i ty was demons t ra ted v ia use o f a deg lycosy la ted ve rs ion o f ave lumab to ab roga te Fc recep to r b ind ing , and v ia sys tem ic dep le t ion o f na tu ra l k i l le r (NK ) ce l ls . In bo th se t t ings , loss o f in v ivo ADCC po ten t ia l s ign i f ican t ly reduced an t i- tumo r ac t iv i ty . The comb ina t ion o f ave lumab w i th common ly used cance r t rea tmen ts , such as cy to tox ic agen ts and rad ia t ion the rapy , resu l ted in imp roved an t i- tumo r ac t iv i ty . The mos t p rom is ing comb ina t ion pa r tne rs fo r ave lumab we re gemc i tab ine o r 5- f luo rou rac i l and oxa l ip la t in , the co re componen ts o f FOLFOX . Rad ia t ion the rapy was found to be h igh ly syne rg is t ic w i th ave lumab , capab le o f caus ing comp le te reg ress ion o f es tab l ished tumo rs . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
12,page_12,"OSTPDL1 Page 6 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Va r ious immunomon i to r ing assays we re inco rpo ra ted in to the in v ivo s tud ies . T rea tmen t w i th ave lumab resu l ted in a cons is ten t inc rease in the pe rcen tage o f CD8+PD-1+ T ce l ls and an inc reased f requency o f CD8+ T ce l ls w i th an e f fec to r memo ry (TEM ) pheno type as de te rm ined by f low cy tome t ry . These changes co r re la ted w i th an t i- tumo r e f fec t . Inc reases in tumo r an t igen-spec i f ic T ce l l responses , as measu red by enzyme- l inked immunoso rben t spo t and pen tame r immunoassays , we re ev iden t fo l low ing t rea tmen t w i th ave lumab . These responses we re enhanced when comb ined w i th FOLFOX o r rad ia t ion . Th is has led to specu la t ion tha t inc reases in CD8+PD-1+ T ce l ls , CD8+ TEM ce l ls , and an t igen- spec i f ic T ce l l responses may be leve raged as pha rmacodynam ic b ioma rke rs w i th t rans la t iona l re levance to the c l in ica l se t t ing 2 .2 .3P rec l in ica l Pha rmacok ine t ic S tud ies Ave lumab demons t ra ted p ronounced non- l inea r pha rmacok ine t ic (PK ) cha rac te r is t ics in m ice and monkeys in s ing le dose s tud ies a t doses be low 20 mg/kg , sugges t ing a comb ina t ion o f f i rs t o rde r ca tabo l ic c lea rance and sa tu rab le ta rge t-med ia ted c lea rance . Tox icok ine t ic da ta f rom repea ted dose tox ic i ty s tud ies in m ice , ra ts and monkeys ind ica ted tha t the PK o f ave lumab was l inea r w i th in the dose range o f 20 to 140mg/kg , sugges t ing tha t the ta rge t med ia ted c lea rance cou ld be sa tu ra ted when h ighe r doses a re adm in is te red . S im i la r te rm ina l ha l f- l ives o f app rox ima te ly 60 to 70 hou rs we re obse rved in tox ic i ty s tud ies in m ice and monkeys . A PK/pha rmacodynam ic (PD ) s tudy in C57BL/6 m ice was used to co r re la te recep to r occupancy da ta o f ave lumab in b lood w i th d rug comb ina t ions . A p lasma concen t ra t ion o f 58 .5 µg/mL was ca lcu la ted as requ i red fo r 95% ta rge t occupancy in th is mode l . Ave lumab is immunogen ic in m ice , ra ts , and monkeys w i th a lowe r inc idence o f an t i-d rug an t ibod ies (ADAs ) a t h ighe r doses . The la t te r is p robab ly due to in te r fe rence o f f ree ave lumab w i th the immunogen ic i ty assay (d rug in te r fe rence ) . In an ima ls , the gene ra ted ADAs seem to have the po ten t ia l to inc rease the c lea rance o f the ave lumab . As the fu l ly human ave lumab rep resen ts a fo re ign p ro te in to the immune sys tem o f an ima ls , the obse rved immunogen ic i ty o f ave lumab in roden ts and non- human p r ima tes is no t deemed p red ic t ive fo r an immune response to ave lumab in humans . 2 .2 .4P rec l in ica l Tox ico logy S tud ies The tox ico log ica l p ro f i le o f ave lumab was eva lua ted in repea t-dose tox ic i ty s tud ies o f 4-week du ra t ion w i th once week ly IV bo lus in jec t ion/ in fus ion o f ave lumab in m ice , ra ts , and cynomo lgus monkeys . A repea t-dose tox ic i ty s tudy w i th in te rm i t ten t once week ly IV in fus ion o f ave lumab ove r 13 weeks fo l lowed by an 8-week recove ry pe r iod in cynomo lgus monkeys was a lso conduc ted . In add i t ion , in v i t ro cy tok ine S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
13,page_13,"OSTPDL1 Page 7 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 re lease assays (CRA ) in human and cynomo lgus monkey who le b lood and pe r iphe ra l b lood mononuc lea r ce l ls (PBMCs ) fo l lowed by an op t im ized CRA in phy to-hemagg lu t in in (PHA ) p re-s t imu la ted PBMCs f rom 16 human vo lun tee rs was comp le ted . T issue c ross reac t iv i ty (TCR ) s tud ies in no rma l human and cynomo lgus monkey t issues have a lso been pe r fo rmed . On the bas is o f the b ind ing a f f in i ty da ta , the cynomo lgus monkey and the mouse we re se lec ted as re levan t spec ies fo r the nonc l in ica l sa fe ty tes t ing o f ave lumab . Due to seve re hype rsens i t iv i ty reac t ions a f te r repea ted adm in is t ra t ion o f ave lumab in m ice and the low b ind ing a f f in i ty in ra ts , roden t spec ies a re no t cons ide red app rop r ia te fo r nonc l in ica l sa fe ty tes t ing o f ave lumab and the re fo re , a s ing le spec ies app roach (cynomo lgus monkey on ly ) is app l ied . In cynomo lgus monkeys , c l in ica l s igns o f hype rsens i t iv i ty have no t been seen a f te r repea ted t rea tmen t w i th ave lumab a t dose leve ls o f 20 , 60 , and 140 mg/kg , respec t ive ly , in e i the r the p i lo t 4-week s tudy o r in the p ivo ta l 13-week IV repea t-dose tox ic i ty s tudy . Fo r bo th s tud ies , a no obse rved adve rse e f fec t leve l (NOAEL ) o f 140 mg/kg fo r sys tem ic tox ic i ty was es tab l ished . In i t ia l cy tok ine re lease assays in human and cynomo lgus monkey who le b lood and PBMCs revea led no c lea r-cu t ev idence fo r re lease o f p ro- in f lamma to ry cy tok ines . Howeve r , a subsequen t , op t im ized CRA demons t ra ted ev idence o f po ten t ia l cy tok ine re lease in PHA p re- s t imu la ted PBMCs . Howeve r , c l in ica l expe r ience has demons t ra ted tha t the re la t ive r isk o f an in fus ion reac t ion is low (app rox ima te ly 2% ) and w i th p re-med ica t ion , the inc idence o f in fus ion reac t ion d rops to less than 1% , ind ica t ing tha t the op t im ized CRA ove res t ima tes the r isk o f cy tok ine re lease in the c l in ica l se t t ing . 2 .3 C l in ica l S tud ies 2 .3 .1Adu l t S tud ies C l in ica l da ta rega rd ing pha rmacok ine t ics and sa fe ty fo r ave lumab is ava i lab le f rom fou r ongo ing c l in ica l t r ia ls fo r the t rea tmen t o f adu l t me tas ta t ic o r loca l ly advanced so l id tumo rs , ac ross Phases I , I I (EMR 100070-003 ) , and I I I . EMR 100070-001 is a Phase I open labe l mu l t ip le ascend ing dose t r ia l w i th two pa r ts : a dose esca la t ion coho r t w i th a 3+3 en ro l lmen t des ign to de te rm ine the max imum to le ra ted dose (MTD ) o f ave lumab w i th dose leve ls o f 1 , 3 , 10 and 20 mg/kg eve ry 2 weeks , and an expans ion coho r t fo r 16 d i f fe ren t tumo r sub types . EMR 100070-002 is a Phase I t r ia l to inves t iga te the to le rab i l i ty , sa fe ty , pha rmacok ine t ics (PKs ) , b io log ica l and c l in ica l ac t iv i ty o f ave lumab in Japanese pa t ien ts w i th me tas ta t ic o r loca l ly advanced so l id tumo rs w i th an expans ion coho r t fo r As ian pa t ien ts w i th gas t r ic cance r , and was conduc ted in a s im i la r dose S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
14,page_14,"OSTPDL1 Page 8 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 esca la t ion des ign as EMR 100070-001 w i th dose leve ls o f 3 , 10 and 20 mg/kg eve ry 2 weeks . EMR 100070-003 is a Phase I I , s ing le a rm , open- labe l t r ia l inves t iga t ing the ac t iv i ty and sa fe ty o f ave lumab in sub jec ts w i th Me rke l ce l l ca rc inoma . EMR 100070-004 is a Phase I I I open- labe l t r ia l o f ave lumab ve rsus doce taxe l in sub jec ts w i th NSCLC tha t has p rog ressed a f te r p la t inum-doub le t con ta in ing the rapy . Da ta fo r dose esca la t ion and PKs a re ava i lab le fo r Phase 1 t r ia ls EMR 100070-001 and EMR 100070-002 . Fo r EMR 100070-001 , 53 sub jec ts we re inc luded in the dose esca la t ion coho r t . Ha l f- l ives we re 69 , 85 , 102 and 120hou rs fo r each dose leve l , respec t ive ly . C max and AUC inc reased mo re than p ropo r t iona l ly to dose be tween 1 to 10 mg/kg , bu t p ropo r t iona l ly fo r doses above 10 mg/kg . G iven no s ign i f ican t d i f fe rence be tween the 10 mg/kg and 20 mg/kg g roups , th is PK cha rac te r is t ic sugges ts tha t ta rge t med ia ted d rug d ispos i t ion is invo lved in the c lea rance o f ave lumab and a h igh PD-L1 ta rge t occupancy (TO ) is l ike ly ach ieved a t the t rough concen t ra t ions fo r doses o f 10 mg/kg . F low cy tome t ry o f pe r iphe ra l b lood CD3+ T ce l ls in hea l thy vo lun tee rs obse rved a concen t ra t ion o f 1 µg/mL ave lumab requ i red fo r >95% TO ; based on t rough se rum leve ls obse rved in EMR 100070-001 , a l l sub jec ts rece iv ing 10 mg/kg we re p ro jec ted to reach o r exceed >95% TO th roughou t the en t i re dos ing in te rva l . The MTD was no t reached . The dose esca la t ion coho r t was comp le ted and a dose o f 10 mg/kg eve ry 2 weeks was de te rm ined to be the b io log ica l ly op t ima l dose fo r fu r the r eva lua t ion in the expans ion po r t ion . S im i la r resu l ts we re seen fo r PKs in the Phase I t r ia l EMR 100070-002 . C max and AUC inc reased p ropo r t iona l w i th dose , and ha l f- l ives we re 92 , 127 , and 115 hou rs fo r each dose leve l , respec t ive ly . Sa fe ty da ta a re ava i lab le fo r 1300 sub jec ts t rea ted in the poo led t rea tmen t expans ion coho r ts o f EMR 100070-001 , 52 sub jec ts in the ongo ing EMR 100070-002 , 88 sub jec ts in the ongo ing Phase I I t r ia l EMR 100070-003 , and 75 pa t ien ts t rea ted on the ongo ing Phase I I I t r ia l EMR 100070-004 . Fo r EMR 100070-001 , d rug- re la ted t rea tmen t-eme rgen t adve rse even ts (TEAEs ; a l l g rades ) occu r red in 62 .5% o f pa t ien ts ; the mos t f requen t t rea tmen t- re la ted TEAEs we re fa t igue (16 .3% ) , in fus ion- re la ted reac t ion ( IRR ) (16 .1% ) , nausea (8 .3% ) , ch i l ls (7 .8% ) , d ia r rhea (6 .1% ) , and py rex ia (5 .5% ) . D rug- re la ted TEAEs ≥ g rade 3 we re repo r ted in 124 pa t ien ts (9 .5% ) in the poo led expans ion coho r t o f EMR 100070-001 ; the mos t common o f these we re inc reased gamma-g lu tamy l t rans fe rase (GGT ) (0 .7% ) and IRR (0 .7% ) . O the r G rade > 3 t rea tmen t- re la ted TEAEs inc luded e leva ted l ipase , fa t igue , anem ia , dyspnea , inc reased t ransam inases , pneumon i t is and au to immune hepa t i t is . Po ten t ia l ly immune-med ia ted AEs we re obse rved in 7 .6% , inc lud ing hypo thy ro id ism (3 .5% ) , pneumon i t is (1% ) , hype r thy ro id ism (0 .5% ) , ad rena l insu f f ic iency and d ry eye (0 .4% ) , au to immune hepa t i t is and co l i t is (0 .3% ) , and myos i t is (0 .2% ) . 79 sub jec ts (6 .1% ) had a d rug- re la ted TEAE lead ing to t rea tmen t S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
15,page_15,"OSTPDL1 Page 9 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 d iscon t inua t ion . 25 (1 .9% ) o f these we re due to an in fus ion- re la ted reac t ion ; 5 (0 .4% ) we re d iscon t inued fo r inc reased GGT leve ls . O the r even ts resu l t ing in d iscon t inua t ion (each in 3 pa t ien ts o r less ) inc luded e leva ted t ransam inases , inc reased c rea t ine phosphok inase , inc reased l ipase , a r th ra lg ia , au to immune hepa t i t is , co l i t is , dyspnea , fa t igue , and myos i t is . 142 pa t ien ts (10 .9% ) expe r ienced a TEAE lead ing to dea th ; 5 (0 .4% ) o f these we re de te rm ined to be re la ted to t rea tmen t . These adve rse even ts inc luded rad ia t ion pneumon i t is , pneumon i t is , resp i ra to ry d is t ress , acu te hepa t ic fa i lu re , and au to immune hepa t i t is w i th resu l tan t fa ta l l ive r fa i lu re . Fo r the 52 sub jec ts w i th ava i lab le sa fe ty da ta on EMR 100070-002 , 19 se r ious TEAEs we re expe r ienced in 15 sub jec ts , 14 o f wh ich we re G rade 3 o r h ighe r . E leven sub jec ts expe r ienced 13 IRR even ts , 12 o f wh ich we re deemed non-se r ious ; the lone se r ious IRR was re la ted to subsequen t chemo the rapy a f te r t r ia l d iscon t inua t ion and no t ave lumab . 3 po ten t ia l immune re la ted adve rse even ts inc luded hypo thy ro id ism , hype r thy ro id ism and co l i t is . 3 sub jec ts had TEAEs resu l t ing in fa ta l ou tcome , one o f wh ich was t rea tmen t- re la ted (g rade 5 tumo r lys is synd rome , g rade 5 acu te k idney in ju ry ) . Fo r 88 pa t ien ts en ro l led on the Phase I I t r ia l EMR 100070-003 , 78 se r ious TEAEs we re repo r ted in 35 sub jec ts ; 57 G rade > 3 even ts we re repo r ted . E igh t t rea tmen t- re la ted TEAEs we re iden t i f ied in 6 sub jec ts inc lud ing chond roca lc inos is , en te roco l i t is , synov i t is , inc reased t ransam inases , tubu lo in te rs t i t ia l neph r i t is , hypo thy ro id ism , and IRR ; a l l we re g rade 2 even ts . 2 sub jec ts had po ten t ia l immune re la ted adve rse even ts inc lud ing hypo thy ro id ism and g rade 2 encepha lopa thy (no t re la ted to t rea tmen t ) . P re l im ina ry sa fe ty da ta is ava i lab le fo r the Phase I I I t r ia l EMR 100070-004 , w i th app rox ima te ly 75 pa t ien ts random ized to rece ive ave lumab and an add i t iona l 75 rece iv ing doce taxe l . Sa fe ty da ta is b l inded and ass ignmen t o f even ts to e i the r d rug is no t poss ib le . A to ta l o f 70 se r ious TEAEs a re repo r ted in 39 pa t ien ts , inc lud ing 25 G rade > 3 t rea tmen t re la ted even ts . S ix g rade 4 t rea tmen t- re la ted se r ious TEAEs we re obse rved in 4 sub jec ts inc lud ing in fus ion re la ted reac t ion , ao r t ic aneu rysm , dec reased neu t roph i l coun t , in tes t ina l pe r fo ra t ion , pe r i ton i t is , and pa ra ly t ic i leus . Fa ta l TEAEs occu r red in 8 sub jec ts , inc lud ing d isease p rog ress ion (4 ) , COPD/dyspnea , gene ra l phys ica l hea l th de te r io ra t ion , and resp i ra to ry fa i lu re . Two fa ta l se r ious TEAEs (sep t ic shock , pneumon ia ) in one sub jec t we re cons ide red t rea tmen t- re la ted . The sa fe ty p ro f i le o f ave lumab is cons is ten t w i th f ind ings repo r ted fo r o the r an t i-PD-1 o r an t i-PD-L1 an t ibod ies . In fus ion- re la ted reac t ions inc lud ing hype rsens i t iv i ty and immune- re la ted AEs/au to immune d iso rde rs have been iden t i f ied as impo r tan t r isks fo r ave lumab . Respec t ive r isk m i t iga t ion measu res have been imp lemen ted in ongo ing c l in ica l s tud ies w i th ave lumab . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
16,page_16,"OSTPDL1 Page 10 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 C l in ica l e f f icacy in fo rma t ion o f ave lumab is based on da ta f rom non- sma l l ce l l lung cance r (NSCLC ) and ova r ian cance r expans ion coho r ts in the ongo ing Phase I t r ia l EMR 100070-001 , and fo r 20 sub jec ts in the gas t r ic cance r expans ion coho r t o f the ongo ing Phase I t r ia l EMR 100070-002 . The ob jec t ive response ra te (ORR ) fo r sub jec ts t rea ted in the NSCLC coho r t was 14 .1% (26/184 ) . N ine teen o f 26 (73% ) responde rs had the i r f i rs t documen ted response by week 12 , bu t 7 (27% ) demons t ra ted response by week 18 o r la te r , sugges t ing a ro le fo r longe r fo l low-up du ra t ion . The med ian PFS and OS fo r the coho r t we re 11 .6 weeks and 8 .4 mon ths , respec t ive ly . C l in ica l ac t iv i ty o f ave lumab was a lso eva lua ted re t rospec t ive ly by tumo r PD-L1 exp ress ion . An ob jec t ive response was obse rved in 20 o f 122 sub jec ts (16 .4% ) who we re PD-L1 pos i t ive (de f ined as hav ing a t leas t 1% PD-L1 pos i t ive tumo r ce l ls ) compa red w i th 2 o f 20 sub jec ts (10% ) who we re cons ide red PD-L1 nega t ive (de f ined as hav ing less than 1% PD-L1 pos i t ive tumo r ce l ls ) . A longe r med ian PFS (12 vs . 5 .9 weeks ) and OS (8 .9 vs . 4 .6 mon ths ) we re bo th obse rved in PD-L1 pos i t ive compa red w i th PD-L1 nega t ive sub jec ts . Fo r the ova r ian cance r expans ion coho r t , the ob jec t ive response ra te based on con f i rmed and uncon f i rmed responses fo r t rea ted sub jec ts was 10 .7% (8 o f 75 sub jec ts ) . The med ian PFS fo r the ova r ian cance r coho r t was 11 .4 weeks . P re l im ina ry e f f icacy da ta fo r gas t r ic cance r pa t ien ts on EMR 100070-002 as o f a da ta cu to f f o f Ma rch 11 th 2015 demons t ra ted 3 o f 20 sub jec ts w i th con f i rmed pa r t ia l responses (PRs ) , w i th a med ian PFS o f 11 .9 weeks . The p resence o f human an t i-human an t ibod ies (HAHAs ) we re a lso assessed , as th is may impac t d rug e f f icacy ; inc idence was low w i th 11 ou t o f 377 sub jec ts w i th pos t- t rea tmen t samp les tes t ing pos i t ive fo r the p resence o f HAHAs . Cu r ren t ly the re a re add i t iona l c l in ica l t r ia ls open o r in deve lopmen t fo r ave lumab in adu l ts a t va r ious leve ls . These inc lude s ing le agen t use o r comb ina t ions w i th chemo the rap ies and/o r immuno the rap ies fo r a va r ie ty o f adu l t ma l ignanc ies . Da ta a re no t ava i lab le fo r these s tud ies . 2 .3 .2Ped ia t r ic S tud ies The re have been no ped ia t r ic phase I o r I I s tud ies us ing ave lumab tha t have been conduc ted to da te . The re fo re th is t r ia l w i l l eva lua te ave lumab us ing a dosage and schedu le o f adm in is t ra t ion tha t has been shown to be sa fe in adu l ts w i th re f rac to ry so l id tumo rs , and we w i l l c lose ly mon i to r fo r tox ic i t ies in a l l pa t ien ts . Pa t ien ts w i th os teosa rcoma a re typ ica l ly d iagnosed in the second and th i rd decade o f l i fe . Seve ra l o the r s tud ies have a l lowed fo r the use o f adu l t dos ing to be ex tended to pa t ien ts age 12 yea rs o r g rea te r due to body su r face a rea requ i remen ts tha t a re mo re c lose ly a l igned w i th adu l t pa t ien ts , inc lud ing recen t COG phase I I s tud ies spec i f ica l ly ta rge t ing pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma w i th agen ts such as e r ibu l in mesy la te and g lemba tumumab vedo t in . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
17,page_17,"OSTPDL1 Page 11 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 2 .4 Ra t iona le fo r th is S tudy Th is s tudy w i l l eva lua te ave lumab in pa t ien ts w i th os teosa rcoma us ing dos ing tha t has p rev ious ly been de te rm ined in adu l t s tud ies . Rev iew o f COG phase I I t r ia ls en ro l l ing os teosa rcoma pa t ien ts revea ls tha t ove r 80% o f en ro l led pa t ien ts have been age 12 yea rs o r o lde r . Ob jec t ive response us ing t rad i t iona l c r i te r ia such as the Response Eva lua t ion C r i te r ia in So l id Tumo rs (REC IST ) has p roven cha l leng ing fo r os teosa rcoma , as i ts dense ca lc i f ied s t ruc tu re l im i ts i ts ab i l i ty to demons t ra te a rad iog raph ic rep resen ta t ion o f d rug ac t iv i ty . Us ing d isease con t ro l (de f ined as ex tended s tab i l iza t ion o f d isease fo r 4 cyc les o f the rapy o r g rea te r ) as an add i t iona l endpo in t may a l low fo r the ab i l i ty to de tec t a s igna l o f ac t iv i ty . The re fo re ob jec t ive response w i l l be eva lua ted as a p r ima ry endpo in t , bu t s tab le d isease con t ro l w i l l a lso be mon i to red . 2 .5 Ove rv iew o f P roposed S tudy Th is is a Phase 2 s tudy us ing a t rad i t iona l S imon two-s tage des ign . Pa t ien ts 12 yea rs o r g rea te r w i th recu r ren t/ re f rac to ry os teosa rcoma w i l l be adm in is te red ave lumab a t a dose o f 10 mg/kg in t ravenous ly ( IV ) ove r 60 m inu tes on days 1 and 15 o f each cyc le , w i th a cyc le las t ing 28 days . Eva lua t ions to assess d isease con t ro l and response w i l l be comp le ted a f te r cyc les 2 and 4 , and then w i l l be comp le ted eve ry 3 cyc les . Co r re la t ive b io log ic s tud ies w i l l be ob ta ined and w i l l inc lude measu res o f immune ac t iva t ion , inc lud ing pheno typ ic and func t iona l ana lys is o f pe r iphe ra l b lood mononuc lea r ce l ls (PBMCs ) and se rum ana lyses o f cy tok ines , chemok ines , so lub le CD-27 , so lub le CD40L , an t ibod ies , and tumo r-assoc ia ted an t igens . In add i t ion to assessmen t o f d isease con t ro l , response assessmen ts w i l l use s tanda rd REC IST c r i te r ia . De te rm ina t ion o f p rog ress ion w i l l use measu remen ts acco rd ing to REC IST c r i te r ia a t 16 weeks . 2 .6 Ra t iona le fo r Co r re la t ive B io logy S tud ies As an IgG-1 an t ibody ta rge t ing PD-L1 , ave lumab may po ten t ia l ly cause an t i- tumo r ac t iv i ty th rough inh ib i t ion o f the PD-1/PD-L1 in te rac t ion and resu l tan t remova l o f inh ib i t ion o f the immune sys tem to ta rge t tumo r ce l ls , o r may be re la ted to ADCC p rope r t ies ; the re fo re the mechan ism o f ac t ion o f ave lumab is no t fu l ly unde rs tood . The re fo re , co r re la t ive b io logy s tud ies w i l l inves t iga te the ac t iva t ion s ta tus o f the immune sys tem th rough eva lua t ion o f se rum ma rke rs a t base l ine and a f te r t rea tmen t w i th ave lumab . Th is w i l l inc lude cy tok ines ( IFN-γ , IL-10 , IL-12 , IL-2 , IL-4 , TGF-β ) , chemok ines , so lub le CD27 , so lub le CD40 l igand , and tumo r- assoc ia ted an t igens . P ro l i fe ra t ion o f 123 un ique subse ts o f PBMCs w i l l be eva lua ted by f low cy tome t ry a t base l ine and a f te r exposu re to ave lumab . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
18,page_18,"OSTPDL1 Page 12 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Inc reased numbe rs o f mu ta t ions have been assoc ia ted w i th o f tumo rs respons ive to immune b lockade t rea tmen t ( inc lud ing CTLA-4 and PD-1 ) . The p roposed mechan ism o f ac t ion in immune b lockade the rapy is the ac t iva t ion o f hos t CD4 and CD8 T ce l l responses aga ins t tumo r an t igens , w i th tumo r neoan t igens cons ide red to be the p r ima ry ta rge ts o f e f f icac ious responses . 27 , 34 In o rde r fo r a tumo r mu ta t ion to gene ra te a neoan t igen , i t mus t occu r w i th in a pep t ide con tex t tha t can b ind to a hos t ma jo r h is tocompa t ib i l i ty comp lex (MHC ) . Fu r the r , th is mu ta t ion-bea r ing pep t ide s t i l l needs to be p rocessed and p resen ted e f f ic ien t ly and e l ic i t a cogna te T ce l l response . The re fo re , i t is expec ted tha t tumo rs w i th h igh numbe rs o f mu ta t ions a re mo re l ike ly to gene ra te ind iv idua l mu ta t ions tha t mee t a l l the requ i remen ts to be immunogen ic neoep i topes . In the sma l l numbe r o f s tud ies tha t have been conduc ted us ing compu ta t iona l ly p red ic ted neoep i topes , ~2-10% o f the p red ic ted ep i topes we re con f i rmed to have e l ic i ted de tec tab le T ce l l responses by te t rame r s ta in ing , w i th some va r ia t ion l ike ly due to d i f fe rences in the me thod o f p red ic t ion . 35 Hos t T ce l ls p lay a c r i t ica l ro le in con t ro l l ing many fo rms o f cance r , bu t can p rog ress ive ly lose the i r an t i- tumo r func t ions du r ing p ro longed exposu re to h igh leve ls o f an t igen and in f lamma t ion . 36 Rep ress ion o f CD8 T ce l l e f fec to r func t ions , common ly re fe r red to as T ce l l exhaus t ion , is a ma jo r obs tac le fo r cu r ren t the rapeu t ic s t ra teg ies a imed a t u t i l iz ing the hos t immune sys tem . 37 Acqu is i t ion o f the func t iona l ly exhaus ted s ta te in an t igen-spec i f ic T ce l ls is con t ro l led by the exp ress ion o f inh ib i to ry recep to rs . 38 , 39 These recen t advances in ou r mechan is t ic unde rs tand ing o f T ce l l exhaus t ion have led to immune checkpo in t b lockade the rap ies tha t reve rse the exhaus ted s ta te by b lock ing the l iga t ion o f inh ib i to ry recep to rs exp ressed on the su r face o f tumo r-spec i f ic CD8 T ce l ls . 40 I t is now appa ren t tha t the deve lopmen t o f the fu l ly exhaus ted pheno type is co r re la ted to the success ive up- regu la t ion o f mu l t ip le inh ib i to ry recep to rs , inc lud ing co-exp ress ion o f PD-1 w i th Lag3 , 2B4 , and T im3 . 41 , 42 S imu l taneous exp ress ion o f a l l fou r recep to rs iden t i f ies a fu l ly exhaus ted ce l l , wh i le ce l ls tha t exp ress a sma l le r subse t o f these recep to rs m igh t s t i l l re ta in some func t ion . A f te r checkpo in t b lockade , the loss o f inh ib i to ry recep to r exp ress ion w i l l se rve as co r re la te o f rescued func t iona l i ty . S tud ies have a lso demons t ra ted tha t inc reased PD-1 exp ress ion can be used as a su r roga te ma rke r fo r ce l ls exposed to an t igen , wh ich has recen t ly been emp loyed as a s t ra tegy to iden t i fy tumo r-spec i f ic CD8 T ce l ls 43 ; in th is wo rk , a l l tumo r-spec i f ic ce l ls exp ressed PD-1 . Few da ta a re ava i lab le rega rd ing the pe rcen tage o f CD8+ T ce l ls tha t a re PD-1 pos i t ive in ped ia t r ic pa t ien ts w i th cance r ; be tween 30 and 70% o f CD8+ T ce l ls we re found to be pos i t ive fo r PD-1 in 27 hea l thy adu l t samp les 44 . Based on the ro le PD-1 exp ress ion p lays in T ce l l exhaus t ion , as we l l as i ts u t i l i ty in iden t i fy ing ac t iva ted tumo r-spec i f ic CD8 T ce l ls , we w i l l pe r fo rm co r re la t ive s tud ies to de te rm ine changes in the immunopheno typ ic S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
19,page_19,"OSTPDL1 Page 13 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 p ro f i le o f PD-1 h igh CD8+ T ce l ls f rom se r ia l pe r iphe ra l b lood samp les ob ta ined be fo re and du r ing t rea tmen t . We w i l l be measu r ing the change in the pe rcen tage o f PD-1 h igh CD8+ T ce l ls in pe r iphe ra l b lood samp les ob ta ined be fo re and 6 weeks a f te r s ta r t o f the rapy . Eme rg ing ev idence ind ica tes tha t immune checkpo in t b lockade resu l ts in expans ion o f a c lona l popu la t ion o f tumo r-spec i f ic ce l ls . 45 Wh i le th is expans ion is g roundb reak ing , the o l igoc lona l i ty o f T ce l ls w i l l p rov ide a se lec t ive p ressu re aga ins t spec i f ic an t igens and may even tua l ly enhance tumo r escape . The re fo re we mus t be t te r unde rs tand the mechan isms fo r the res t r ic ted c lona l i ty o f re juvena ted CD8 T ce l ls in ind iv idua ls tha t rece ive immune checkpo in t b lockade the rapy in o rde r to deve lop s t ra teg ies the a l low fo r a g rea te r b read th o f tumo r-spec i f ic T ce l ls to respond to immune checkpo in t b lockade . Repe r to i re d ive rs i ty has been es tab l ished as a key co r re la te o f e f f icac ious immune responses aga ins t in fec t ions in m ice and humans . 46 , 47 Th is inc ludes d ive rs i ty o f ep i tope ta rge ts , as we l l as repe r to i re d ive rs i ty w i th in an ep i tope-spec i f ic response . We hypo thes ize tha t the gene ra t ion o f success fu l an t i- tumo r immune responses a f te r checkpo in t b lockade requ i res the ac t iva t ion o f d ive rse T ce l l repe r to i res . Conve rse ly , the inab i l i ty to rec ru i t and reac t iva te a su f f ic ien t ly d ive rse repe r to i re may be a key co r re la te o f t rea tmen t fa i lu re . The cha rac te r iza t ion o f the an t i- tumo r T ce l l repe r to i re has to da te been pe r fo rmed by g row ing T ce l l l ines , o r us ing p red ic t ive a lgo r i thms to de tec t po ten t ia l T ce l l responses based on neoep i topes . In the la t te r case , these a re a lmos t exc lus ive ly C lass I- res t r ic ted responses , though a few repo r ts have demons t ra ted a robus t ro le fo r an t i- tumo r C lass I I- res t r ic ted T ce l ls . 48 , 49 We p ropose to use an unb iased app roach to de f ine the T ce l l repe r to i re in tumo r-assoc ia ted T ce l ls (whe re tumo r t issue is ava i lab le ) o r in an t igen-exposed (PD-1 +) T ce l ls f rom the pe r iphe ra l b lood o f tumo r pa t ien ts be fo re and a f te r t rea tmen t w i th ave lumab . Us ing s ing le ce l l techn iques , we w i l l comp rehens ive ly cha rac te r ize the repe r to i re o f PD1+ ce l ls a t base l ine and fo l low ing t rea tmen t , w i th a focus on iden t i fy ing c lono types tha t expand a f te r t rea tmen t . Se lec ted c lono types tha t expand fo l low ing t rea tmen t w i l l be c loned and exp ressed in a ce l l l ine tha t w i l l repo r t ou t T ce l l recep to r ac t iva t ion us ing a Nu r77-GFP cons t ruc t . In pa t ien ts whe re tumo r t issue o r tumo r sequence is ava i lab le , we w i l l in i t ia l ly sc reen the repo r te r l ines aga ins t the neoan t igens p resen t in the tumo r , us ing t ransgen ic an t igen p resen t ing ce l ls t rans fec ted w i th the app rop r ia te HLA and a syn the t ic cons t ruc t con ta in ing a l l the iden t i f ied neoan t igens . I f pos i t ive h i ts a re iden t i f ied , the spec i f ic neoan t igen (s ) w i l l be cha rac te r ized . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
20,page_20,"OSTPDL1 Page 14 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 F igu re 1 : D i f fe ren t ia l DNA me thy la t ion p rog ramm ing among human na ïve and memo ry CD8 T ce l l subse ts is coup led to the i r func t iona l s ta te . (A ) FACS based iso la t ion s t ra tegy to pu r i fy na ïve and memo ry CD8 T ce l ls subse ts f rom the pe r iphe ra l b lood o f hea l thy ind iv idua ls . TN = na ïve , TEM = e f fec to r-memo ry , TCM = cen t ra l-memo ry CD8 T ce l ls . Rep resen ta t ive FACS- based ga t ing s t ra tegy to iden t i fy the fo l low ing CD8 T ce l ls : Na ïve = CCR7 + CD45RO - , TEM= CCR7 - CD45RO +, and TCM= CCR7 + CD45RO +. (B ) B isu l f i te sequenc ing ana lys is o f Id2 , P r f1 (Pe r fo r in ) , PD-1 , and GzmB (G ranzyme B ) regu la to ry loc i f rom genom ic DNA o f FACS so r ted na ïve , TEM , and TCM CD8 T ce l ls . Ca r toon rep resen ta t ion o f the p romo te r reg ion is dep ic ted to the le f t o f the rep resen ta t ive me thy la t ion p ro f i l ing fo r each reg ion . Open c i rc les rep resen t unme thy la ted CpG s i te wh i le c losed c i rc les rep resen t me thy la ted CpG . Each ho r izon ta l l ine rep resen ts a sequenced c lone and each numbe r rep resen ts a CpG s i te d isp layed in the ca r toon rep resen ta t ion o f t ransc r ip t iona l s ta r t . (C ) G raph ica l summa ry fo r the ave rage % CpG me thy la t ion in Id2 , P r f1 (pe r fo r in ) , PD-1 , and GzmB (g ranzyme b ) loc i . Da ta rep resen ts mean +/- SEM (n=2-6 hea l thy dono rs ) . Seve ra l s tud ies have demons t ra ted tha t CD8 T ce l l exhaus t ion gene exp ress ion p rog rams can become re in fo rced and he r i tab ly ma in ta ined . 50- 52 T ransc r ip t iona l memo ry is o f ten med ia ted by ep igene t ic mod i f ica t ion to the genome , the re fo re we hypo thes ize tha t acqu i red exhaus t ion- spec i f ic ep igene t ic p rog rams mus t be e rased in o rde r fo r PD-1 b lockade to be e f fec t ive on a l l exhaus ted T ce l ls . In suppo r t o f th is hypo thes is , we have recen t ly de te rm ined tha t cond i t iona l de le t ion o f the DNA me thy l t rans fe rase 3a (Dnm t3a cKO ) inh ib i ts acqu is i t ion o f de novo DNA me thy la t ion p rog rams in an t igen-spec i f ic CD8 T ce l ls and p reven ts T ce l l exhaus t ion du r ing ch ron ic v i ra l in fec t ion (Youngb lood B , unpub l ished da ta ) . Impo r tan t ly , Dnm t3a de f ic ien t an t igen-spec i f ic CD8 T ce l ls re ta in the i r ab i l i ty to moun t a po lyc lona l e f fec to r response , and u l t ima te ly con t ro l the ch ron ic pa thogen . Mo reove r , Dnm t3a cKO ce l ls rema in res is tan t to T ce l l exhaus t ion even when the cKO ce l ls a re fo rced to pe rs is t in an env i ronmen t tha t has a r t i f ic ia l ly h igh leve ls o f an t igen fo r seve ra l mon ths . Ou r da ta se rve as p roo f o f p r inc ip le tha t acqu i red ep igene t ic p rog rams p romo te T ce l l exhaus t ion , and have s ign i f ican t imp l ica t ions fo r gene ra t ing a g rea te r b read th o f long- l ived tumo r- spec i f ic T ce l l responses a f te r immune the rapy . We have recen t ly deve loped p ro toco ls fo r pe r fo rm ing who le-genome me thy la t ion ana lys is us ing low inpu t genom ic DNA . We have app l ied th is me thodo logy to S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
21,page_21,"OSTPDL1 Page 15 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 de te rm ine the ep igene t ic s igna tu re o f func t iona l human memo ry CD8 T ce l ls (F igu re 1 ) . F rom ou r who le-genome ana lys is we have iden t i f ied d i f fe ren t ia l ly me thy la ted reg ions among the T ce l l subse ts . We have deve loped a PCR based assay to measu re the ep igene t ic s igna tu re o f human memo ry CD8 T ce l l subse ts (F igu re 1B & 1C ) . These da ta p rov ide ins igh t in to the po ised s ta te fo r exp ress ion o f c r i t ica l e f fec to r mo lecu les and inh ib i to ry recep to rs among the memo ry CD8 T ce l l subse ts . We p ropose to pe r fo rm loc i-spec i f ic and who le genome b isu l f i te sequenc ing me thy la t ion ana lys is o f PD-1+ CD8 T ce l ls f rom pa t ien ts be fo re and a f te r the rapy w i th ave lumab to iden t i fy ep igene t ic p rog rams tha t a re coup led to the ab i l i ty o f hos t T ce l ls to be re juvena ted fo l low ing PD-1 b lockade the rapy . 2 .7 Ra t iona le fo r Qua l i ty o f L i fe S tud ies Cance r and i ts t rea tmen t can cause med ica l and psychosoc ia l comp l ica t ions tha t adve rse ly a f fec t a pa t ien t ’s qua l i ty o f l i fe (phys ica l , emo t iona l , soc ia l and cogn i t ive func t ion ing ) du r ing and a f te r t rea tmen t . Once comp l ica t ions and the i r ou tcomes a re spec i f ied and measu red , in te rven t ions des igned to p reven t o r d im in ish the comp l ica t ions can be deve loped , imp lemen ted in c l in ica l ca re , and the i r e f fec ts eva lua ted . Un t i l recen t ly , the ma jo r i ty o f s tud ies eva lua t ing qua l i ty o f l i fe in pa t ien ts w i th ch i ldhood cance r had been conduc ted in su rv ivo rsh ip popu la t ions . 53-56 Many o f these s tud ies inc luded s ing le t ime po in ts o f assessmen ts , c ross- sec t iona l des igns , inc lus ion o f on ly one o r a l im i ted numbe r o f qua l i ty o f l i fe doma ins , o r inc luded a he te rogeneous samp le no t spec i f ic to any d iagnos is . 57 , 58 Mo re recen t ly , seve ra l s tud ies have eme rged imp lemen t ing qua l i ty o f l i fe measu res du r ing ac t ive t rea tmen t . 59-63 The ma jo r i ty o f repo r ts o f qua l i ty o f l i fe in os teosa rcoma pa t ien ts tend to invo lve long- te rm su rv ivo rs ra the r than pa t ien ts who a re ac t ive ly unde rgo ing t rea tmen t . 64-66 Two s tud ies inc luded mo re than a s ing le da ta po in t and the se lec ted t ime po in ts va r ied , rang ing f rom end o f t rea tmen t to 8 yea rs a f te r the end o f t rea tmen t o r a t the t ime o f de f in i t ive su rge ry and then annua l ly fo r the nex t th ree yea rs . 67 , 68 A numbe r o f add i t iona l s tud ies ex is t wh ich inc lude pa t ien ts w i th os teosa rcoma a long w i th a va r ie ty o f o the r d iagnoses , o r inc lude pa t ien ts w i th bo th ped ia t r ic and adu l t os teosa rcoma ; da ta a re repo r ted in g roup fash ion and i t is imposs ib le to ex t rac t sco res spec i f ic to pa t ien ts w i th os teosa rcoma . 69-78 A p rospec t ive s tudy o f pa t ien ts w i th h igh g rade , loca l ized os teosa rcoma eva lua ted hea l th- re la ted qua l i ty o f l i fe (HRQOL ) and symp tom d is t ress a t fou r t ime po in ts inc lud ing d iagnos is , p r io r to de f in i t ive su rge ry , app rox ima te ly 2 mon ths pos t-su rge ry , and 3 to 6 mon ths a f te r comp le t ion o f t rea tmen t . S ign i f ican t imp rovemen ts in mos t doma ins and dec reases in symp tom d is t ress we re demons t ra ted ac ross t ime po in ts du r ing the rapy . 63 The in te rna t iona l co l labo ra t ive EURAMOS t r ia l fo r new ly d iagnosed os teosa rcoma pa t ien ts inc luded se l f- and S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
22,page_22,"OSTPDL1 Page 16 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 pa ren t- repo r ted qua l i ty o f l i fe measu res us ing the EORTC QLQ-C30 ques t ionna i re ; resu l ts have no t ye t been repo r ted . 79 Repea ted qua l i ty o f l i fe measu remen ts tha t a re l inked to spec i f ic c l in ica l ind ica to rs may resu l t in mo re c l in ica l ly use fu l and in te rp re tab le f ind ings . Fu r the rmo re , l i t t le to no da ta ex is t exam in ing hea l th- re la ted qua l i ty o f l i fe measu res in pa t ien ts w i th recu r ren t os teosa rcoma . Be t te r unde rs tand ing o f HRQOL ou tcomes may iden t i fy oppo r tun i t ies to imp rove t rea tmen t- re la ted mo rb id i t ies , fac i l i ta te dec is ion mak ing , es tab l ish e f fec t ive commun ica t ion s t ra teg ies and imp rove sa t is fac t ion w i th ca re fo r pa t ien ts and the i r fam i l ies . 80 , 81 In the se t t ing o f a d isease wh ich has p rev ious ly demons t ra ted poo r p rognos is a f te r p rog ress ion o r recu r rence , HRQOL measu res may a id in the iden t i f ica t ion o f reasonab le the rapeu t ic app roaches tha t a l low fo r op t im iza t ion o f pa t ien ts ’ qua l i ty o f l i fe in ba lance w i th t rea tmen t goa ls . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
23,page_23,"OSTPDL1 Page 17 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 2 .7 .1Pa t ien t Repo r ted Ou tcome Measu remen t In fo rma t ion Sys tem (PROM IS ) – Ped ia t r ic and Adu l t P ro f i les The PROM IS is a se t o f ques t ionna i res u t i l ized to assess pa t ien t repo r ted ou tcomes (PROs ) cons is ten t w i th goa ls es tab l ished by the Na t iona l Ins t i tu te o f Hea l th (N IH ) . The PROM IS Ped ia t r ic P ro f i le (se l f- repo r t ) is va l ida ted fo r use w i th ind iv idua ls ages 8 to 17 yea rs , and the PROM IS Adu l t P ro f i le (se l f- repo r t ) is va l ida ted fo r ind iv idua ls ages 18 yea rs and o lde r . Bo th the PROM IS Ped ia t r ic and Adu l t P ro f i les inc lude PROs ac ross a numbe r o f doma ins inc lud ing : 1 ) phys ica l func t ion mob i l i ty , 2 ) anx ie ty , 3 ) dep ress ive symp toms , 4 ) fa t igue , 5 ) pee r re la t ionsh ips , and 6 ) pa in in te r fe rence . On doma ins o the r than the phys ica l func t ion mob i l i ty doma in , responden ts ra te how o f ten s ta temen ts desc r ibe the i r func t ion ing . Fo r the phys ica l func t ion mob i l i ty doma in , pa r t ic ipan ts use a 5-po in t L ike r t ra t ing sca le to ra te how much d i f f icu l ty is expe r ienced w i th engagemen t in va r ious ac t iv i t ies . Sco r ing tab les a re then used to conve r t raw sco res fo r each doma in in to age-no rmed T-sco res . The PROM IS measu res have demons t ra ted s t rong psychome t r ic p rope r t ies . 82 L i te ra tu re is ava i lab le fo r i ts use in ped ia t r ic onco logy resea rch , 83 , 84 as we l l as in adu l ts w i th lowe r ex t rem i ty bone me tas tases . 85 The PROM IS measu res have shown known-g roup va l id i ty w i th ab i l i ty to d is t ingu ish subg roups o f ch i ld ren w i th a ch ron ic hea l th cond i t ion f rom o the r cond i t ions as we l l as gene ra l popu la t ion samp les . 86 , 87 Add i t iona l ly , the ab i l i ty to de te rm ine a c l in ica l m in ima l ly impo r tan t d i f fe rence has been es tab l ished w i th the PROM IS ques t ionna i res , wh ich has been a me thodo log ica l l im i ta t ion o f o the r HRQOL ins t rumen ts . 88 Pa t ien ts w i l l comp le te the PROM IS Ped ia t r ic o r Adu l t P ro f i le (based on the i r age a t t ime o f adm in is t ra t ion ) a t fou r t ime po in ts du r ing the s tudy : a t d iagnos is p r io r to the s ta r t o f t rea tmen t , a t the end o f cyc le 2 (8 weeks + 1 week ) , a t the end o f cyc le 4 (16 weeks + 1 week ) , and a t end o f ave lumab the rapy . M ixed e f fec t mode ls w i l l be pe r fo rmed to assess changes in qua l i ty o f l i fe doma ins ove r t ime and to assess fo r impac t o f c l in ica l fac to rs on sco res in qua l i ty o f l i fe doma ins . 3 .0 EL IG IB IL ITY CR ITER IA AND STUDY ENROLLMENT Acco rd ing to ins t i tu t iona l and N IH po l icy , the s tudy w i l l access ion resea rch pa r t ic ipan ts rega rd less o f gende r and e thn ic backg round . Ins t i tu t iona l expe r ience con f i rms b road rep resen ta t ion in th is rega rd . A l l c l in ica l and labo ra to ry s tud ies to de te rm ine e l ig ib i l i ty mus t be pe r fo rmed w i th in 7 days p r io r to en ro l lmen t un less o the rw ise ind ica ted . Labo ra to ry va lues used to assess e l ig ib i l i ty mus t be no o lde r than 7 days a t the s ta r t o f the rapy . I f a pos t-en ro l lmen t lab va lue is ou ts ide the l im i ts o f e l ig ib i l i ty , o r labo ra to ry va lues a re > 7 days o ld , then the fo l low ing labo ra to ry eva lua t ions mus t be re-checked w i th in 48 hou rs p r io r to S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
24,page_24,"OSTPDL1 Page 18 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 in i t ia t ing the rapy : CBC w i th d i f fe ren t ia l , b i l i rub in , ALT (SGPT ) and se rum c rea t in ine . Imag ing s tud ies , whe re app l icab le , mus t be ob ta ined w i th in 2 weeks p r io r to en ro l lmen t . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
25,page_25,"OSTPDL1 Page 19 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 3 .1 Inc lus ion C r i te r ia 3 .1 .1Pa t ien ts mus t be > 12 yea rs o f age bu t < 50 yea rs o f age a t the t ime o f en ro l lmen t . 3 .1 .2Pa t ien ts mus t have h is to log ic ve r i f ica t ion o f os teosa rcoma a t in i t ia l d iagnos is o r re lapse . 3 .1 .3Pa t ien ts mus t have had ev idence o f hav ing re lapsed , p rog ressed o r become re f rac to ry to conven t iona l the rapy . 3 .1 .4Pa t ien ts mus t have measu rab le d isease , documen ted by c l in ica l , rad iog raph ic o r h is to log ic c r i te r ia . D isease mus t be b i- d imens iona l ly measu rab le by compu ted tomog raphy (CT ) o r magne t ic resonance imag ing (MR I ) . 3 .1 .5Pa t ien ts mus t have a pe r fo rmance s ta tus o f ≥ 50 us ing the Ka rno fsky sca le fo r pa t ien ts > 16 yea rs o f age and the Lansky sca le fo r pa t ien ts ≤ 16 yea rs o f age . 3 .1 .6Pa t ien ts mus t have a l i fe expec tancy o f ≥ 6 weeks . 3 .1 .7Pa t ien ts mus t have fu l ly recove red f rom the acu te tox ic e f fec ts o f a l l p r io r chemo the rapy , immuno the rapy , o r rad io the rapy p r io r to en te r ing th is s tudy . a .Mye losupp ress ive chemo the rapy : mus t no t have rece ived w i th in 3 weeks o f en t ry on to th is s tudy b .B io log ic (an t i-neop las t ic agen t ) : a t leas t 7 days s ince the comp le t ion o f the rapy w i th a b io log ic agen t . c .Immuno the rap ies : a t leas t 42 days mus t have e lapsed s ince a p r io r the rapy tha t inc luded a monoc lona l an t ibody o r any o the r type o f immuno the rapy (e .g . ch ime r ic an t igen recep to r (CAR ) T ce l l the rapy ) . d .Rad ia t ion the rapy (RT ) : ≥ 2 weeks fo r loca l pa l l ia t ive RT (sma l l po r t ) ; ≥ 6 mon ths mus t have e lapsed i f p r io r c ran iosp ina l RT o r i f ≥ 50% rad ia t ion o f the pe lv is ; ≥ 6 weeks mus t have e lapsed i f o the r subs tan t ia l bone ma r row (BM ) rad ia t ion . 3 .1 .8O rgan Func t ion Requ i remen ts : a .Adequa te bone ma r row func t ion de f ined as : ·Pe r iphe ra l abso lu te neu t roph i l coun t (ANC ) ≥ 1500/mm 3 ·P la te le t coun t ≥ 100 ,000/mm 3 ( t rans fus ion independen t ) ·Hemog lob in ≥ 9 .0 g/dL (may rece ive RBC t rans fus ions ) S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
26,page_26,"OSTPDL1 Page 20 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 b .Adequa te rena l func t ion de f ined as : ·C rea t in ine c lea rance o r rad io iso tope GFR ≥70 mL/m in/1 .73m 2 OR ·Se rum c rea t in ine based on age/gende r as fo l lows : ( th resho ld c rea t in ine va lues we re de r ived f rom the Schwa r tz fo rmu la fo r es t ima t ing GFR ) 89 Age Max imum c rea t in ine (mg/DL ) Ma le Fema le 12 to < 13 yea rs 1 .2 1 .2 13 to <16 yea rs 1 .5 1 .4 ≥ 16 yea rs 1 .7 1 .4 c .Adequa te l ive r func t ion de f ined as : ·To ta l B i l i rub in ≤ 1 .5x the ins t i tu t iona l uppe r l im i t o f no rma l ( IULN ) fo r age ·ALT (SGPT ) and AST (SGOT ) < 2 .5 x IULN fo r age (o r < 5 x IULN fo r pa t ien ts w i th documen ted me tas ta t ic d isease to the l ive r ) ·Se rum a lbum in > 2 g/dL d .Se rum l ipase ≤ uppe r l im i t o f no rma l ( IULN ) . e .Pa t ien ts mus t have documen ted pu lse ox ime t ry ≥ 92% on room a i r . 3 .1 .9Fema le pa t ien ts o f ch i ldbea r ing po ten t ia l mus t have a nega t ive se rum o r u r ine p regnancy tes t w i th in 7 days o f en ro l lmen t . 3 .1 .10 Ma le o r fema le pa t ien ts who a re sexua l ly ac t ive and o f rep roduc t ive po ten t ia l mus t ag ree to use an e f fec t ive con t racep t ive me thod th roughou t the s tudy and fo r a t leas t 60 days a f te r las t ave lumab t rea tmen t adm in is t ra t ion . Abs t inence is an accep tab le fo rm o f con t racep t ion . 3 .1 .11 Pa t ien ts mus t no t cu r ren t ly be us ing o the r inves t iga t iona l agen ts . 3 .1 .12 Pa t ien ts mus t no t cu r ren t ly be us ing o the r an t i-cance r agen t . 3 .1 .13 Pa t ien ts mus t be ab le to comp ly w i th the sa fe ty mon i to r ing o f the s tudy in the op in ion o f the inves t iga to r . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
27,page_27,"OSTPDL1 Page 21 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 3 .1 .14 W r i t ten , in fo rmed consen t and assen t fo l low ing Ins t i tu t iona l Rev iew Boa rd , NC I , FDA and OHRP gu ide l ines . 3 .2 Exc lus ion C r i te r ia 3 .2 .1Cen t ra l ne rvous sys tem (CNS ) me tas tases . 3 .2 .2Cu r ren t use o f immunosupp ress ive med ica t ion , EXCEPT fo r the fo l low ing : a . in t ranasa l , inha led , top ica l s te ro ids , o r loca l s te ro id in jec t ion (e .g . , in t ra-a r t icu la r in jec t ion ) ; b . Sys tem ic co r t icos te ro ids a t phys io log ic doses ≤ 10 mg/day o f p redn isone o r equ iva len t ; c . S te ro ids as p remed ica t ion fo r hype rsens i t iv i ty reac t ions (e .g . , CT scan p remed ica t ion ) . 3 .2 .3Ac t ive au to immune d isease tha t m igh t de te r io ra te when rece iv ing an immuno-s t imu la to ry agen t . Pa t ien ts w i th d iabe tes type I , v i t i l igo , pso r ias is , o r hypo- o r hype r thy ro id d iseases no t requ i r ing immunosupp ress ive t rea tmen t a re e l ig ib le . 3 .2 .4Ac t ive in fec t ion requ i r ing sys tem ic the rapy . 3 .2 .5Known h is to ry o f tes t ing pos i t ive fo r H IV o r known acqu i red immunode f ic iency synd rome . 3 .2 .6Hepa t i t is B v i rus (HBV ) o r hepa t i t is C v i rus (HCV ) in fec t ion a t sc reen ing (pos i t ive HBV su r face an t igen o r HCV RNA i f an t i-HCV an t ibody sc reen ing tes t pos i t ive ) . 3 .2 .7Pa t ien t who has rece ived vacc ina t ion w i th in 4 weeks o f the f i rs t dose o f ave lumab and wh i le on t r ia ls is p roh ib i ted excep t fo r adm in is t ra t ion o f inac t iva ted vacc ines . 3 .2 .8Known p r io r seve re hype rsens i t iv i ty to inves t iga t iona l p roduc t o r any componen t in i ts fo rmu la t ions , inc lud ing known seve re hype rsens i t iv i ty reac t ions to monoc lona l an t ibod ies (NC I CTCAE v4 .03 G rade ≥ 3 ) . 3 .2 .9C l in ica l ly s ign i f ican t ( i .e . , ac t ive ) ca rd iovascu la r d isease : ce reb ra l vascu la r acc iden t/s t roke (< 6 mon ths p r io r to en ro l lmen t ) , myoca rd ia l in fa rc t ion (< 6 mon ths p r io r to en ro l lmen t ) , uns tab le ang ina , conges t ive hea r t fa i lu re (≥ New Yo rk Hea r t Assoc ia t ion C lass i f ica t ion C lass I I , see Append ix I I ) , o r se r ious ca rd iac a r rhy thm ia requ i r ing med ica t ion . 3 .2 .10 Pe rs is t ing tox ic i ty re la ted to p r io r the rapy (NC I CTCAE v . 4 .03 G rade > 1 ) ; howeve r , a lopec ia , senso ry neu ropa thy G rade ≤ 2 , o r S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
28,page_28,"OSTPDL1 Page 22 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 o the r G rade ≤ 2 no t cons t i tu t ing a sa fe ty r isk based on inves t iga to r ’s judgmen t a re accep tab le 3 .2 .11 O the r seve re acu te o r ch ron ic med ica l cond i t ions inc lud ing co l i t is , in f lamma to ry bowe l d isease , pneumon i t is , pu lmona ry f ib ros is o r psych ia t r ic cond i t ions inc lud ing recen t (w i th in the pas t yea r ) o r ac t ive su ic ida l idea t ion o r behav io r ; o r labo ra to ry abno rma l i t ies tha t may inc rease the r isk assoc ia ted w i th s tudy pa r t ic ipa t ion o r s tudy t rea tmen t adm in is t ra t ion o r may in te r fe re w i th the in te rp re ta t ion o f s tudy resu l ts and , in the judgmen t o f the inves t iga to r , wou ld make the pa t ien t inapp rop r ia te fo r en t ry in to th is s tudy . 3 .2 .12 Pa t ien ts w i th ac t ive d ia r rhea > CTCAE v4 .03 G rade 2 . 3 .2 .13 Pa t ien ts who have p rev ious ly rece ived a p r io r o rgan t ransp lan ta t ion , inc lud ing a l logene ic s tem ce l l t ransp lan ta t ion . 3 .2 .14 Fema le pa t ien ts who a re p regnan t o r ac t ive ly b reas t feed ing . 3 .2 .15 Pa t ien ts who have p rev ious ly rece ived an t i-PD1 o r an t i-PD- L1 the rapy . Pa t ien ts who have p rev ious ly rece ived an t i-CTLA-4 the rapy (e .g . ip i l imumab ) a re e l ig ib le fo r s tudy . 3 .3 Rec ru i tmen t and Sc reen ing Pa r t ic ipan ts w i l l be rec ru i ted by s tudy inves t iga to rs th rough the i r c l in ica l p rac t ice . 3 .4 En ro l lmen t a t S t . Jude A membe r o f the s tudy team w i l l con f i rm po ten t ia l pa r t ic ipan t e l ig ib i l i ty as de f ined in Sec t ion 3 .1-3 .2 , comp le te and s ign the ‘Pa r t ic ipan t E l ig ib i l i ty Check l is t ’ . The s tudy team w i l l en te r the e l ig ib i l i ty check l is t in fo rma t ion in to the Pa t ien t P ro toco l Manage r (PPM ) sys tem . E l ig ib i l i ty w i l l be rev iewed , and a resea rch pa r t ic ipan t-spec i f ic consen t fo rm and assen t documen t (whe re app l icab le ) w i l l be gene ra ted . The comp le te s igned consen t / assen t fo rm (s ) mus t be faxed o r ema i led to the CPDMO a t 595- 6265 to comp le te the en ro l lmen t p rocess . The CPDMO is s ta f fed 7 :30 am-5 :00 pm CST , Monday th rough F r iday . A s ta f f membe r f rom the S t . Jude Ce rne r M i l lenn ium (M ILL I ) he lp l ine is on ca l l Sa tu rday , Sunday , and ho l idays f rom 8 :00 am to 6 :00 pm . I f you have a p rospec t ive resea rch en ro l lmen t and need ass is tance re leas ing you r consen t , p lease ca l l the M ILL I he lp l ine (901-338-0596 ) on ca l l numbe r . 3 .5 En ro l lmen t a t Co l labo ra t ing S i tes S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
29,page_29,"OSTPDL1 Page 23 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Co l labo ra t ing S i te resea rch pa r t ic ipan ts shou ld be reg is te red a t S t . Jude w i th in 24 hou rs o f en ro l lmen t a t the s i te . The comp le ted E l ig ib i l i ty Check l is t and en t i re s igned In fo rmed Consen t shou ld be faxed to 901- 595-6265 . P lease ca l l 901-595-2568 i f con f i rma t ion o f the en ro l lmen t in fo rma t ion is needed . The P ro toco l E l ig ib i l i ty Coo rd ina to r w i l l then reg is te r the resea rch pa r t ic ipan t in the Pa t ien t P ro toco l Manage r (PPM ) sys tem . 4 .0 TREATMENT PLAN 4 .1 Ove rv iew o f T rea tmen t P lan Th is is a s ing le a rm phase 2 s tudy w i th a two s tage des ign and an endpo in t spec i f ic to os teosa rcoma . Ave lumab w i l l be g iven on days 1 and 15 o f each 4 week cyc le . T rea tmen t w i l l be d iscon t inued i f the re is c lea r ev idence o f p rog ress ion w i th inc rease in tumo r s ize g rea te r than 20% , o r w i th d rug re la ted dose l im i t ing tox ic i ty tha t requ i res remova l f rom the rapy , as de f ined in Sec t ion 10 .1 . The rapy may o the rw ise con t inue fo r a max imum du ra t ion o f 24 mon ths o r 26 cyc les , wh icheve r occu rs f i rs t . In i t ia l rad iog raph ic assessmen ts w i l l take p lace a f te r cyc le 2 and cyc le 4 and w i l l be compa red to imag ing ob ta ined p r io r to in i t ia t ion o f the rapy . Fo r pa t ien ts who rema in on p ro toco l the rapy , imag ing the rea f te r w i l l take p lace eve ry 3 rd cyc le . 4 .2 T rea tmen t Du r ing Cyc le 1 and Subsequen t Cyc les One cyc le o f ave lumab t rea tmen t is desc r ibed be low . A cyc le may be repea ted eve ry 28 days i f the pa t ien t has a t leas t s tab le d isease and has me t labo ra to ry pa rame te rs as de f ined in the e l ig ib i l i ty sec t ion , and de ta i led be low . 4 .2 .1P remed ica t ion In o rde r to m i t iga te in fus ion- re la ted reac t ions , a p remed ica t ion w i th an an t ih is tam ine and w i th pa race tamo l (ace tam inophen ) 30 to 60 m inu tes p r io r to each dose o f ave lumab is manda to ry ( fo r examp le , 25-50 mg d iphenhyd ram ine and 500-650 mg pa race tamo l IV o r o ra l ) . Th is may be mod i f ied based on loca l t rea tmen t s tanda rds and gu ide l ines , as app rop r ia te . 4 .2 .2Se t t ing Ave lumab shou ld be adm in is te red in a se t t ing tha t a l lows fo r immed ia te access to an in tens ive ca re un i t o r equ iva len t env i ronmen t and adm in is t ra t ion o f the rapy fo r anaphy lax is , such as the ab i l i ty to imp lemen t immed ia te resusc i ta t ion measu res . S te ro ids (dexame thasone 10mg ) , ep ineph r ine (1 :1 ,000 d i lu t ion ) , a l le rgy S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
30,page_30,"OSTPDL1 Page 24 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 med ica t ions ( IV an t ih is tam ines ) , b ronchod i la to rs , o r equ iva len ts , and oxygen shou ld be ava i lab le fo r immed ia te access . 4 .2 .3Obse rva t ion Pe r iod Fo l low ing ave lumab in fus ions , pa t ien ts mus t be obse rved fo r 2 hou rs pos t- in fus ion fo r po ten t ia l in fus ion- re la ted reac t ions . 4 .2 .4Ave lumab Adm in is t ra t ion P r io r to ave lumab in fus ion : D iphenhyd ram ine : IV ove r 5-15 m inu tes (pe r ins t i tu t iona l gu ide l ines ) Days : 1 and 15 Dose : 1 mg/kg (MAX 50mg ) No te : Equ iva len t an t ih is tam ine the rapy may be cons ide red . Ace tam inophen : By mou th (PO ) Days : 1 and 15 Dose : 10-15 mg/kg (MAX 1000mg ) No te : In the se t t ing o f l im i ted PO in take and pe r ins t i tu t iona l gu ide l ines , IV ace tam inophen may be cons ide red . Ave lumab in fus ion : Ave lumab : In t ravenous ly ove r 60 m inu tes Days : 1 and 15 Dose : 10 mg/kg/dose 4 .3 C r i te r ia fo r S ta r t ing Subsequen t Cyc les A cyc le may be repea ted eve ry 28 days i f the pa t ien t has aga in me t the pa rame te rs fo r o rgan func t ion requ i remen ts as de f ined in the e l ig ib i l i ty c r i te r ia (Sec t ion 3 .0 ) , has no t me t any o f the c r i te r ia fo r remova l f rom the rapy , and has no t expe r ienced a dose l im i t ing tox ic i ty . A de lay o f up to 7 days f rom the schedu led da te o f the nex t schedu led t rea tmen t dose may be a l lowed . 5 .0 DOSE MOD IF ICAT IONS FOR TOX IC IT IES 5 .1 Adve rse D rug Reac t ions Requ i r ing Ave lumab D iscon t inua t ion o r Mod i f ica t ion Any G rade 4 ADRs requ i re t rea tmen t d iscon t inua t ion w i th ave lumab excep t fo r s ing le labo ra to ry va lues ou t o f no rma l range tha t a re un l ike ly re la ted to s tudy t rea tmen t as assessed by the Inves t iga to r , do no t have any c l in ica l co r re la te , and reso lve w i th in 7 days w i th adequa te med ica l managemen t . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
31,page_31,"OSTPDL1 Page 25 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Any G rade 3 ADRs requ i re t rea tmen t d iscon t inua t ion w i th ave lumab excep t fo r any o f the fo l low ing : ·T rans ien t (≤ 6 hou rs ) G rade 3 f lu- l ike symp toms o r feve r , wh ich is con t ro l led w i th med ica l managemen t ·T rans ien t (≤ 24 hou rs ) G rade 3 fa t igue , loca l reac t ions , headache , nausea , emes is tha t reso lves to G rade ≤ 1 ·S ing le labo ra to ry va lues ou t o f no rma l range (exc lud ing G rade ≥ 3 l ive r func t ion tes t inc rease ) tha t a re un l ike ly re la ted to s tudy t rea tmen t acco rd ing to the Inves t iga to r , do no t have any c l in ica l co r re la te , and reso lve to G rade ≤ 1 w i th in 7 days w i th adequa te med ica l managemen t ·Tumo r f la re phenomenon de f ined as loca l pa in , i r r i ta t ion , o r rash loca l ized a t s i tes o f known o r suspec ted tumo r ·G rade 3 rash tha t reso lves to G rade ≤ 1 w i th s te ro id t rea tmen t ·Change in ECOG PS to ≥ 3 tha t does no t reso lve to £ 2 w i th in 14 days ( in fus ions shou ld no t be g iven on the fo l low ing cyc le , i f the ECOG PS is ≥ 3 on the day o f s tudy d rug adm in is t ra t ion ) Any G rade 2 ADR shou ld be managed as fo l lows : ·I f a G rade 2 ADR reso lves to G rade ≤ 1 by the las t day o f the cu r ren t cyc le , t rea tmen t may con t inue . ·Upon the second occu r rence o f the same G rade 2 ADR (excep t fo r ho rmone insu f f ic ienc ies tha t can be managed by rep lacemen t the rapy ) in the same pa r t ic ipan t , t rea tmen t w i th ave lumab has to be pe rmanen t ly d iscon t inued . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
32,page_32,"OSTPDL1 Page 26 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 5 .2 T rea tmen t Mod i f ica t ion fo r Symp toms o f In fus ion-Re la ted Reac t ions In o rde r to m i t iga te in fus ion- re la ted reac t ions , a l l pa r t ic ipan ts w i l l rece ive p re t rea tmen t w i th H1 b locke rs and ace tam inophen 30 to 60 m inu tes p r io r to each in fus ion . A p remed ica t ion reg imen o f 1 mg/kg d iphenhyd ram ine (MAX 50 mg ) and 10-15mg/kg ace tam inophen (MAX 1000 mg ) is recommended p r io r to each dose o f d rug . Pa r t ic ipan ts mus t be obse rved fo r 2 hou rs pos t- in fus ion . Th is reg imen may be mod i f ied based on loca l t rea tmen t s tanda rds and gu ide l ines as app rop r ia te . NC I-CTCAE G rade T rea tmen t Mod i f ica t ion fo r S tudy D rug G rade 1 – m i ld M i ld t rans ien t reac t ion ; in fus ion in te r rup t ion no t ind ica ted ; in te rven t ion no t ind ica ted . Dec rease the s tudy d rug in fus ion ra te by 50% and mon i to r c lose ly fo r any wo rsen ing . The to ta l in fus ion t ime fo r s tudy d rug shou ld no t exceed 120 m inu tes . G rade 2 – mode ra te The rapy o r in fus ion in te r rup t ion ind ica ted bu t responds p romp t ly to symp toma t ic t rea tmen t ( fo r examp le , an t ih is tam ines , NSA IDs , na rco t ics , IV f lu ids ) ; p rophy lac t ic med ica t ions ind ica ted fo r £ 24 h . S top s tudy d rug in fus ion . Resume in fus ion a t 50% o f p rev ious ra te once in fus ion- re la ted reac t ion has reso lved o r dec reased to a t leas t G rade 1 in seve r i ty , and mon i to r c lose ly fo r any wo rsen ing . G rade 3 o r G rade 4 – seve re o r l i fe- th rea ten ing G rade 3 : P ro longed ( fo r examp le , no t rap id ly respons ive to symp toma t ic med ica t ion and/o r b r ie f in te r rup t ion o f in fus ion ) ; recu r rence o f symp toms fo l low ing in i t ia l imp rovemen t ; hosp i ta l iza t ion ind ica ted fo r c l in ica l seque lae . G rade 4 : L i fe- th rea ten ing consequences ; u rgen t in te rven t ion ind ica ted . S top the s tudy d rug in fus ion immed ia te ly and d isconnec t in fus ion tub ing f rom the pa r t ic ipan t . Pa r t ic ipan ts have to be w i thd rawn immed ia te ly f rom s tudy d rug t rea tmen t and mus t no t rece ive any fu r the r s tudy d rug t rea tmen t . ·Once the ave lumab in fus ion ra te has been dec reased by 50% o r in te r rup ted due to an in fus ion- re la ted reac t ion , i t mus t rema in dec reased fo r a l l subsequen t in fus ions . ·I f the pa t ien t has a second in fus ion- re la ted reac t ion G rade ≥ 2 on the s lowe r in fus ion ra te , the in fus ion shou ld be s topped and the pa t ien t shou ld be removed f rom s tudy t rea tmen t . ·I f hype rsens i t iv i ty reac t ion occu rs , the pa t ien t mus t be t rea ted acco rd ing to the bes t ava i lab le med ica l p rac t ice . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
33,page_33,"OSTPDL1 Page 27 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
34,page_34,"OSTPDL1 Page 28 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 5 .2 .1Seve re Hype rsens i t iv i ty Reac t ion Hype rsens i t iv i ty reac t ions mus t be t rea ted acco rd ing to bes t med ica l p rac t ices . Pa t ien ts shou ld a lso be ins t ruc ted to repo r t any de layed reac t ions to the inves t iga to r immed ia te ly : a .Symp toms : Impa i red a i rway , dec reased oxygen sa tu ra t ion (<92% ) , con fus ion , le tha rgy , hypo tens ion , pa le/c lammy sk in , cyanos is b .Managemen t : ep ineph r ine in jec t ion , dexame thasone (o r equ iva len t ) in fus ion , con t inuous mon i to r ing , and po ten t ia l ICU managemen t Pa t ien ts who expe r ience an acu te seve re hype rsens i t iv i ty reac t ion shou ld no longe r rece ive ave lumab the rapy . 5 .2 .2In f luenza-L ike Symp toms Fo r p rophy lax is o f in f luenza- l ike symp toms , pa t ien ts may rece ive a non- s te ro ida l an t i- in f lamma to ry d rug (NSA ID ) such as ibup ro fen 10mg/kg (MAX 800 mg ) o r nap roxen sod ium 10mg/kg (MAX 500 mg ) may be adm in is te red 2 hou rs be fo re and 8 hou rs a f te r the s ta r t o f each ave lumab in fus ion . 5 .2 .3Tumo r Lys is Synd rome Because ave lumab can induce ADCC , the re is a po ten t ia l r isk o f tumo r lys is synd rome . Shou ld th is occu r , pa r t ic ipan ts shou ld be t rea ted as pe r loca l gu ide l ines fo r tumo r lys is synd rome inc lud ing IV f lu ids , f requen t mon i to r ing o f e lec t ro ly tes (u r ic ac id , K +, Ca ++ , PO 4) , and use o f a l lopu r ino l o r rasbu r icase as needed . 5 .3 Managemen t o f Immune-Med ia ted Adve rse Reac t ions S ince inh ib i t ion o f PD-L1 s t imu la tes the immune sys tem , immune- re la ted AEs ( i rAEs ) may occu r . T rea tmen t o f i rAEs is ma in ly dependen t upon seve r i ty (NC I-CTCAE g rade ) : ·G rade 1 to 2 : t rea t symp toma t ica l ly o r w i th mode ra te dose s te ro ids , mo re f requen t mon i to r ing . ·G rade 1 to 2 (pe rs is ten t ) : manage s im i la r to h igh g rade AE (G rade 3 to 4 ) ·G rade 3 to 4 : t rea t w i th h igh dose co r t icos te ro ids T rea tmen t o f gas t ro in tes t ina l , de rma to log ica l , pu lmona ry , hepa t ic and endoc r ine i rAEs shou ld fo l low gu ide l ines se t fo r th be low . Fo r G rade 2 tox ic i t ies requ i r ing de lay o f ave lumab the rapy as l is ted in the tab les be low , s tudy d rug shou ld be he ld un t i l < G rade 1 . Pa t ien ts who S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
35,page_35,"OSTPDL1 Page 29 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 expe r ience G rade 2 tox ic i t ies tha t do no t reso lve to < G rade 1 desp i te symp toma t ic/med ica l in te rven t ion w i th in 14 days shou ld have s tudy d rug d iscon t inued ; in the se t t ing o f c l in ica l bene f i t , inves t iga to rs may d iscuss con t inua t ion o f s tudy d rug w i th the P I on a case-by-case bas is . Gas t ro in tes t ina l i rAEs I t is recommended tha t co l i t is o r en te roco l i t is o f G rade 1 be eva lua ted fo r o the r non- immune med ia ted causes , then mon i to red c lose ly and t rea ted symp toma t ica l ly w i thou t s te ro ids , inc lud ing a t r ia l o f lope ram ide may be used . Fo r G rade ≥ 2 co l i t is o r en te roco l i t is , recommenda t ions inc lude endoscopy . Even i f co lonoscopy does no t revea l g ross f ind ings o f co l i t is , b iops ies shou ld be pe r fo rmed and s t rong cons ide ra t ion shou ld be g iven to uppe r endoscopy and b iops ies . Pa t ien ts w i th g ross o r b iopsy p roven co l i t is o r en te r i t is shou ld rece ive IV s te ro ids ( recommend 1 mg/kg me thy lp redn isone da i ly x 7 days ) fo l lowed by a m in imum 30 day tape r . In pa t ien ts w i th G rade 3 o r 4 en te roco l i t is tha t does no t respond to h igh dose s te ro ids a f te r 7 days , fu r the r the rap ies shou ld be adm in is te red as c l in ica l ly ind ica ted in consu l ta t ion w i th gas t roen te ro logy subspec ia l is ts . Conce rn fo r immune-med ia ted l ive r tox ic i ty may be e l ic i ted fo l low ing hepa t ic enzyme (AST , ALT ) e leva t ion o f 3- fo ld ove r base l ine and/o r r igh t uppe r quad ran t abdom ina l pa in o r unexp la ined nausea o r vom i t ing . O the r e t io log ies fo r t ransam in i t is shou ld be cons ide red and eva lua ted and may inc lude bu t a re no t l im i ted to neop las t ic , concu r ren t med ica t ions , v i ra l hepa t i t is , and o the r tox ic e t io log ies . Eva lua t ion fo r au to immune e t io log ies may be eva lua ted by ANA , pANC , and an t i-smoo th musc le an t ibody tes ts as we l l as hepa to logy consu l ta t ion w i th poss ib le b iopsy . Panc rea t i t is has ra re ly been assoc ia ted w i th checkpo in t inh ib i to rs and shou ld be cons ide red in cases o f abdom ina l pa in assoc ia ted w i th e leva t ions o f amy lase and l ipase . T rea tmen t o f panc rea t i t is shou ld be suppo r t ive and may inc lude consu l ta t ion w i th gas t roen te ro logy subspec ia l is ts . G rade 3 o r 4 amy lase o r l ipase abno rma l i t ies tha t a re no t assoc ia ted w i th d iabe tes me l l i tus , assoc ia ted l ive r o r ga l lb ladde r in f lamma t ion , o r c l in ica l man i fes ta t ions o f panc rea t i t is and wh ich dec rease to ≤ G rade 2 w i th in 7 days w i l l no t requ i re d iscon t inua t ion o f ave lumab . Any pa t ien t expe r ienc ing d ia r rhea (wh ich may be de f ined as wa te ry s too l , o r inc rease in the f requency s too ls above g rade 1 w i th u rgency o r noc tu rna l bowe l movemen t , o r me lena o r hema tochez ia ) shou ld be fu r the r eva lua ted fo r e t io logy tha t shou ld inc lude a sea rch fo r an in fec t ious e t io logy , C . D i f f ic i le co l i t is and o the r a l te rna t ive in fec t ions as c l in ica l ly ind ica ted . Cons ide ra t ion shou ld be g iven to d iscon t inu ing med ica t ions known to exace rba te co l i t is . Seve r i ty o f D ia r rhea / Co l i t is (NC I-CTCAE Managemen t Fo l low-up S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
36,page_36,"OSTPDL1 Page 30 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 v4 .03 ) G rade 1 D ia r rhea : < 4 s too ls/day ove r base l ine Co l i t is : asymp toma t ic Con t inue ave lumab the rapy Symp toma t ic t rea tmen t (e .g . lope ram ide ) C lose mon i to r ing fo r wo rsen ing symp toms Educa te pa r t ic ipan t to repo r t wo rsen ing immed ia te ly I f wo rsens : t rea t as G rade 2 o r 3 to 4 . G rade 2 D ia r rhea : 4 to 6 s too ls/day ove r base l ine ; IV f lu ids ind ica ted < 24 hou rs , no t in te r fe r ing w i th ADLs Co l i t is : abdom ina l pa in , b lood in s too l De lay ave lumab the rapy Symp toma t ic t rea tmen t I f imp roves to G rade 1 w i th in 7 days , resume ave lumab the rapy I f pe rs is ts > 5 to 7 days o r recu r : 0 .5-1 .0 mg/kg/day me thy lp redn iso lone (o r equ iva len t ) . When symp toms imp rove to G rade 1 , tape r s te ro ids ove r a t leas t 1 mon th . Cons ide r p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions , and resume ave lumab the rapy pe r p ro toco l . I f wo rsens o r pe rs is ts > 3 to 5 days w i th o ra l s te ro ids : t rea t as g rade 3 to 4 G rade 3 to 4 D ia r rhea (G rade 3 ) : ≥ 7 s too ls/day ove r base l ine ; incon t inence ; IV f lu ids ≥ 24 hou rs ; in te r fe r ing w i th ADLs Co l i t is (G rade 3 ) : seve re abdom ina l pa in , med ica l in te rven t ion ind ica ted , pe r i tonea l s igns G rade 4 : l i fe- th rea ten ing , pe r fo ra t ion D iscon t inue ave lumab the rapy pe r p ro toco l S ta r t 1 .0-2 .0 mg/kg/day me thy lp redn iso lone IV (o r equ iva len t ) Add p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions Cons ide r endoscopy I f imp roves : con t inue s te ro ids un t i l G rade 1 , then tape r ove r a t leas t 1 mon th I f pe rs is ts > 3 to 5 days o r recu rs a f te r imp rovemen t : Add in f l ix imab 5 mg/kg un less o the rw ise con t ra ind ica ted (no te : in f l ix imab shou ld no t be used in cases o f pe r fo ra t ion o r seps is ) De rma to log ica l i rAEs G rade o f Rash (NC I-CTCAE v4 ) Managemen t Fo l low-up G rade 1 to 2 Cove r ing < 30% body su r face a rea Symp toma t ic the rapy ( fo r examp le , an t ih is tam ines , top ica l s te ro ids ) I f pe rs is ts > 1 to 2 weeks o r recu rs : Cons ide r sk in b iopsy S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
37,page_37,"OSTPDL1 Page 31 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Con t inue ave lumab the rapy De lay ave lumab the rapy Cons ide r 0 .5 to 1 .0 mg/kg/day me thy lp redn iso lone IV o r o ra l equ iva len t . Once imp rov ing , tape r s te ro ids ove r a t leas t 1 mon th , cons ide r p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions , and resume ave lumab the rapy . I f wo rsens : T rea t as G rade 3 to 4 G rade 3 to 4 Cove r ing > 30% body su r face a rea ; l i fe- th rea ten ing consequences De lay o r d iscon t inue ave lumab the rapy Cons ide r sk in b iopsy De rma to logy consu l t 1 .0 to 2 .0 mg/kg/day me thy lp redn iso lone IV o r IV equ iva len t I f imp roves to G rade 1 : Tape r s te ro ids ove r a t leas t 1 mon th and add p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions . Resume ave lumab the rapy Pu lmona ry i rAEs G rade o f Pneumon i t is (NC I-CTCAE v4 ) Managemen t Fo l low-up G rade 1 (Rad iog raph ic changes on ly ) Cons ide r de lay o f ave lumab the rapy Mon i to r fo r symp toms eve ry 2 to 3 days Cons ide r Pu lmona ry and In fec t ious D isease consu l ts Re- image a t leas t eve ry 3 weeks I f wo rsens : T rea t as G rade 2 o r G rade 3 to 4 G rade 2 (M i ld to mode ra te new symp toms ) De lay ave lumab the rapy Pu lmona ry and In fec t ious D isease consu l ts Mon i to r symp toms da i ly , cons ide r hosp i ta l iza t ion 1 mg/kg/day me thy lp redn iso lone IV o r o ra l equ iva len t Cons ide r b ronchoscopy , lung b iopsy Re- image eve ry 1 to 3 days I f imp roves : When symp toms re tu rn to nea r base l ine , tape r s te ro ids ove r a t leas t 1 mon th and then resume ave lumab the rapy and cons ide r p rophy lac t ic an t ib io t ics I f no t imp rov ing a f te r 2 weeks o r wo rsen ing : S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
38,page_38,"OSTPDL1 Page 32 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 T rea t as G rade 3 to 4 G rade 3 o r 4 Seve re new symp toms ; new / wo rsen ing hypox ia ; l i fe- th rea ten ing D iscon t inue ave lumab the rapy Hosp i ta l ize Pu lmona ry and ID consu l ts 2 to 4 mg/kg/day me thy lp redn iso lone IV o r equ iva len t Add p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions Cons ide r b ronchoscopy , lung b iopsy I f imp roves to base l ine : Tape r s te ro ids ove r a t leas t 6 weeks I f no t imp rov ing a f te r 48 hou rs o r wo rsen ing : Add add i t iona l immunosupp ress ion (e .g . , in f l ix imab , cyc lophospham ide , in t ravenous immunog lobu l in , o r mycopheno la te mo fe t i l ) Hepa t ic i rAEs G rade o f L ive r Tes t E leva t ion (NC I-CTCAE v4 ) Managemen t Fo l low-up G rade 1 AST o r ALT > IULN to 3 .0 x IULN and/o r to ta l b i l i rub in > IULN to 1 .5 x IULN Con t inue ave lumab the rapy Con t inue l ive r func t ion mon i to r ing I f wo rsens : T rea t as G rade 2 o r 3-4 G rade 2 AST o r ALT > 3 .0 to ≤ 5 x IULN and/o r to ta l b i l i rub in >1 .5 to ≤ 3 x IULN De lay ave lumab the rapy Inc rease f requency o f mon i to r ing to eve ry 3 days I f re tu rns to Base l ine : Resume rou t ine mon i to r ing , resume ave lumab the rapy I f e leva t ions pe rs is t > 5 to 7 days o r wo rsen : 0 .5 to 1 mg/kg/day me thy lp redn iso lone o r o ra l equ iva len t and when LFT re tu rns to G rade 1 o r base l ine , tape r s te ro ids ove r a t leas t 1 mon th , cons ide r p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions , and resume ave lumab the rapy G rade 3 AST o r ALT >5-20 x IULN and/o r to ta l b i l i rub in >3- 10 x IULN G rade 4 AST o r ALT >20 IULN B i l i rub in >10 IULN D iscon t inue ave lumab the rapy Inc rease f requency o f mon i to r ing to eve ry 1-2 days 1 to 2 mg/kg/day me thy lp redn iso lone IV o r I f re tu rns to G rade 2 : Tape r s te ro ids ove r a t leas t 1 mon th I f does no t imp rove in > 3 to 5 days , wo rsens o r rebounds : Add mycopheno la te S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
39,page_39,"OSTPDL1 Page 33 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 IV equ iva len t 2 .0 mg/kg/day Add p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions Consu l t gas t roen te ro log is t Cons ide r ob ta in ing MR I/CT scan o f l ive r and l ive r b iopsy i f c l in ica l ly wa r ran ted mo fe t i l 1 g ram (g ) tw ice da i ly I f no response w i th in an add i t iona l 3 to 5 days , cons ide r o the r immunosupp ressan ts pe r loca l gu ide l ines Endoc r ine i rAEs Pa t ien ts expe r ienc ing symp toms such as fa t igue , mya lg ia , impo tence , men ta l s ta tus changes , cons t ipa t ion , o r o the r symp toms though t to be assoc ia ted w i th endoc r ine abno rma l i t ies shou ld be eva lua ted fo r thy ro id , p i tu i ta ry , o r ad rena l endoc r inopa th ies and an endoc r ino log is t shou ld be consu l ted . Pa t ien ts w i th G rade 2 hypo thy ro id ism shou ld be eva lua ted by an endoc r ino log is t fo r fu r the r managemen t . Pa t ien ts w i th G rade 2 hypo thy ro id ism adequa te ly managed w i th thy ro id ho rmone rep lacemen t may con t inue on p ro toco l the rapy . Pa t ien ts w i th G rade 3 o r g rea te r hypo thy ro id ism w i l l be cons ide red to have had a dose- l im i t ing tox ic i ty . These pa t ien ts shou ld be managed acco rd ing to tab le be low and eva lua t ion by an endoc r ino log is t is recommended fo r fu r the r managemen t . Pa t ien ts who en te r the s tudy on thy ro id rep lacemen t shou ld have the i r med ica t ion ad jus ted to ma in ta in TSH in the no rma l range . Endoc r ine D iso rde r Managemen t Fo l low-up Asymp toma t ic TSH abno rma l i ty Con t inue ave lumab the rapy I f TSH < 0 .5 x LLN , o r TSH > 2x IULN , o r cons is ten t ly ou t o f range in 2 subsequen t measu remen ts : inc lude T4 a t subsequen t cyc les as c l in ica l ly ind ica ted ; cons ide r endoc r ino logy consu l t Symp toma t ic endoc r inopa thy Eva lua te endoc r ine func t ion Cons ide r p i tu i ta ry scan Symp toma t ic w i th abno rma l lab/p i tu i ta ry scan : De lay ave lumab the rapy 1 to 2 mg/kg/day me thy lp redn iso lone IV o r o ra l equ iva len t In i t ia te app rop r ia te ho rmone the rapy No abno rma l lab/p i tu i ta ry MR I scan bu t symp toms pe rs is t : I f imp roves (w i th o r w i thou t ho rmone rep lacemen t ) : Tape r s te ro ids ove r a t leas t 1 mon th and cons ide r p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions Resume ave lumab the rapy Pa r t ic ipan ts w i th ad rena l insu f f ic iency may need to con t inue s te ro ids w i th m ine ra loco r t ico id componen t S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
40,page_40,"OSTPDL1 Page 34 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Repea t labs in 1 to 3 weeks MR I in 1 mon th Susp ic ion o f ad rena l c r is is ( fo r examp le , seve re dehyd ra t ion , hypo tens ion , shock ou t o f p ropo r t ion to cu r ren t i l lness ) De lay o r d iscon t inue ave lumab the rapy Ru le ou t seps is S t ress dose o f IV s te ro ids w i th m ine ra loco r t ico id ac t iv i ty IV f lu ids Consu l t endoc r ino log is t I f ad rena l c r is is ru led ou t , then t rea t as above fo r symp toma t ic endoc r inopa thy Ca rd iac i rAEs Myoca rd i t is Managemen t Fo l low-up New onse t o f ca rd iac s igns o r symp toms and / o r new labo ra to ry ca rd iac b ioma rke r e leva t ions (e .g . t ropon in , CK-MB , BNP ) o r ca rd iac imag ing abno rma l i t ies sugges t ive o f myoca rd i t is . W i thho ld ave lumab the rapy Hosp i ta l ize . In the p resence o f l i fe th rea ten ing ca rd iac decompensa t ion , cons ide r t rans fe r to a fac i l i ty expe r ienced in advanced hea r t fa i lu re and a r rhy thm ia managemen t . Ca rd io logy consu l t to es tab l ish e t io logy and ru le-ou t immune- med ia ted myoca rd i t is . Gu ide l ine based suppo r t ive t rea tmen t as app rop r ia te pe r ca rd io logy consu l t . * Cons ide r myoca rd ia l b iopsy i f recommended pe r ca rd io logy consu l t . I f symp toms imp rove and immune-med ia ted e t io logy is ru led ou t , re- s ta r t ave lumab the rapy . I f symp toms do no t imp rove/wo rsen , v i ra l myoca rd i t is is exc luded , and immune-med ia ted e t io logy is suspec ted o r con f i rmed fo l low ing ca rd io logy consu l t , manage as immune- med ia ted myoca rd i t is . Immune-med ia ted myoca rd i t is Pe rmanen t ly d iscon t inue ave lumab . Gu ide l ine based suppo r t ive t rea tmen t as app rop r ia te pe r ca rd io logy Once imp rov ing , tape r s te ro ids ove r a t leas t 1 mon th and add p rophy lac t ic an t ib io t ics fo r oppo r tun is t ic in fec t ions . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
41,page_41,"OSTPDL1 Page 35 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 consu l t . * Me thy lp redn iso lone 1-2 mg/kg/day . I f no imp rovemen t o r wo rsen ing , cons ide r add i t iona l immunosupp ress ions (e .g . aza th iop r ine , cyc lospo r ine A ) S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
42,page_42,"OSTPDL1 Page 36 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 5 .4 Au to immune o r Immune Sys tem D iso rde rs A f fec t ing O the r O rgan Sys tems Pa t ien ts expe r ienc ing symp toms tha t may be assoc ia ted w i th au to immune o r immune-med ia ted adve rse even ts poss ib ly , p robab ly o r de f in i te ly re la ted to p ro toco l the rapy shou ld be eva lua ted and mon i to red c lose ly . These may inc lude bu t a re no t l im i ted to pneumon i t is , sa rco id- l ike g ranu loma and neu ro log ic even ts inc lud ing hypophys i t is , encepha l i t is , asep t ic men ing i t is , and c ran ia l neu ropa thy espec ia l ly seven th c ran ia l ne rve (CNV I I ) pa lsy . Cons ide ra t ion shou ld be g iven to subspec ia l ty consu l ta t ion pa r t icu la r ly i f sys tem ic immune supp ress ion is cons ide red . 5 .5 Cen t ra l Venous Ca the te r Wh i le no t requ i red fo r the pu rposes o f th is s tudy , the inse r t ion o f a cen t ra l venous ca the te r/ l ine (CVL ) is recommended fo r a l l pa t ien ts fo r in t ravenous ( IV ) adm in is t ra t ion o f s tudy d rug as we l l as o the r suppo r t ive med ica t ions and labo ra to ry b lood d raws . P lacemen t o f the CVL may be pe r fo rmed by the t rea t ing ins t i tu t ion based on loca l gu ide l ines fo r bes t med ica l p rac t ice . 5 .6 Concom i tan t The rapy Concu r ren t cance r the rapy , inc lud ing chemo the rapy , rad ia t ion the rapy , immuno the rapy o r b io log ic the rapy may NOT be adm in is te red to pa t ien ts rece iv ing s tudy d rug . I f these t rea tmen ts a re adm in is te red the pa t ien t w i l l be removed f rom p ro toco l the rapy . Immuno the rapy and immunosupp ress ive d rugs ( i .e . , sys tem ic co r t icos te ro ids excep t fo r sho r t te rm t rea tmen t o f a l le rg ic reac t ions o r fo r the t rea tmen t o f immune- re la ted adve rse even ts ) shou ld no t be adm in is te red du r ing the s tudy . Fo r pa t ien ts w i th ad rena l insu f f ic iency , phys io log ica l dos ing o f s te ro ids is accep tab le . He rba l remed ies w i th immunos t imu la t ing p rope r t ies (e .g . , m is t le toe ex t rac t ) o r in te r fe rence w i th ma jo r o rgan func t ion (e .g . , hype r ic in ) shou ld no t be used du r ing the s tudy . Vacc ines shou ld no t be adm in is te red du r ing t rea tmen t , w i th the excep t ion o f adm in is t ra t ion o f the inac t ive in f luenza vacc ine . No o the r inves t iga t iona l agen ts may be g iven wh i le the pa t ien t is on s tudy . 6 .0 DRUG INFORMAT ION 6 .1 Ave lumab (MSB0010718C , an t i-PD-L1 ) Sou rce and pha rmaco logy : Ave lumab is a fu l ly human an t ibody o f the immunog lobu l in ( IgG ) 1 iso type tha t spec i f ica l ly ta rge ts and b locks PD- L1 . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
43,page_43,"OSTPDL1 Page 37 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Fo rmu la t ion and s tab i l i ty : The p roduc t is a s te r i le , c lea r and co lo r less so lu t ion p resen ted a t concen t ra t ion o f 20mg/mL in Un i ted S ta tes Pha rmacope ia (USP ) type I g lass v ia ls c losed w i th a rubbe r s toppe r and sea led w i th an a lum inum F l ip O f f© c r imp sea l c losu re . Each s ing le use 20mg/mL v ia l con ta ins 200mg o f ave lumab as a p rese rva t ive- f ree ace ta te-bu f fe red so lu t ion (ph 5 .2 ) con ta in ing mann i to l and po lyso rba te 20 (Tween 20 ) . On ly exc ip ien ts tha t con fo rm to the cu r ren t USP a re used . S to rage : Ave lumab v ia ls mus t be s to red a t 2 °C to 8 °C un t i l use . V ia ls tha t a re s to red a t room o r h ighe r tempe ra tu re fo r ex tended pe r iods o f t ime may be sub jec t to deg rada t ion . The d rug p roduc t mus t no t be f rozen . Rough shak ing o f so lu t ion mus t be avo ided . So lu t ion p repa ra t ion : Ave lumab mus t be d i lu ted w i th 0 .9% sa l ine so lu t ion (sod ium ch lo r ide in jec t ion ) supp l ied in an in fus ion bag to a to ta l vo lume o f 250mL . P r io r to p repa ra t ion o f d i lu t ion , each v ia l shou ld be a l lowed to equ i l ib ra te to room tempe ra tu re . Fo r m ix ing pu rposes , a f te r d i lu t ion o f ave lumab in the in fus ion bag , the m ix tu re shou ld be gen t ly inve r ted 10 t imes . V ia l con ten ts f rom d i f fe ren t lo ts shou ld no t be m ixed in the same in fus ion . S tab i l i ty : The chem ica l and phys ica l in-use s tab i l i ty fo r the in fus ion so lu t ion o f ave lumab in 0 .9% sa l ine so lu t ion (sod ium ch lo r ide in jec t ion ) has been demons t ra ted fo r a to ta l o f 24 hou rs a t room tempe ra tu re . Howeve r , f rom a m ic rob io log ica l po in t o f v iew , th is so lu t ion shou ld be used immed ia te ly and is no t in tended to be s to red un less d i lu t ion has taken p lace in a con t ro l led and va l ida t ion asep t ic cond i t ion Supp l ie r : P f ize r w i l l supp ly ave lumab to a l l pa r t ic ipa t ing ins t i tu t ions . Tox ic i ty : Mos t common ly repo r ted adve rse even ts a re fa t igue , in f luenza- l ike i l lness , py rex ia , lymphopen ia . See Inves t iga to r ’s B rochu re fo r fu l l desc r ip t ion . Dosage and rou te o f adm in is t ra t ion : Ave lumab shou ld be adm in is te red as an in t ravenous in fus ion ove r 60 m inu tes . P remed ica t ion is requ i red ; see t rea tmen t p lan sec t ions . 7 .0 REQU IRED EVALUAT IONS , TESTS , AND OBSERVAT IONS 7 .1 Eva lua t ions Be fo re and Du r ing The rapy A l l pa r t ic ipan ts en ro l led a t S t . Jude Ch i ld ren ’s Resea rch Hosp i ta l shou ld be inv i ted to pa r t ic ipa te in the S t . Jude t issue bank ing p ro toco l (TBANK ) and pha rmacogene t ics p ro toco l PGEN5 a t the t ime o f s tudy en t ry . A l l c l in ica l and labo ra to ry s tud ies to de te rm ine e l ig ib i l i ty mus t be pe r fo rmed w i th in 7 days p r io r to en ro l lmen t un less o the rw ise ind ica ted . Imag ing S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
44,page_44,"OSTPDL1 Page 38 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 s tud ies mus t be ob ta ined w i th in 14 days p r io r to the s ta r t o f p ro toco l the rapy ( repea t tumo r imag ing i f necessa ry ) . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
45,page_45,"OSTPDL1 Page 39 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Eva lua t ions , Tes ts and Obse rva t ions S tud ies to be Ob ta ined Base l ine Du r ing Cyc le 1 P r io r to Cyc le 2 P r io r to Subsequen t Cyc les End o f The rapy H is to ry X XXX Phys ica l exam w i th v i ta l s igns XWeek ly XXX He igh t , we igh t , BSA X XXX Pe r fo rmance s ta tus X XXX CBC , d i f f , p la te le ts 1XWeek ly XXX E lec t ro ly tes , inc lud ing CA ++ , PO 4, Mg ++1 X XXX BUN/c rea t in ine 1X XXX ALT (SGPT ) , AST and to ta l b i l i rub in 1X XXX To ta l p ro te in/a lbum in X XXX Amy lase , l ipase , CRP X XXX P regnancy tes t ( fema les ) 2X XXX F ree T4 and TSH 3X XXX Co r t iso l X XXX Tumo r d isease eva lua t ion 4 X End o f cyc le 2 End o f Cyc le 4 , then eve ry 3 cyc les X CT Ches t 5X End o f cyc le 2 End o f Cyc le 4 , then eve ry 3 mon ths X 18 F-FDG PET/PET-CT o r bone scan 6X End o f cyc le 2 End o f Cyc le 4 , then eve ry 3 mon ths X Pu lse ox ime t ry X Xw i th Tumo r D isease Eva lua t ion X Qua l i ty o f L i fe X X7X Co r re la t ive resea rch s tud ies (see Sec t ion 8 .0 ) Co r re la t ive b io logy (base l ine and p r io r to cyc le 3 on ly ) X X Tumo r t issue ( i f ava i lab le ) X 1B lood chem is t ry and hema to logy assessmen ts : mus t be pe r fo rmed a t base l ine , p r io r to each ave lumab dose , a t end o f t rea tmen t v is i t and a t 30 days pos t- t rea tmen t sa fe ty fo l low-up . 2Women o f ch i ldbea r ing po ten t ia l requ i re a nega t ive p regnancy tes t p r io r to s ta r t ing t rea tmen t and mus t be w i l l ing to adhe re to e f fec t ive con t racep t ive du r ing and fo r 60 days a f te r the las t dose o f ave lumab . Ma les who a re sexua l ly ac t ive w i th women o f ch i ldbea r ing po ten t ia l mus t be w i l l ing to adhe re to e f fec t ive con t racep t ion du r ing and fo r 60 days a f te r the las t dose o f ave lumab . Abs t inence is an accep tab le me thod o f b i r th con t ro l . 3F ree T4 and TSH mus t be pe r fo rmed a t base l ine and a t leas t eve ry 8 weeks du r ing t rea tmen t and a t end o f t rea tmen t o r 30 days pos t- t rea tmen t sa fe ty fo l low-up ( i f no t pe r fo rmed in the p rev ious 8 weeks ) 4 MR I o f p r ima ry tumo r and CT o r MR I o f a l l non-p r ima ry les ions mee t ing e l ig ib i l i ty c r i te r ia . Use the same imag ing moda l i ty fo r a l l d isease eva lua t ions . AP and la te ra l rad iog raphs shou ld be ob ta ined o f the p r ima ry tumo r ( i f p resen t ) as we l l as any ske le ta l me tas tases . 5CT o f the ches t is requ i red fo r a l l pa t ien ts to assess fo r the deve lopmen t o f p rog ress ive pu lmona ry d isease . 6 18 F-FDG PET/PET-CT o r bone scan is requ i red w i th each d isease eva lua t ion . I t is recommended to ob ta in MR I o r CT scan on any pos i t ive bone les ion on 18 F-FDG PET/PET-CT o r bone scan . Inves t iga to rs a re encou raged to use S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
46,page_46,"OSTPDL1 Page 40 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 the same moda l i ty used a t base l ine to fo l low pos i t ive les ions tha t a re iden t i f ied w i th 18 F-FDG PET/PET-CT o r bone scan 7QOL ques t ionna i res w i l l be comp le ted a t base l ine , a t the end o f cyc le 2 (8 weeks +1week ) , a t the end o f cyc le 4 (16 weeks +1week ) and a t the end o f ave lumab the rapy . 7 .2 Ex tended Sa fe ty Fo l low-up G iven the po ten t ia l r isk fo r de layed immune- re la ted tox ic i t ies , sa fe ty fo l low-up mus t be pe r fo rmed up to 90 days a f te r the las t dose o f ave lumab adm in is t ra t ion . The ex tended sa fe ty fo l low-up beyond 30 days a f te r las t s tudy d rug adm in is t ra t ion may be pe r fo rmed e i the r v ia a s i te v is i t o r v ia a te lephone ca l l w i th subsequen t s i te v is i t reques ted in case any conce rns no ted du r ing the te lephone ca l l . 8 .0 CORRELAT IVE RESEARCH STUD IES 8 .1 Tumo r T issue A l l pa t ien ts en ro l l ing on th is p ro toco l requ i re ins t i tu t iona l h is to log ica l con f i rma t ion o f os teosa rcoma a t the t ime o f o r ig ina l d iagnos is . Even though b iopsy to con f i rm recu r rence is s t rong ly encou raged , h is to log ic con f i rma t ion o f recu r rence/ re lapse is NOT requ i red fo r inc lus ion in th is s tudy . Fo r pa t ien ts who have ava i lab le t issue f rom d iagnos is/ recu r rence , subm iss ion o f t issue fo r b io log ic s tud ies is s t rong ly encou raged . Tumo r t issue tha t becomes ava i lab le fo r b io log ica l s tud ies w i l l be p rocessed in to s ing le ce l l suspens ions . Pu r i f ica t ion o f tumo r-assoc ia ted lymphocy tes w i l l be pe r fo rmed by Pe rco l l g rad ien t cen t r i fuga t ion and then f rozen in app rop r ia te f reez ing med ia o r d i rec t ly so r ted fo r lymphocy te ana lyses (desc r ibed be low ) . 8 .2 Immuno log ic Resea rch – NC I Tes t ing Ba t te ry A l l pa t ien ts 18 yea rs o f age and o lde r w i l l have 6 (10m l ) g reen top tubes and 2 (7m l ) SST and pa t ien ts less than 18 yea rs o f age w i l l have 2 (10m l ) g reen top tubes and 1 (7m l ) SST . See Labo ra to ry Manua l fo r add i t iona l in fo rma t ion on co l lec t ion , p rocess ing and sh ipmen t o f samp les . T im ing : p r io r to s ta r t o f the rapy and p r io r to s ta r t ing Cyc le 3 . B lood samp les may be used fo r o the r resea rch s tud ies , wh ich may inc lude pheno typ ic and func t iona l ana lys is o f immune ce l l subse ts , c i rcu la t ing tumo r ce l l eva lua t ion , and ana lys is fo r cy tok ines , chemok ines , an t ibod ies , tumo r-assoc ia ted an t igens and / o r o the r ma rke rs . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
47,page_47,"OSTPDL1 Page 41 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 The samp les w i l l be p rocessed a t The C l in ica l Suppo r t Labo ra to ry a t the F rede r ick Na t iona l Labo ra to ry fo r Cance r Resea rch (see Append ix I I I ) : The resa Bu rks Le ido-F rede r ick 1050 Boy les S t ree t B ldg 469 , Room 121 F rede r ick MD 21702 Phone 301-846-5125 o r 301-846-1707 On days samp les a re d rawn , Jen Bangh a t the C l in ica l Suppo r t Labo ra to ry shou ld be no t i f ied (phone : (301 ) 846-5893 ; fax (301 ) 846-6536 ) . She w i l l a r range same-day cou r ie r de l ive ry o f the spec imens . The resea rch samp les w i l l con ta in labe ls on the b lood tubes tha t have the pa t ien t 's in i t ia ls , da te o f b i r th , the ass igned p ro toco l , and the da te the samp les we re d rawn . The t ransm i t ta l fo rms accompany ing the samp les a lso con ta in the same in fo rma t ion . Once a pa t ien t ’s t rea tmen t schedu le has been de te rm ined , i t shou ld be faxed to Ca ro l ine Jochems a t the Labo ra to ry o f Tumo r Immuno logy and B io logy / N IH (Fax : (301 ) 496-2756 ; phone : (301 ) 402-6274 ) fo r p lann ing pu rposes . Pa rame te rs o f immune ac t iva t ion Immuno log ic tes t ing w i l l inc lude : ·Pe r iphe ra l b lood mononuc lea r ce l ls (PBMC ) oPheno typ ic and func t iona l ana lys is o f 123 immune ce l l subse ts by f low cy tome t ry (CD4 , CD8 , and regu la to ry T- lymphocy tes , B- lymphocy tes , NK ce l ls , NKT ce l ls , dend r i t ic ce l ls , mye lo id de r ived supp resso r ce l ls and ra t ios o f e f fec to r to supp resso r ce l ls ) . ·Se rum o Ana lys is o f cy tok ines ( i fn-γ , IL-10 , IL-12 , IL-2 , IL-4 , TGF-β , e tc . ) , chemok ines , so lub le CD27 , so lub le CD40L , an t ibod ies , tumo r-assoc ia ted an t igens and/o r o the r ma rke rs S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
48,page_48,"OSTPDL1 Page 42 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 F low-cy tome t ry ana lys is o f PBMC immune ce l l subse ts : 27 ma rke rs , 123 subse ts 1 . CD4 : He lpe r T lymphocy tes (33 subse ts ) 2 . CD8 : Cy to tox ic T lymphocy tes (30 subse ts ) •Ma tu ra t ion s ta tus o f T lymphocy tes ( in CD4 and CD8 ) : ‒Na ïve : CD45RA + CCR7 + ‒Cen t ra l Memo ry : CD45RA - CCR7 + ‒E f fec to r Memo ry : CD45RA - CCR7 - ‒Te rm ina l (EMRA ) : CD45RA + CCR7 - •T lymphocy te ma rke rs ( in to ta l and memo ry CD4 and CD8 ) : ‒CTLA-4 : inh ib i t ion ‒PD-1 : ac t iva t ion/ inh ib i t ion ‒PD-L1 : ac t iva t ion/c ross- inh ib i t ion ‒T IM-3 : inh ib i t ion ‒41BB : co-s t iac t iva t ion ‒ICOS : ac t iva t ion (on ly on CD4 ) 3 . T regs : Regu la to ry T lymphocy tes (CD4 + CD25 + FoxP3 + CD127 -) (7 subse ts ) •CD45RA : T regs h igh ly expandab le in v i t ro •CTLA-4 : T reg supp ress ion •CD49d : “con tam ina t ing ” e f fec to r lymphocy tes (non-T regs ) •ICOS : T reg supp ress ion •PD-1 : ac t iva t ion/ inh ib i t ion •PD-L1 : c ross- inh ib i t ion 4 . B lymphocy tes : CD19 + (3 subse ts ) •PD-1 : ac t iva t ion/ inh ib i t ion •PD-L1 : c ross- inh ib i t ion 5 . NK : Na tu ra l k i l le r ce l ls (CD56 + CD3 -) (20 subse ts ) •CD16 + CD56 d im : Ma tu re NK , ly t ic •CD16 + CD56 b r : Func t iona l in te rmed ia te , ly t ic , cy tok ine p roduc t ion •CD16 - CD56 b r : Imma tu re , cy tok ine p roduc t ion , abundan t in p lacen ta •CD16 - CD56 d im : non- ly t ic , non-cy tok ine p roduc t ion •T IM-3 : ac t iva t ion •PD-1 : ac t iva t ion/ inh ib i t ion •PD-L1 : c ross- inh ib i t ion 6 . NK-T : CD56 + CD3 + (4 subse ts ) •T IM-3 : ac t iva t ion •PD-1 : ac t iva t ion/ inh ib i t ion •PD-L1 : c ross- inh ib i t ion 7 . cDCs (Conven t iona l DCs ) : CD3 -CD56 -HLA-DR +CD1c +CD303 - (5 subse ts ) 8 . pDCs (p lasmacy to id DCs ) : CD3 -CD56 -HLA-DR +CD1c -CD303 + (5 subse ts ) •Ma rke rs o f DC ac t iva t ion ‒CD83 : ac t iva t ion ‒T IM-3 : inh ib i t ion ‒PD-L1 : c ross- inh ib i t ion ‒PD1 : ac t iva t ion/ inh ib i t ion 9 . MDSCs : Mye lo id-de r ived supp resso r ce l ls (CD11b + HLA-DR low/- CD33 +) (16 subse ts ) •CD14 : Common Mye lo id Ma rke r (h igh in monocy tes , d im in g ranu locy tes ) •CD15 : G ranu locy te ma rke r •CD16 : mos t imma tu re monocy t ic MDSCs •PD-1 : ac t iva t ion/ inh ib i t ion •PD-L1 : c ross- inh ib i t ion S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
49,page_49,"OSTPDL1 Page 43 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Samp les sen t to the C l in ica l Suppo r t Labo ra to ry a t NC I A l l da ta assoc ia ted w i th pa t ien t samp les a re p ro tec ted by us ing a secu re da tabase . A l l samp les d rawn a t the N IH C l in ica l Cen te r w i l l be t ranspo r ted to the C l in ica l Suppo r t Labo ra to ry a t the F rede r ick Na t iona l Labo ra to ry fo r Cance r Resea rch by cou r ie rs . Samp les w i l l be t racked and managed by the Cen t ra l Repos i to ry da tabase . A l l samp les w i l l be s to red in l iqu id n i t rogen . These f reeze rs a re loca ted a t NC I F rede r ick Cen t ra l Repos i to ry in F rede r ick , Ma ry land . F ishe r B ioSe rv ices manages the NC I F rede r ick Cen t ra l Repos i to r ies unde r subcon t rac t to Le idos B iomed ica l , Inc . NC I F rede r ick Cen t ra l Repos i to r ies s to re , among o the r th ings , b io log ica l spec imens in suppo r t o f N IH c l in ica l s tud ies . A l l spec imens a re s to red in secu re , l im i ted access fac i l i t ies w i th su f f ic ien t secu r i ty , back-up and eme rgency suppo r t capab i l i ty and mon i to r ing to ensu re long- te rm in teg r i ty o f the spec imens fo r resea rch . Spec imens a re s to red in acco rdance w i l l app l icab le HHS and FDA P ro tec t ion o f Human Sub jec ts Regu la t ions in acco rdance w i th F ishe r B ioSe rv ices Fede ra l-w ide Assu rance . F ishe r B ioSe rv ices ’ ro le is l im i ted to c l in ica l resea rch da tabases and repos i to r ies con ta in ing pa t ien t spec imens . F ishe r B ioSe rv ices ne i the r conduc ts no r has any ves ted in te res t in resea rch on human sub jec ts , bu t does p rov ide se rv ices and suppo r ts the e f fo r ts o f i ts cus tome rs , many o f wh ich a re invo lved in resea rch on human sub jec ts . The F ishe r B ioSe rv ices IRB rev iews po l ic ies and p rocedu res fo r labe l ing , da ta co l lec t ion and s to rage , access , and secu r i ty . The IRB w i l l rev iew p ro tec t ion o f p r ivacy issues p r io r to accep tance o f any new wo rk and in the even t o f change impac t ing p r ivacy issues in ex is t ing wo rk . I t is the in ten t and pu rpose o f F ishe r B ioSe rv ices to accep t on ly de- iden t i f ied samp les and samp le in fo rma t ion . To the bes t o f ou r ab i l i ty , eve ry e f fo r t w i l l be made to ensu re tha t p ro tec ted in fo rma t ion is no t sen t e lec t ron ica l ly o r by ha rd copy o r on v ia l labe ls . Samp le da ta a re s to red in the B ioSpec imen Inven to ry (BS I ) Sys tem I I . Th is inven to ry t rack ing sys tem is used to manage the s to rage and re t r ieva l o f spec imens as we l l as ma in ta in spec imen da ta . BS I is des igned fo r con t ro l led , concu r ren t access . I t p rov ides a rea l- t ime , mu l t i-use r env i ronmen t fo r t rack ing m i l l ions o f spec imens . The sys tem con t ro ls how and in wha t o rde r da tabase upda tes and sea rches a re pe r fo rmed . Th is con t ro l p reven ts dead locks and race cond i t ions . Fo r secu r i ty , BS I has use r passwo rd access , 3 types o f use r access leve ls , and 36 use r pe rm iss ions ( leve ls o f access ) tha t can be se t to con t ro l access to the sys tem func t ions . BS I p rov ides aud i t t rack ing fo r p rocesses tha t a re done to spec imens inc lud ing sh ipp ing , re tu rn ing to inven to ry , a l iquo t ing , thaw ing , add i t ives , and o the r p rocesses . BS I t racks the ances t ry o f spec imens as they a re a l iquo ted , as we l l as d isc repanc ies and d isc repancy S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
50,page_50,"OSTPDL1 Page 44 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 reso lu t ion fo r spec imens rece ived by the repos i to ry . I f a spec imen goes ou t o f the inven to ry , the sys tem ma in ta ins da ta assoc ia ted w i th the w i thd rawa l reques t . V ia ls a re labe led w i th a un ique BS I ID , wh ich is p r in ted in bo th eye- readab le and ba r-coded fo rma t . No pa t ien t-spec i f ic in fo rma t ion is encoded in th is ID . Inves t iga to rs a re g ran ted v iew , inpu t and w i thd rawa l au tho r i ty on ly fo r the i r spec imens . They may no t v iew spec imen da ta o r access spec imens fo r wh ich they have no t been au tho r ized . Access to spec imen s to rage is con f ined to repos i to ry s ta f f . V is i to rs to the repos i to r ies a re esco r ted by repos i to ry s ta f f a t a l l t imes . NC I P ro toco l Comp le t ion/Samp le Des t ruc t ion A l l spec imens ob ta ined in the p ro toco l a re used as de f ined in the p ro toco l . Any spec imens tha t a re rema in ing a t the comp le t ion o f the p ro toco l w i l l be s to red in the cond i t ions desc r ibed above . The s tudy w i l l rema in open so long as samp le o r da ta ana lys is con t inues . Samp les f rom consen t ing sub jec ts w i l l be s to red un t i l they a re no longe r o f sc ien t i f ic va lue o r i f a sub jec t w i thd raws consen t fo r the i r con t inued use , a t wh ich t ime they w i l l be des t royed . Once p r ima ry resea rch ob jec t ives fo r the p ro toco l a re ach ieved , in t ramu ra l resea rche rs can reques t access to rema in ing samp les p rov id ing they have an IRB app roved p ro toco l and pa t ien t consen t . The P I w i l l repo r t any loss o r des t ruc t ion o f samp les to the NC I IRB as soon as he is made awa re o f such loss . The P I w i l l repo r t des t royed samp les to the IRB i f samp les become unsa lvageab le because o f env i ronmen ta l fac to rs (ex . b roken f reeze r o r lack o f d ry ice in a sh ipp ing con ta ine r ) o r i f a pa t ien t w i thd raws consen t . Samp les w i l l a lso be repo r ted as los t i f they a re los t in t rans i t be tween fac i l i t ies o r m isp laced by a resea rche r . F reeze r p rob lems , los t samp les o r o the r p rob lems assoc ia ted w i th samp les w i l l a lso be repo r ted to the IRB , the NC I C l in ica l D i rec to r , and the o f f ice o f the CCR , NC I . 8 .3 Immuno log ic Resea rch – S t . Jude Tes t ing Ba t te ry Th ree a l iquo ts o f pe r iphe ra l b lood mononuc lea r ce l ls (PBMCs ) ( rep resen t ing a 10 mL d raw in B lue/B lack CPT tubes ) w i l l be ob ta ined fo r tes t ing fo r TCR repe r to i re , T ce l l pheno type , t ransc r ip t iona l p ro f i le , and ep igene t ic landscape . Samp les may be f rozen fo r the pu rposes o f sh ipp ing and hand l ing . Shou ld tumo r t issue be ava i lab le f rom resec t ion o f the pa t ien t ’s p r ima ry tumo r AND/OR me tas ta t ic s i tes o f d isease , s ing le ce l l suspens ions o f tumo r ce l ls shou ld a lso be ob ta ined fo r ana lys is . See Labo ra to ry Manua l fo r add i t iona l in fo rma t ion on co l lec t ion , p rocess ing and sh ipmen t o f samp les S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
51,page_51,"OSTPDL1 Page 45 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 T im ing : p r io r to s ta r t o f the rapy and p r io r to cyc le 3 . Samp les shou ld be sen t v ia FedEx ove rn igh t se rv ices to : Pau l G . Thomas , PhD In teg ra ted Resea rch Cen te r , Room E7054 S t . Jude Ch i ld ren ’s Resea rch Hosp i ta l 262 Danny Thomas P lace Memph is , TN 38105 On the day o f samp le acqu is i t ion , p lease con tac t Pau l Thomas o r Ben Youngb lood a t (901 ) 595-6749 to a r range fo r p ickup o f ma te r ia ls . Samp les w i l l be s ta ined w i th f luo rescen t ly labe led an t ibod ies and so r ted fo r s ing le ce l l ana lys is (1/3 o f the samp le ) w i th the rema in ing samp le so r ted on spec i f ic ce l l pheno types fo r t ransc r ip t iona l and ep igene t ic ana lys is . P repa ra t ion o f s ing le ce l l suspens ion : Tumo r samp le ( f rom f resh ly- resec ted su rg ica l spec imen ) is we ighed and sequen t ia l ly m inced in to sma l l p ieces (app rox . 3 mm in s ize ) us ing sc isso rs o r sca lpe l . Tumo r t issue is d iges ted a t 37 oC in RPM I med ium supp lemen ted w i th 5% FBS , Co l lagenase 4 , and DNase I . D iges ted tumo rs a re homogen ized by p ipe t t ing , and f i l te red th rough a 70 um ce l l s t ra ine r . The rema in ing und iges ted p ieces a re fo rced to pass th rough the s t ra ine r us ing a sy r inge p lunge r . The s ing le ce l l suspens ion is washed 3 t imes w i th ice co ld PBS , and RBC a re lysed ( i f needed ) us ing an ammon ium ch lo r ide iso ton ic so lu t ion . The numbe r o f l ive ce l ls is de te rm ined us ing a hemocy tome te r a f te r exc lus ion o f dead ce l ls by T rypan b lue dye . Po lypa rame t r ic immunopheno typ ic ana lys is : Ce l ls a re labe led w i th f luo rescen t con juga ted an t ibod ies aga ins t the l is ted human ep i topes , and subsequen t ly ana lyzed in a f low cy tome te r (BD LSR I I ) . We w i l l eva lua te PD-L1 exp ress ion in ce l l su r face o f in f i l t ra t ing leukocy tes (CD45+ f rac t ion ) as we l l as in CD45- f rac t ion , wh ich p r ima ry cons is ts o f tumo r ce l ls . Spec i f ic i ty F luo ropho re C lone CCR7 F ITC G043H7 PD1 PE EH12 .2H7 T IM3 PECY7 F38-2E2 CD45RO APC UCHL1 CD3 APCCY7 SK7 CD8a PB (421 ) RPA-T8 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
52,page_52,"OSTPDL1 Page 46 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Samp les sen t to S t . Jude A l l da ta assoc ia ted w i th pa t ien t samp les a re p ro tec ted by us ing a secu re da tabase . A l l samp les w i l l be s to red in l iqu id n i t rogen . These f reeze rs a re loca ted a t S t . Jude in a secu re fac i l i ty . A l l spec imens a re s to red in secu re , l im i ted access fac i l i t ies w i th su f f ic ien t secu r i ty , back-up and eme rgency suppo r t capab i l i ty and mon i to r ing to ensu re long- te rm in teg r i ty o f the spec imens fo r resea rch . Spec imens a re s to red in acco rdance w i l l app l icab le HHS and FDA P ro tec t ion o f Human Sub jec ts Regu la t ions in acco rdance w i th S JCRH Fede ra l-w ide Assu rance . The S t . Jude IRB rev iews po l ic ies and p rocedu res fo r labe l ing , da ta co l lec t ion and s to rage , access , and secu r i ty . The IRB w i l l rev iew p ro tec t ion o f p r ivacy issues p r io r to accep tance o f any new wo rk and in the even t o f change impac t ing p r ivacy issues in ex is t ing wo rk . I t is the in ten t and pu rpose o f the inves t iga to rs a t S t . Jude to accep t on ly de- iden t i f ied samp les and samp le in fo rma t ion . To the bes t o f ou r ab i l i ty , eve ry e f fo r t w i l l be made to ensu re tha t p ro tec ted in fo rma t ion is no t sen t e lec t ron ica l ly o r by ha rd copy o r on v ia l labe ls . 9 .0 EVALUAT ION CR ITER IA 9 .1 Response De f in i t ions and C r i te r ia fo r So l id Tumo rs See the tab le in sec t ion 7 .1 fo r the schedu le o f tumo r eva lua t ions . In add i t ion to the schedu led scans , a con f i rma to ry scan shou ld be ob ta ined 28 days fo l low ing in i t ia l documen ta t ion o f ob jec t ive response . Response and p rog ress ion w i l l be eva lua ted in th is s tudy us ing the rev ised Response Eva lua t ion C r i te r ia in So l id Tumo rs (REC IST ) gu ide l ine (ve rs ion 1 .1 ) 90 . Key po in ts a re tha t up to 5 ta rge t les ions may be iden t i f ied and tha t changes in the la rges t d iame te r (un id imens iona l CD45 BV605 H I30 PDL1 BV786 M IH1 7AAD n/a (dead ce l l exc lus ion dye ) S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
53,page_53,"OSTPDL1 Page 47 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 measu remen t ) o f the tumo r les ions bu t the sho r tes t d iame te r o f ma l ignan t lymph nodes a re used in the REC IST v 1 .1 c r i te r ia . 9 .1 .1De f in i t ions Eva luab le fo r ob jec t ive response : Pa t ien ts who exh ib i t ob jec t ive d isease p rog ress ion p r io r to the end o f cyc le 1 w i l l be cons ide red eva luab le fo r response . Fo r a l l o the r pa t ien ts , on ly those pa t ien ts who have measu rab le d isease p resen t a t base l ine , have rece ived a t leas t one cyc le o f the rapy , and have had the i r d isease re-eva lua ted w i l l be cons ide red eva luab le fo r response . Eva luab le Non-Ta rge t D isease Response : Pa t ien ts who have les ions p resen t a t base l ine tha t a re eva luab le bu t do no t mee t the de f in i t ions o f measu rab le d isease , have rece ived a t leas t one cyc le o f the rapy , and have had the i r d isease re-eva lua ted w i l l be cons ide red eva luab le fo r non- ta rge t d isease . The response assessmen t is based on the p resence , absence , o r unequ ivoca l p rog ress ion o f the les ions . 9 .1 .2D isease Pa rame te rs Measu rab le d isease : Measu rab le les ions a re de f ined as those tha t can be accu ra te ly measu red in a t leas t one d imens ion ( longes t d iame te r to be reco rded ) as ≥20 mm by ches t x- ray , as ≥10 mm w i th CT scan , o r ≥10 mm w i th ca l ipe rs by c l in ica l exam . A l l tumo r measu remen ts mus t be reco rded in m i l l ime te rs (o r dec ima l f rac t ions o f cen t ime te rs ) . No te : Tumo r les ions tha t a re s i tua ted in a p rev ious ly i r rad ia ted a rea m igh t o r m igh t no t be cons ide red measu rab le . I f the inves t iga to r th inks i t app rop r ia te to inc lude them , the cond i t ions unde r wh ich such les ions shou ld be cons ide red mus t be de f ined in the da tabase . Ma l ignan t lymph nodes : To be cons ide red pa tho log ica l ly en la rged and measu rab le , a lymph node mus t be ≥15 mm in sho r t ax is when assessed by CT scan (CT scan s l ice th ickness no g rea te r than 5 mm ) . A t base l ine and in fo l low-up , on ly the sho r t ax is w i l l be measu red and fo l lowed . Non-measu rab le d isease : A l l o the r les ions (o r s i tes o f d isease ) , inc lud ing sma l l les ions ( longes t d iame te r <10 mm o r pa tho log ica l lymph nodes w i th ≥ 10 to <15 mm sho r t ax is ) , a re cons ide red non-measu rab le d isease . Bone les ions , lep tomen ingea l d isease , asc i tes , p leu ra l/pe r ica rd ia l e f fus ions , lymphang i t is cu t is/pu lmon i t is , in f lamma to ry b reas t d isease , and abdom ina l masses (no t fo l lowed by CT o r MR I ) , a re cons ide red as non-measu rab le . No te : Cys t ic les ions tha t mee t the c r i te r ia fo r rad iog raph ica l ly de f ined s imp le cys ts shou ld no t be cons ide red as ma l ignan t les ions (ne i the r S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
54,page_54,"OSTPDL1 Page 48 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 measu rab le no r non-measu rab le ) s ince they a re , by de f in i t ion , s imp le cys ts . ‘Cys t ic les ions ’ though t to rep resen t cys t ic me tas tases can be cons ide red as measu rab le les ions , i f they mee t the de f in i t ion o f measu rab i l i ty desc r ibed above . Howeve r , i f non-cys t ic les ions a re p resen t in the same pa t ien t , these a re p re fe r red fo r se lec t ion as ta rge t les ions . Ta rge t les ions : A l l measu rab le les ions up to a max imum o f 2 les ions pe r o rgan and 5 les ions in to ta l , rep resen ta t ive o f a l l invo lved o rgans , shou ld be iden t i f ied as ta rge t les ions and reco rded and measu red a t base l ine . Ta rge t les ions shou ld be se lec ted on the bas is o f the i r s ize ( les ions w i th the longes t d iame te r ) , be rep resen ta t ive o f a l l invo lved o rgans , bu t in add i t ion shou ld be those tha t lend themse lves to rep roduc ib le repea ted measu remen ts . I t may be the case tha t , on occas ion , the la rges t les ion does no t lend i tse l f to rep roduc ib le measu remen t in wh ich c i rcums tance the nex t la rges t les ion tha t can be measu red rep roduc ib ly shou ld be se lec ted . A sum o f the d iame te rs ( longes t fo r non-noda l les ions , sho r t ax is fo r noda l les ions ) fo r a l l ta rge t les ions w i l l be ca lcu la ted and repo r ted as the base l ine sum d iame te rs . I f lymph nodes a re to be inc luded in the sum , then on ly the sho r t ax is is added in to the sum . The base l ine sum d iame te rs w i l l be used as re fe rence to fu r the r cha rac te r ize any ob jec t ive tumo r reg ress ion in the measu rab le d imens ion o f the d isease . Non- ta rge t les ions : A l l o the r les ions (o r s i tes o f d isease ) inc lud ing any measu rab le les ions ove r and above the 5 ta rge t les ions shou ld be iden t i f ied as non- ta rge t les ions and shou ld a lso be reco rded a t base l ine . Measu remen ts o f these les ions a re no t requ i red , bu t the p resence , absence , o r in ra re cases unequ ivoca l p rog ress ion o f each shou ld be no ted th roughou t fo l low-up . 9 .1 .3Me thods fo r Eva lua t ion o f Measu rab le D isease A l l measu remen ts shou ld be taken and reco rded in me t r ic no ta t ion us ing a ru le r o r ca l ipe rs . The same me thod o f assessmen t and the same techn ique shou ld be used to cha rac te r ize each iden t i f ied and repo r ted les ion a t base l ine and du r ing fo l low-up . Imag ing-based eva lua t ion is p re fe r red to eva lua t ion by c l in ica l exam ina t ion un less the les ion (s ) be ing fo l lowed canno t be imaged bu t a re assessab le by c l in ica l exam . C l in ica l les ions : C l in ica l les ions w i l l on ly be cons ide red measu rab le when they a re supe r f ic ia l (e .g . , sk in nodu les and pa lpab le lymph nodes ) and ≥10 mm d iame te r as assessed us ing ca l ipe rs (e .g . , sk in nodu les ) . In the case o f sk in les ions , documen ta t ion by co lo r pho tog raphy , inc lud ing a ru le r to es t ima te the s ize o f the les ion , is recommended . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
55,page_55,"OSTPDL1 Page 49 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Ches t x- ray : Les ions on ches t x- ray a re accep tab le as measu rab le les ions when they a re c lea r ly de f ined and su r rounded by ae ra ted lung . Howeve r , CT is p re fe rab le . Conven t iona l CT and MR I : Th is gu ide l ine has de f ined measu rab i l i ty o f les ions on CT scan based on the assump t ion tha t CT s l ice th ickness is 5 mm o r less . I f CT scans have s l ice th ickness g rea te r than 5 mm , the m in imum s ize fo r a measu rab le les ion shou ld be tw ice the s l ice th ickness . MR I is a lso accep tab le in ce r ta in s i tua t ions (e .g . fo r body scans ) . Idea l ly , the same type o f scanne r shou ld be used and the image acqu is i t ion p ro toco l shou ld be fo l lowed as c lose ly as poss ib le to p r io r scans . PET-CT : A t p resen t , the low dose o r a t tenua t ion co r rec t ion CT po r t ion o f a comb ined PET-CT is no t a lways o f op t ima l d iagnos t ic CT qua l i ty fo r use w i th REC IST measu remen ts . Howeve r , i f the s i te can documen t tha t the CT pe r fo rmed as pa r t o f a PET-CT is o f iden t ica l d iagnos t ic qua l i ty to a d iagnos t ic CT (w i th IV and o ra l con t ras t ) , then the CT po r t ion o f the PET- CT can be used fo r REC IST measu remen ts and can be used in te rchangeab ly w i th conven t iona l CT in accu ra te ly measu r ing cance r les ions ove r t ime . No te , howeve r , tha t the PET po r t ion o f the CT in t roduces add i t iona l da ta wh ich may b ias an inves t iga to r i f i t is no t rou t ine ly o r se r ia l ly pe r fo rmed . Tumo r ma rke rs : Tumo r ma rke rs a lone canno t be used to assess response . I f ma rke rs a re in i t ia l ly above the uppe r no rma l l im i t , they mus t no rma l ize fo r a pa t ien t to be cons ide red in comp le te c l in ica l response . Cy to logy , h is to logy : These techn iques can be used to d i f fe ren t ia te be tween pa r t ia l responses (PR ) and comp le te responses (CR ) in ra re cases (e .g . , res idua l les ions in tumo r types , such as ge rm ce l l tumo rs , whe re known res idua l ben ign tumo rs can rema in ) . Cy to logy shou ld be ob ta ined i f an e f fus ion appea rs o r wo rsens du r ing t rea tmen t when the measu rab le tumo r has me t c r i te r ia fo r response o r s tab le d isease . 18 F-FDG PET/PET-CT : Wh i le 18 F-FDG PET/PET-CT response assessmen ts need add i t iona l s tudy , i t is some t imes reasonab le to inco rpo ra te the use o f 18 F-FDG PET/PET-CT scann ing to comp lemen t CT scann ing in assessmen t o f p rog ress ion (pa r t icu la r ly poss ib le 'new ' d isease ) . New les ions on the bas is o f 18 F-FDG PET/PET-CT imag ing can be iden t i f ied acco rd ing to the fo l low ing a lgo r i thm : a .Nega t ive 18 F-FDG PET/PET-CT a t base l ine , w i th a pos i t ive 18 F-FDG PET/PET-CT a t fo l low-up is a s ign o f PD based on a new les ion . b .No 18 F-FDG PET/PET-CT a t base l ine and a pos i t ive 18 F-FDG PET/PET-CT a t fo l low-up : I f the pos i t ive 18 F-FDG PET/PET-CT a t fo l low-up co r responds to a new s i te o f d isease con f i rmed by CT , S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
56,page_56,"OSTPDL1 Page 50 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 th is is PD . I f the pos i t ive 18 F-FDG PET/PET-CT a t fo l low-up is no t con f i rmed as a new s i te o f d isease on CT , add i t iona l fo l low-up CT scans a re needed to de te rm ine i f the re is t ru ly p rog ress ion occu r r ing a t tha t s i te ( i f so , the da te o f PD w i l l be the da te o f the in i t ia l abno rma l 18 F-FDG PET/PET-CT scan ) . I f the pos i t ive 18 F-FDG PET/PET-CT a t fo l low-up co r responds to a p re-ex is t ing s i te o f d isease on CT tha t is no t p rog ress ing on the bas is o f the ana tom ic images , th is is no t PD . No te : A ‘pos i t ive ’ 18 F-FDG PET/PET-CT scan les ion means one tha t is FDG av id w i th an up take g rea te r than tw ice tha t o f the su r round ing t issue on the a t tenua t ion co r rec ted image . 9 .2 Response C r i te r ia fo r Pa t ien ts w i th So l id Tumo r and Measu rab le D isease 9 .2 .1Eva lua t ion o f Ta rge t Les ions Comp le te response (CR ) : D isappea rance o f a l l ta rge t and non- ta rge t les ions . Any pa tho log ica l lymph nodes (whe the r ta rge t o r non- ta rge t ) mus t have reduc t ion in sho r t ax is to <10 mm . I f immunocy to logy is ava i lab le , no d isease mus t be de tec ted by tha t me thodo logy . Pa r t ia l response (PR ) : A t leas t a 30% dec rease in the sum o f the d iame te rs o f ta rge t les ions , tak ing as re fe rence the base l ine sum d iame te rs . P rog ress ive d isease (PD ) : A t leas t a 20% inc rease in the sum o f the d iame te rs o f ta rge t les ions , tak ing as re fe rence the sma l les t sum on s tudy ( th is inc ludes the base l ine sum i f tha t is the sma l les t on s tudy ) . In add i t ion to the re la t ive inc rease o f 20% , the sum mus t a lso demons t ra te an abso lu te inc rease o f a t leas t 5 mm . (No te : the appea rance o f one o r mo re new les ions is a lso cons ide red p rog ress ions ) . No te : in p resence o f SD o r PR in ta rge t d isease bu t unequ ivoca l p rog ress ion in non- ta rge t o r non- measu rab le d isease , the pa t ien t has PD i f the re is an ove ra l l leve l o f subs tan t ia l wo rsen ing in non- ta rge t d isease such tha t the ove ra l l tumo r bu rden has inc reased su f f ic ien t ly to me r i t d iscon t inua t ion o f the rapy . S tab le d isease (SD ) : Insu f f ic ien t sh r inkage to qua l i fy fo r PR o r insu f f ic ien t inc rease to qua l i fy fo r PD , tak ing as re fe rence the sma l les t sum d iame te rs wh i le on s tudy . 9 .2 .2Eva lua t ion o f Non-Ta rge t Les ions Comp le te response (CR ) : D isappea rance o f a l l non- ta rge t les ions and no rma l iza t ion o f tumo r ma rke r leve l . A l l lymph nodes mus t be non- pa tho log ica l in s ize (<10 mm sho r t ax is ) S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
57,page_57,"OSTPDL1 Page 51 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 No te : I f tumo r ma rke rs a re in i t ia l ly above the uppe r no rma l l im i t , they mus t no rma l ize fo r a pa t ien t to be cons ide red in comp le te c l in ica l response . Non-CR/Non-PD : Pe rs is tence o f one o r mo re non- ta rge t les ion (s ) and/o r ma in tenance o f tumo r ma rke r leve l above the no rma l l im i ts P rog ress ive d isease (PD ) : Appea rance o f one o r mo re new les ions and/o r unequ ivoca l p rog ress ion o f ex is t ing non- ta rge t les ions . Unequ ivoca l p rog ress ion shou ld no t no rma l ly t rump ta rge t les ion s ta tus . I t mus t be rep resen ta t ive o f ove ra l l d isease s ta tus change , no t a s ing le les ion inc rease . Ove ra l l bes t response assessmen t : Each pa t ien t w i l l be c lass i f ied acco rd ing to h is “bes t response ” fo r the pu rposes o f ana lys is o f t rea tmen t e f fec t . Bes t response is de te rm ined as ou t l ined in Sec t ion 9 .4 f rom a sequence o f ove ra l l response assessmen ts . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
58,page_58,"OSTPDL1 Page 52 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 9 .3 Response C r i te r ia fo r Eva luab le D isease No te : a l l pa r t ic ipan ts mus t have measu rab le d isease , bu t they can a lso have eva luab le d isease in add i t ion to measu rab le d isease . Eva luab le d isease : The p resence o f a t leas t one les ion , w i th no les ion tha t can be accu ra te ly measu red in a t leas t one d imens ion . Such les ions may be eva luab le by nuc lea r med ic ine techn iques , immunocy tochem is t ry techn iques , tumo r ma rke rs o r o the r re l iab le measu res . Comp le te response (CR ) : D isappea rance o f a l l eva luab le d isease . Pa r t ia l response (PR ) : Pa r t ia l responses canno t be de te rm ined in pa t ien ts w i th eva luab le d isease . S tab le d isease (SD ) : Tha t wh ich does no t qua l i fy as Comp le te Response (CR ) , Pa r t ia l Response (PR ) , o r P rog ress ive D isease . P rog ress ive d isease (PD ) : The appea rance o f one o r mo re new les ions o r ev idence o f labo ra to ry , c l in ica l , o r rad iog raph ic p rog ress ion . Ove ra l l bes t response assessmen t : Each pa t ien t w i l l be c lass i f ied acco rd ing to h is “bes t response ” fo r the pu rposes o f ana lys is o f t rea tmen t e f fec t . Bes t response is de te rm ined as ou t l ined in Sec t ion 9 .4 f rom a sequence o f ove ra l l response assessmen ts . 9 .4 Bes t Response 9 .4 .1Eva lua t ion o f Bes t Ove ra l l Response The bes t ove ra l l response is the bes t response reco rded f rom the s ta r t o f the t rea tmen t un t i l d isease p rog ress ion/ recu r rence ( tak ing as re fe rence fo r p rog ress ive d isease the sma l les t measu remen ts reco rded s ince the t rea tmen t s ta r ted ) . The pa t ien t 's bes t response ass ignmen t w i l l depend on the ach ievemen t o f bo th measu remen t and con f i rma t ion c r i te r ia . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
59,page_59,"OSTPDL1 Page 53 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Tab le 1 : Pa t ien ts w i th Measu rab le D isease ( i .e . , Ta rge t D isease ) Ta rge t Les ions Non-Ta rge t Les ions New Les ions Ove ra l l Response CR CR No CR CR Non-CR/Non-PD No PR CR No t eva lua ted No PR PR Non-CR/Non- PD/no t eva lua ted No PR SD Non-CR/Non- PD/no t eva lua ted No SD PD Any Yes o r No PD Any PD * Yes o r No PD Any Any Yes PD * In excep t iona l c i rcums tances , unequ ivoca l p rog ress ion in non- ta rge t les ions may be accep ted as d isease p rog ress ion . No te : Pa t ien ts w i th a g loba l de te r io ra t ion o f hea l th s ta tus requ i r ing d iscon t inua t ion o f t rea tmen t w i thou t any ob jec t ive ev idence o f d isease p rog ress ion a t tha t t ime shou ld be repo r ted as “symp toma t ic de te r io ra t ion . ” Eve ry e f fo r t shou ld be made to documen t the ob jec t ive p rog ress ion even a f te r d iscon t inua t ion o f t rea tmen t . Tab le 2 : Pa t ien ts w i th Non-Measu rab le D isease ( i .e . , Non-Ta rge t D isease ) Non-Ta rge t Les ions New Les ions Ove ra l l Response CR No CR Non-CR/Non-PD No Non-CR/Non-PD * No t a l l eva lua ted No No t eva lua ted Unequ ivoca l PD Yes o r No PD Any Yes PD * “non-CR/non-PD ” is p re fe r red ove r “s tab le d isease ” fo r non- ta rge t d isease s ince SD is inc reas ing ly used as an endpo in t fo r assessmen t o f e f f icacy in some t r ia ls so to ass ign th is ca tego ry when no les ions can be measu red is no t adv ised . Tab le 3 : Sequences o f ove ra l l response assessmen ts w i th co r respond ing bes t response 1s t Assessmen t 2nd Assessmen t Bes t Response P rog ress ion P rog ress ive d isease S tab le , PR , CR P rog ress ion P rog ress ive d isease S tab le S tab le S tab le S tab le PR , CR S tab le S tab le No t done No t REC IST c lass i f iab le PR PR PR PR CR PR PR , CR No t done No t REC IST c lass i f iab le CR CR CR S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
60,page_60,"OSTPDL1 Page 54 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 9 .5 Du ra t ion o f Response Du ra t ion o f ove ra l l response : The du ra t ion o f ove ra l l response is measu red f rom the t ime measu remen t c r i te r ia a re me t fo r CR o r PR (wh icheve r is f i rs t reco rded ) un t i l the f i rs t da te tha t recu r ren t o r p rog ress ive d isease is ob jec t ive ly documen ted ( tak ing as re fe rence fo r p rog ress ive d isease the sma l les t measu remen ts reco rded s ince the t rea tmen t s ta r ted ) . The du ra t ion o f ove ra l l CR is measu red f rom the t ime measu remen t c r i te r ia a re f i rs t me t fo r CR un t i l the f i rs t da te tha t p rog ress ive d isease is ob jec t ive ly documen ted . Du ra t ion o f s tab le d isease : S tab le d isease is measu red f rom the s ta r t o f the t rea tmen t un t i l the c r i te r ia fo r p rog ress ion a re me t , tak ing as re fe rence the sma l les t measu remen ts reco rded s ince the t rea tmen t s ta r ted , inc lud ing the base l ine measu remen ts . 9 .6 Tox ic i ty Eva lua t ion C r i te r ia Th is s tudy w i l l u t i l ize the CTCAE v4 .03 fo r tox ic i ty and pe r fo rmance repo r t ing . A copy o f the CTCAE v4 .03 can be down loaded f rom the CTEP home page ( h t tp ://c tep . in fo .n ih .gov ) . Add i t iona l ly , the tox ic i t ies a re to be repo r ted on the app rop r ia te da ta co l lec t ion fo rms . 10 .0 OFF TREATMENT AND OFF STUDY CR ITER IA A genu ine e f fo r t mus t be made to de te rm ine the reason (s ) why a pa r t ic ipan t fa i ls to re tu rn fo r the necessa ry v is i ts o r is d iscon t inued f rom the t r ia l . In fo rma t ion rega rd ing the reason fo r no t comp le t ing the t r ia l w i l l be reco rded on the app rop r ia te case repo r t fo rms . I t w i l l be documen ted whe the r o r no t each pa t ien t comp le ted the c l in ica l s tudy . I f fo r any pa t ien t s tudy t rea tmen t o r obse rva t ions we re d iscon t inued , the reason w i l l be reco rded on the app rop r ia te case repo r t fo rm . Reasons tha t a pa t ien t may d iscon t inue pa r t ic ipa t ion in a c l in ica l s tudy a re l is ted be low . A l l pa t ien ts w i l l be fo l lowed fo r su rv iva l un t i l they mee t the c r i te r ia fo r o f f-s tudy . 10 .1 O f f T rea tmen t C r i te r ia ·C l in ica l o r rad iog raph ic ev idence o f p rog ress ive d isease o f g rea te r than 20% inc rease base l ine ta rge t les ions se lec ted acco rd ing to REC IST c r i te r ia ·Adve rse even ts/ tox ic i ty requ i r ing remova l f rom p ro toco l the rapy ·Re fusa l o f fu r the r p ro toco l the rapy by pa t ien t/pa ren t/gua rd ian ·Non-comp l iance tha t in the op in ion o f the inves t iga to r does no t a l low fo r ongo ing pa r t ic ipa t ion S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
61,page_61,"OSTPDL1 Page 55 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 ·Phys ic ian de te rm ines i t is no t in the pa t ien t ’s bes t in te res t to con t inue on the rapy ·Repea ted e l ig ib i l i ty labo ra to ry s tud ies a re ou ts ide the pa rame te rs requ i red fo r e l ig ib i l i ty p r io r to the s ta r t o f p ro toco l the rapy ·S tudy is te rm ina ted by the sponso r ·P regnancy ·Deve lopmen t o f a second ma l ignancy 10 .2 O f f S tudy C r i te r ia ·Dea th ·Los t to fo l low-up ·Pa t ien t subsequen t en ro l lmen t on ano the r s tudy w i th tumo r the rapeu t ic in ten t (e .g . a t recu r rence ) o r add i t iona l non-p ro toco l an t i- tumo r the rapy . ·W i thd rawa l o f consen t fo r any fu r the r da ta subm iss ion ·Pa t ien t d id no t rece ive p ro toco l t rea tmen t a f te r s tudy en ro l lmen t ·W i thd rawa l o f consen t 11 .0SAFETY AND ADVERSE EVENT REPORT ING REQU IREMENTS 11 .1 Repo r t ing Adve rse Expe r iences and Dea ths to S t . Jude IRB On ly “unan t ic ipa ted p rob lems invo lv ing r isks to pa r t ic ipan ts o r o the rs ” re fe r red to he rea f te r as “unan t ic ipa ted p rob lems ” a re requ i red to be repo r ted to the S t . Jude IRB p romp t ly , bu t in no even t la te r than 10 wo rk ing days a f te r the inves t iga to r f i rs t lea rns o f the unan t ic ipa ted p rob lem . Rega rd less o f whe the r the even t is in te rna l o r ex te rna l ( fo r examp le , an IND sa fe ty repo r t by the sponso r pu rsuan t to 21 CFR 312 .32 ) , on ly adve rse even ts tha t cons t i tu te unan t ic ipa ted p rob lems a re repo r tab le to the S t . Jude IRB . As fu r the r desc r ibed in the de f in i t ion o f unan t ic ipa ted p rob lem , th is inc ludes any even t tha t in the P I ’s op in ion was : ·Unexpec ted ( in te rms o f na tu re , seve r i ty , o r f requency ) g iven (1 ) the resea rch p rocedu res tha t a re desc r ibed in the p ro toco l- re la ted documen ts , such as the IRB-app roved resea rch p ro toco l and in fo rmed consen t documen t , as we l l as o the r re levan t in fo rma t ion ava i lab le abou t the resea rch ; (2 ) the obse rved ra te o f occu r rence (compa red to a c red ib le base l ine fo r compa r ison ) ; and (3 ) the cha rac te r is t ics o f the sub jec t popu la t ion be ing s tud ied ; and ·Re la ted o r poss ib ly re la ted to pa r t ic ipa t ion in the resea rch ; and ·Se r ious ; o r i f no t se r ious sugges ts tha t the resea rch p laces sub jec ts o r o the rs a t a g rea te r r isk o f ha rm ( inc lud ing phys ica l , psycho log ica l , econom ic , o r soc ia l ha rm ) than was p rev ious ly known o r recogn ized . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
62,page_62,"OSTPDL1 Page 56 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Un re la ted , expec ted dea ths tha t occu r a f te r pa t ien t has comp le ted p ro toco l t rea tmen t do no t requ i re repo r t ing to the IRB . Though dea th is “se r ious ” , the even t mus t mee t the o the r two requ i remen ts o f “ re la ted o r poss ib ly re la ted ” and “unexpec ted/unan t ic ipa ted ” to be cons ide red repo r tab le . Howeve r , a l l dea ths wh i le on ac t ive p ro toco l t rea tmen t (o r w i th in 30 days o f las t p ro toco l t rea tmen t ) w i l l be requ i re repo r t ing to the IRB . Dea ths mee t ing repo r t ing requ i remen ts a re to be repo r ted immed ia te ly to the S t . Jude IRB , bu t in no even t la te r than 48 hou rs a f te r the inves t iga to r f i rs t lea rns o f the dea th . The fo l low ing de f in i t ions app ly w i th respec t to repo r t ing adve rse expe r iences : Se r ious adve rse even t (SAE ) : Any adve rse even t tempo ra l ly assoc ia ted w i th the sub jec t ’s pa r t ic ipa t ion in resea rch tha t mee ts any o f the fo l low ing c r i te r ia : ·resu l ts in dea th ; ·is l i fe- th rea ten ing (p laces the sub jec t a t immed ia te r isk o f dea th f rom the even t as i t occu r red ) ; ·requ i res inpa t ien t hosp i ta l iza t ion o r p ro longa t ion o f ex is t ing hosp i ta l iza t ion ; ·resu l ts in a pe rs is ten t o r s ign i f ican t d isab i l i ty/ incapac i ty ; ·resu l ts in a congen i ta l anoma ly/b i r th de fec t ; o r any o the r adve rse even t tha t , based upon app rop r ia te med ica l judgmen t , may jeopa rd ize the sub jec t ’s hea l th and may requ i re med ica l o r su rg ica l in te rven t ion to p reven t one o f the o the r ou tcomes l is ted in th is de f in i t ion (examp les o f such even ts inc lude : any subs tan t ia l d is rup t ion o f the ab i l i ty to conduc t no rma l l i fe func t ions , a l le rg ic b ronchospasm requ i r ing in tens ive t rea tmen t in the eme rgency room o r a t home , b lood dysc ras ias o r convu ls ions tha t do no t resu l t in inpa t ien t hosp i ta l iza t ion , o r the deve lopmen t o f d rug dependency o r d rug abuse ) , a congen i ta l anoma ly/b i r th de fec t , seconda ry o r concu r ren t cance r , med ica t ion ove rdose , o r is any med ica l even t wh ich requ i res t rea tmen t to p reven t any o f the med ica l ou tcomes p rev ious ly l is ted . Unexpec ted adve rse even t : ·Any adve rse even t fo r wh ich the spec i f ic i ty o r seve r i ty is no t cons is ten t w i th the p ro toco l- re la ted documen ts , inc lud ing the app l icab le inves t iga to r b rochu re , IRB app roved consen t fo rm , Inves t iga t iona l New D rug ( IND ) o r Inves t iga t iona l Dev ice Exemp t ion ( IDE ) app l ica t ion , o r o the r re levan t sou rces o f in fo rma t ion , such as S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
63,page_63,"OSTPDL1 Page 57 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 p roduc t labe l ing and package inse r ts ; o r i f i t does appea r in such documen ts , an even t in wh ich the spec i f ic i ty , seve r i ty o r du ra t ion is no t cons is ten t w i th the r isk in fo rma t ion inc luded the re in ; o r ·The obse rved ra te o f occu r rence is a c l in ica l ly s ign i f ican t inc rease in the expec ted ra te (based on a c red ib le base l ine ra te fo r compa r ison ) ; o r ·The occu r rence is no t cons is ten t w i th the expec ted na tu ra l p rog ress ion o f any unde r ly ing d isease , d iso rde r , o r cond i t ion o f the sub jec t (s ) expe r ienc ing the adve rse even t and the sub jec t ’s p red ispos ing r isk fac to r p ro f i le fo r the adve rse even t . In te rna l even ts : Even ts expe r ienced by a resea rch pa r t ic ipan t en ro l led a t a s i te unde r the ju r isd ic t ion o f S t . Jude IRB fo r e i the r mu l t icen te r o r s ing le- cen te r resea rch p ro jec ts . Ex te rna l even ts : Even ts expe r ienced by pa r t ic ipan ts en ro l led a t a s i te ex te rna l to the ju r isd ic t ion o f the S t . Jude Ins t i tu t iona l Rev iew Boa rd ( IRB ) o r in a s tudy fo r wh ich S t . Jude is no t the coo rd ina t ing cen te r o r the IRB o f reco rd . Unan t ic ipa ted p rob lem invo lv ing r isks to sub jec ts o r o the rs : An unan t ic ipa ted p rob lem invo lv ing r isks to sub jec ts o r o the rs is an even t , wh ich was no t expec ted to occu r and wh ich inc reases the deg ree o f r isk posed to resea rch pa r t ic ipan ts . Such even ts , in gene ra l , mee t a l l o f the fo l low ing c r i te r ia : ·unexpec ted ; ·re la ted o r poss ib ly re la ted to pa r t ic ipa t ion in the resea rch ; and ·sugges ts tha t the resea rch p laces sub jec ts o r o the rs a t a g rea te r r isk o f ha rm ( inc lud ing phys ica l , psycho log ica l , econom ic , o r soc ia l ha rm ) than was p rev ious ly known o r recogn ized . An unan t ic ipa ted p rob lem invo lv ing r isk to sub jec ts o r o the rs may ex is t even when ac tua l ha rm does no t occu r to any pa r t ic ipan t . Cons is ten t w i th FDA and OHRP gu idance on repo r t ing unan t ic ipa ted p rob lems and adve rse even ts to IRBs , the S t . Jude IRB does no t requ i re the subm iss ion o f ex te rna l even ts , fo r examp le IND sa fe ty repo r ts , no r is a summa ry o f such even ts/ repo r ts requ i red ; howeve r , i f an even t g iv ing r ise to an IND sa fe ty o r o the r ex te rna l even t repo r t cons t i tu tes an “unan t ic ipa ted p rob lem invo lv ing r isks to sub jec ts o r o the rs ” i t mus t be repo r ted in acco rdance w i th th is po l icy . In gene ra l , to be repo r tab le ex te rna l even ts need to have imp l ica t ions fo r the conduc t o f the s tudy ( fo r examp le , requ i r ing a s ign i f ican t and usua l ly sa fe ty- re la ted change in the p ro toco l and/o r in fo rmed consen t fo rm ) . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
64,page_64,"OSTPDL1 Page 58 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 A l though some adve rse even ts w i l l qua l i fy as unan t ic ipa ted p rob lems invo lv ing r isks to sub jec ts o r o the rs , some w i l l no t ; and the re may be o the r unan t ic ipa ted p rob lems tha t go beyond the de f in i t ions o f se r ious and/o r unexpec ted adve rse even ts . Examp les o f unan t ic ipa ted p rob lems invo lv ing r isks to sub jec ts o r o the rs inc lude : ·Imp rope r ly s tag ing a pa r t ic ipan t ’s tumo r resu l t ing in the pa r t ic ipan t be ing ass igned to an inco r rec t a rm o f the resea rch s tudy ; ·The the f t o f a resea rch compu te r con ta in ing con f iden t ia l sub jec t in fo rma t ion (b reach o f con f iden t ia l i ty ) ; and ·The con tam ina t ion o f a s tudy d rug . Unan t ic ipa ted p rob lems gene ra l ly w i l l wa r ran t cons ide ra t ion o f subs tan t ive changes in the resea rch p ro toco l o r in fo rmed consen t p rocess/documen t o r o the r co r rec t ive ac t ions in o rde r to p ro tec t the sa fe ty , we l fa re , o r r igh ts o f sub jec ts o r o the rs . The p r inc ipa l inves t iga to r has the ob l iga t ion to repo r t a l l se r ious adve rse even ts to the FDA and IRB . 11 .2 Repo r t ing to S t Jude IRB Th is is an inves t iga to r- in i t ia ted s tudy . The p r inc ipa l inves t iga to r , M ichae l W . B ishop and S t . Jude a re conduc t ing the s tudy and ac t ing as the sponso r . The re fo re , the lega l/e th ica l ob l iga t ions o f the p r inc ipa l inves t iga to r inc lude bo th those o f a sponso r and those o f an inves t iga to r . 11 .3Repo r t ing f rom S t . Jude to P f ize r (D rug Manu fac tu re r ) The inves t iga to r p r ima ry respons ib i l i t ies in the sa fe ty repo r t ing a re to iden t i fy and fo l low-up on Se r ious Adve rse Even ts (SAEs ) expe r ienced by pa r t ic ipan ts in the s tudy and to fo rwa rd the in fo rma t ion to the loca l regu la to ry au tho r i t ies and P f ize r , as requ i red by loca l regu la t ions ( fo r regu la to ry repo r t ing ) and I IR ag reemen t ( fo r repo r t ing to P f ize r ) . The fo l low ing repo r tab le even ts mus t be subm i t ted to P f ize r w i th in 24 hou rs (o r immed ia te ly fo r dea th o r l i fe- th rea ten ing even ts ) us ing the p rov ided Inves t iga to r- In i t ia ted Resea rch Se r ious Adve rse Even t Fo rm ( I IR SAE ) w i th the P f ize r Repo r tab le Even ts Fax Cove r Shee t w i th each SAE subm iss ion . ·Adve rse Even ts tha t a re se r ious AND unexpec ted ·Exposu re du r ing P regnancy o r B reas t feed ing (even i f no t assoc ia ted w i th an adve rse even t ) ·Occupa t iona l exposu re (even i f no t assoc ia ted w i th an adve rse even t ) S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
65,page_65,"OSTPDL1 Page 59 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 ·Po ten t ia l d rug- induced l ive r in ju ry (Hy ’s Law cases ) : These even ts a re cons ide red impo r tan t med ica l even ts and shou ld be repo r ted as SAEs . De ta i led gu idance on the sa fe ty repo r t ing is p rov ided in the Sa fe ty Repo r t ing Re fe rence Manua l . Con tac t in fo rma t ion fo r subm iss ion o f repo r tab le even ts to P f ize r : Fax : P f ize r U .S . C l in ica l T r ia l Depa r tmen t , Fax 1-866-997-8322 . o r E-ma i l : CTPG ran ts@p f ize r .com , spec i fy ing : ·P ro toco l ·Resea rch Pa r t ic ipan t ID ·S i te P I ·SAE/Onse t 11 .4Repo r t ing to S t . Jude Regu la to ry A f fa i rs O f f ice and FDA Any unan t ic ipa ted fa ta l o r unan t ic ipa ted l i fe- th rea ten ing even t judged by the P I to be a t leas t poss ib ly due to the s tudy t rea tmen t , w i l l be repo r ted to the FDA by te lephone o r fax as soon as poss ib le bu t no la te r than seven ca lenda r days a f te r no t i f ica t ion o f the even t and fo l lowed by a w r i t ten sa fe ty repo r t as comp le te as poss ib le w i th in e igh t add i t iona l ca lenda r days ( i .e . fu l l repo r t 15 ca lenda r days to ta l a f te r no t i f ica t ion o f even t ) . Unan t ic ipa ted , non- fa ta l and non- l i fe- th rea ten ing adve rse even ts tha t occu r in on-s tudy pa t ien ts and tha t a re cons ide red due to o r poss ib ly due to the inves t iga t iona l agen t , w i l l be repo r ted to the FDA by w r i t ten sa fe ty repo r t as soon as poss ib le bu t no la te r than 15 ca lenda r days o f the no t i f ica t ion o f the occu r rence o f the even t . Expec ted SAEs , even unexpec ted fa ta l SAEs , cons ide red by the P I to be no t re la ted to the s tudy , w i l l be repo r ted to the FDA in the Annua l Rev iew Repo r t a long w i th non-se r ious AEs . A l l FDA co r respondence and repo r t ing w i l l be conduc ted th rough the S t . Jude O f f ice o f Regu la to ry A f fa i rs . Cop ies o f a l l co r respondence to the S t . Jude IRB , inc lud ing SAE repo r ts , a re p rov ided to the S t . Jude Regu la to ry A f fa i rs o f f ice by the S t . Jude s tudy team . FDA- re la ted co r respondence and repo r t ing w i l l be conduc ted th rough the Regu la to ry A f fa i rs o f f ice . 11 .5 Reco rd ing Adve rse Even ts and Se r ious Adve rse Even ts Adve rse even ts (AEs ) w i l l be eva lua ted and documen ted by the c l in ica l s ta f f and inves t iga to rs th roughou t inpa t ien t hosp i ta l iza t ions and each ou tpa t ien t v is i t . CRAs a re respons ib le fo r rev iew ing documen ta t ion S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
66,page_66,"OSTPDL1 Page 60 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 re la ted to AEs and en te r ing d i rec t ly in to CR IS p ro toco l-spec i f ic da tabase fo r a l l adve rse even ts g rade 3 o r h ighe r . Pe r iphe ra l neu ropa thy w i l l be cap tu red i f G rade 2 o r h ighe r . The da ta to be reco rded a re 1 ) the even t desc r ip t ion , 2 ) the NC I CTCAE v4 .0 code and g rade , 3 ) the onse t da te , 4 ) the reso lu t ion da te (o r ongo ing i f i t has no t reso lved a t t ime o f o f f s tudy ) , 4 ) ac t ion taken fo r even t , 5 ) pa t ien t ou tcome 6 ) re la t ionsh ip o f AE to p ro toco l t rea tmen t/ in te rven t ions , 7 ) i f AE was expec ted o r unexpec ted , and 8 ) commen ts , i f app l icab le . AEs tha t a re c lass i f ied as se r ious , unexpec ted , and a t leas t poss ib ly re la ted w i l l be no ta ted as such in the da tabase as “SAEs ” . These even ts w i l l be repo r ted exped i t ious ly to the S t . Jude IRB w i th in the t ime f rames as desc r ibed above . Cumu la t ive summa ry o f G rade 2 c l in ica l ly re levan t even ts and a l l G rades 3-5 even ts w i l l be repo r ted as pa r t o f the p rog ress repo r ts to IRB a t the t ime o f con t inu ing rev iew . Spec i f ic da ta en t ry ins t ruc t ions fo r AEs and o the r p ro toco l- re la ted da ta w i l l be documen ted in p ro toco l-spec i f ic da ta en t ry gu ide l ines , wh ich w i l l be deve loped and ma in ta ined by s tudy team and c l in ica l resea rch in fo rma t ics . The s tudy team w i l l mee t regu la r ly to d iscuss AEs (and o the r s tudy p rog ress as requ i red by ins t i tu t iona l DSMP ) . The P I w i l l rev iew Adve rse Even t repo r ts gene ra ted f rom the resea rch da tabase , and co r rec t ions w i l l be made i f app l icab le . Once the in fo rma t ion is f ina l the P I w i l l s ign and da te repo r ts , to acknow ledge h is/he r rev iew and app rova l o f the AE as en te red in the resea rch da tabase . 11 .6 P rocess fo r Repo r t ing Adve rse Even ts f rom and to Co l labo ra t ing S i tes Adve rse even ts f rom co l labo ra t ing s i tes w i l l a lso be rev iewed by the P I and d iscussed in s tudy team mee t ings as desc r ibed above . SAE repo r ts f rom co l labo ra t ing s i tes fo r AEs tha t a re se r ious , unexpec ted , and a t leas t poss ib ly re la ted to p ro toco l t rea tmen t o r in te rven t ions w i l l be repo r ted to s i te IRB and the S t . Jude IRB w i th in the repo r t ing requ i remen ts desc r ibed above . The P I w i l l de te rm ine i f th is is an even t tha t w i l l need to be repo r ted exped i t ious ly to a l l pa r t ic ipa t ing s i tes , cons ide r ing the fo l low ing c r i te r ia : ·Is the AE se r ious , unexpec ted , and re la ted o r poss ib ly re la ted to pa r t ic ipa t ion in the resea rch ? ·Is the AE expec ted , bu t occu r r ing a t a s ign i f ican t ly h ighe r f requency o r seve r i ty than expec ted ? ·Is th is an AE tha t is unexpec ted ( rega rd less o f seve r i ty tha t may a l te r the IRB ’s ana lys is o f the r isk ve rsus po ten t ia l bene f i t o f the resea rch and , as a resu l t , wa r ran t cons ide ra t ion o f subs tan t ive changes in the resea rch p ro toco l o r in fo rmed consen t p rocess/documen t ? S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
67,page_67,"OSTPDL1 Page 61 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 W i th the subm iss ion o f the “Repo r tab le Even t ” in S t . Jude TRACKS app l ica t ion , the P I w i l l ind ica te i f a l l s i tes shou ld be no t i f ied to repo r t to the i r IRBs , and i f the p ro toco l and/o r consen t shou ld be amended (consen t w i l l be amended i f even t is in fo rma t ion tha t shou ld be commun ica ted to cu r ren t ly en ro l led sub jec ts ) . Gene ra l ly , on ly even ts tha t wa r ran t an amendmen t to the p ro toco l and/o r consen t w i l l be repo r ted exped i t ious ly to a l l s i tes . Howeve r , any even t may be repo r ted exped i t ious ly to a l l s i tes a t the d isc re t ion o f the P I . A cumu la t ive summa ry o f G rade 2-5 AEs and expec ted/un re la ted dea ths tha t occu r mo re than 30 days a f te r p ro toco l t rea tmen t w i l l be repo r ted to a l l s i tes w i th s tudy p rog ress repo r t a t the t ime o f con t inu ing rev iew . Fo r co l labo ra t ing s i tes : Se r ious AND unexpec ted even ts a re to be repo r ted to the S t . Jude P I (D r . M ichae l B ishop ) w i th in 48-72 hou rs v ia fax o r ema i l . Unexpec ted dea ths mus t be repo r ted to the S t . Jude P I by ema i l o r phone ca l l to D r . M ichae l B ishop w i th in 24 hou rs o f the even t . A w r i t ten repo r t mus t fo l low . The s tudy team shou ld be cop ied on a l l co r respondence rega rd ing the even t . Sen t repo r t to : M ichae l W . B ishop , MD , MS Depa r tmen t o f Onco logy , So l id Tumo r D iv is ion S t . Jude Ch i ld ren ’s Resea rch Hosp i ta l 262 Danny Thomas P lace Memph is , TN 38105 Phone : 901-595-6407 Ema i l : M ichae l .B ishop@s t jude .o rg OSTPDL1S tudyTeam@s t jude .o rg 12 .0 DATA COLLECT ION , MON ITOR ING AND CONF IDENT IAL ITY 12 .1 Da ta Co l lec t ion E lec t ron ic case repo r t fo rms (e-CRFs ) w i l l be comp le ted by the c l in ica l t r ia ls s ta f f f rom the Cance r Cen te r Comp rehens ive Cen te r , Deve lopmen ta l The rapeu t ics fo r So l id Tumo r p rog ram . Da ta w i l l be en te red f rom reco rd d i rec t ly in to a secu re CR IS da tabase , deve loped and ma in ta ined by S t . Jude C l in ica l Resea rch In fo rma t ics . Da ta Managemen t w i l l be supe rv ised by the D i rec to r o f C l in ica l T r ia ls Managemen t , and Manage r o f C l in ica l Resea rch Ope ra t ions fo r the Deve lopmen ta l B io logy fo r So l id Tumo rs P rog ram wo rk ing w i th D r . B ishop o r h is des ignee . A l l p ro toco l-spec i f ic da ta and a l l g rade 2-5 adve rse even ts w i l l be reco rded by the c l in ica l resea rch assoc ia tes in to the CR IS da tabase , idea l ly w i th in 2-4 weeks o f comp le t ion o f cyc le . A l l ques t ions w i l l be d i rec ted to the a t tend ing phys ic ian and/o r P I and rev iewed a t S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
68,page_68,"OSTPDL1 Page 62 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 regu la r ly-schedu led wo rk ing mee t ings . The a t tend ing phys ic ians (o r the i r des ignees ) a re respons ib le fo r keep ing up- to-da te roadmaps in the pa t ien t ’s p r ima ry S JCRH med ica l cha r t . Regu la r (a t leas t mon th ly ) summa r ies o f tox ic i ty and p ro toco l even ts w i l l be gene ra ted fo r the P I and the depa r tmen t o f B ios ta t is t ics to rev iew . 12 .2S tudy Mon i to r ing Mon i to r ing o f th is p ro toco l is cons ide red to be in the h igh- r isk 3 ca tego ry (HR-3 ) . The s tudy spec i f ic Mon i to r ing P lan is a sepa ra te documen t f rom th is p ro toco l . The s tudy team w i l l mee t a t app rop r ia te in te rva ls to rev iew case h is to r ies o r qua l i ty summa r ies on pa r t ic ipan ts . H igh l igh ts o f the p ro toco l mon i to r ing p lan a re be low : The C l in ica l Resea rch Mon i to r w i l l assess p ro toco l and regu la to ry comp l iance as we l l as the accu racy and comp le teness o f a l l da ta po in ts fo r the f i rs t two pa r t ic ipan ts then 15% o f s tudy en ro l lees eve ry s ix mon ths . Acc rua l w i l l be t racked con t inuous ly fo r s tud ies tha t have s t ra ta . A l l SAE repo r ts w i l l be mon i to red fo r type , g rade , a t t r ibu t ion , du ra t ion , t ime l iness and app rop r ia teness on a l l s tudy pa r t ic ipan ts sem i-annua l ly . The mon i to r w i l l a lso ve r i fy 100% o f a l l da ta po in ts on the f i rs t two pa r t ic ipan ts and on 15% o f cases the rea f te r . P ro toco l comp l iance mon i to r ing w i l l inc lude pa r t ic ipan t s ta tus , e l ig ib i l i ty , the in fo rmed consen t p rocess , demog raph ics , s tag ing , s tudy ob jec t ives , subg roup ass ignmen t , t rea tmen ts , eva lua t ions , responses , pa r t ic ipan t p ro toco l s ta tus , o f f-s tudy , and o f f- the rapy c r i te r ia . The Mon i to r w i l l gene ra te a fo rma l repo r t wh ich is sha red w i th the P r inc ipa l Inves t iga to r (P I ) , s tudy team and the In te rna l Mon i to r ing Comm i t tee ( IMC ) . Mon i to r ing may be conduc ted mo re f requen t ly i f deemed necessa ry by adm in is t ra t ion , the Ins t i tu t iona l Rev iew Boa rd ( IRB ) , o r the IMC . Con t inu ing rev iews by the IRB and CT-SRC w i l l occu r a t leas t annua l ly . In add i t ion , SAE repo r ts in TRACKS (To ta l Resea rch and Know ledge Sys tem ) a re rev iewed in a t ime ly manne r by the IRB/ OHSP . Sou rce documen t ve r i f ica t ion o f e l ig ib i l i ty fo r a l l S JCRH cases w i l l be pe r fo rmed w i th in two weeks o f comp le t ion o f en ro l lmen t . Th is w i l l inc lude ve r i f ica t ion o f app rop r ia te documen ta t ion o f consen t . Mon i to r ing o f t ime l iness o f se r ious adve rse even t repo r t ing w i l l be done as even ts a re repo r ted in TRACKS . S t . Jude a f f i l ia tes and domes t ic co l labo ra t ing s tudy s i tes w i l l be mon i to red on-s i te by a rep resen ta t ive o f S t . Jude a t in te rva ls spec i f ied in the Da ta and Sa fe ty Mon i to r ing P lan . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
69,page_69,"OSTPDL1 Page 63 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 12 .3 Con f iden t ia l i ty Da ta abs t rac ted f rom the sub jec t ’s med ica l reco rd and en te red in to CRFs w i l l be en te red in to a secu re , passwo rd p ro tec ted , p ro toco l-spec i f ic da tabase ma in ta ined by S t . Jude C l in ica l Resea rch In fo rma t ics . The da tabase w i l l be s to red in secu re s i tes . A l l pa r t ic ipan ts w i l l be g iven a un ique numbe r and tha t w i l l be the i r iden t i f ie r in the t r ia l . Tha t numbe r w i l l be reco rded on an en ro l lmen t log , l ink ing the numbe r to the pa r t ic ipan t ’s name , and tha t log w i l l be s to red secu re ly in the t r ia l mas te r f i le . The p r ivacy o f the s tudy sub jec t and a l l con f iden t ia l i t ies w i l l be hand led acco rd ing to ins t i tu t iona l and ICH gu ide l ines . Any pub l ica t ion o r p resen ta t ion w i l l no t iden t i fy ind iv idua l sub jec ts by name . The med ica l reco rds o f s tudy pa r t ic ipan ts may be rev iewed by the S t . Jude IRB , FDA , and c l in ica l resea rch mon i to rs . 13 .0STAT IST ICAL CONS IDERAT IONS 13 .1S tudy Des ign 13 .1 .1 P r ima ry ob jec t ives P r ima ry ob jec t ive 1 : To es t ima te the response ra te to fou r cyc les o f ave lumab in pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma . P r ima ry ob jec t ive 2 : To es t ima te the 12-week p rog ress ion- f ree su rv iva l o f pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma a f te r t rea tmen t w i th ave lumab . Respons ib le inves t iga to rs : M ichae l B ishop , A lbe r to Pappo Respons ib le B ios ta t is t ic ians : J ian rong Wu Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 12/31/2021 The s tudy is des igned by t rea t ing REC IST response (CR+PR ) a f te r 4-cyc le t rea tmen t o f ave lumab and the 16-week p rog ress ion- f ree su rv iva l (PFS ) as dua l b ina ry endpo in ts us ing the me thod p roposed by Koche rg insky e t a l (so f twa re ava i lab le upon reques t ) . 91 Fo r each pa t ien t , two ou tcomes : REC IST response (CR+PR ) and 16-week PFS w i l l be reco rded a t the end o f 4-cyc le t rea tmen t o f ave lumab , he re 16-week PFS is de f ined as a b ina ry endpo in t fo r pa t ien ts who had response (CR+PR ) o r s tab le d isease (SD ) a f te r 4-cyc le t rea tmen t o f ave lumab . Pa t ien ts who fa i l to be eva lua ted fo r response o r PFS a t the end o f the 4-cyc le w i l l be coun ted as fa i lu re (no response and d isease p rog ress ion ) . The fo l low ing tab le summa r izes the samp le s ize and the dec is ion ru le fo r the in te r im and f ina l ana lyses based on 10% type I e r ro r and 90% powe r and us ing the me thod p roposed by Koche rg insky e t a l . The p roposed des ign be low (Tab le 13 .1 ) is used to S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
70,page_70,"OSTPDL1 Page 64 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 gua rd aga ins t fu t i l i ty and to fac i l i ta te the samp le s ize ca lcu la t ion based on the fo l low ing nu l l and a l te rna t ive hypo theses : H0 : p r≤5% and pnp ≤15% vs . the a l te rna t ive Ha : p r>20% o r pnp >35% whe re p r is the t rue response ra te and pnp is the t rue non- p rog ress ion ra te . A to ta l o f 32 pa t ien ts a re needed fo r the s tudy w i th one in te r im ana lys is a f te r the f i rs t 18 pa t ien ts had response and PFS eva lua t ion . Acc rua l w i l l be tempo ra r i ly suspended a t the t ime the in te r im samp le s ize is reached (when the f i rs t 18 eva luab le pa t ien ts a re en ro l led ) un t i l the in te r im ru les a re eva lua ted . The s tudy w i l l be c losed i f the th resho lds be low a t s tage 1 a re exceeded : Tab le 13 .1 : B iva r ia te B inom ia l Two-s tage Des ign S tage Samp le S ize Dec is ion ru le 118 Con t inue t r ia l i f : # o f response ≥ 2 o r # o f pa t ien ts w i thou t PD a f te r 4-cyc le ≥ 3 232 Conc lude the rapy is p rom is ing i f : # o f response ≥ 4 o r # o f pa t ien ts w i thou t PD a f te r 4-cyc le ≥ 9 Th is des ign y ie lds 90% powe r to de tec t a t rue response ra te o f a t leas t 20% o r a t rue 16-week p rog ress ion- f ree ra te (CR+PR+SD ) o f a t leas t 35% . The type I e r ro r is es t ima ted as 9 .2% i f the t rue response ra te is no mo re than 5% and the t rue 16-week p rog ress ion- f ree ra te is no mo re than 35% , w i th app rox ima te ly 45% p robab i l i ty o f ea r ly s topp ing in th is case . Pa t ien ts who a re removed f rom t rea tmen t due to tox ic i ty w i l l be a lso be t rea ted as fa i lu res (non- response and d isease p rog ress ion ) . Thus , a to ta l o f 40 pa t ien ts w i l l insu re tha t 32 pa t ien ts a re eva luab le fo r the p r ima ry ob jec t ives . I t is an t ic ipa ted tha t the s tudy w i l l en ro l l 10 pa t ien ts pe r yea r , thus the s tudy acc rua l du ra t ion w i l l be app rox ima te ly 4 yea rs and the response and 16-week PFS da ta fo r a l l pa t ien ts w i l l be ava i lab le in app rox ima te 4 .5 yea rs . 13 .2Seconda ry Ob jec t ives 13 .2 .1 To desc r ibe the tox ic i t ies assoc ia ted w i th the adm in is t ra t ion o f ave lumab in pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
71,page_71,"OSTPDL1 Page 65 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 Respons ib le inves t iga to rs : M ichae l B ishop , A lbe r to Pappo Respons ib le B ios ta t is t ic ians : J ian rong Wu Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 3/31/2023 Ta rge t tox ic i t ies fo r ave lumab t rea tmen t a re de f ined as any g rade 3-5 dyspnea , pneumon i t is , in fus ion- re la ted reac t ions , o r immune re la ted adve rse even ts a t leas t poss ib ly a t t r ibu tab le to the agen t obse rved any t ime du r ing the 26-cyc le t rea tmen t pe r iod tha t a pa t ien t is on s tudy ( inc lud ing the pe r iod be tween o f f t rea tmen t and o f f s tudy ) . Due to a l im i ted numbe r o f pa t ien ts , fo l low ing ad hoc s topp ing ru le w i l l be used to s top the t r ia l acc rua l i f 3 o r mo re pa t ien ts in the f i rs t 10 pa t ien ts had ta rge t tox ic i t ies . Subsequen t ly , the ta rge t tox ic i t ies w i l l be mon i to red in a con t inuous fash ion . Tha t is a t any t ime a f te r 10 th pa t ien t , the t r ia l acc rua l w i l l be s topped i f the ra te o f ta rge t tox ic i ty exceeds 20% . A l l tox ic i ty w i l l be ca re fu l ly mon i to red in th is t r ia l . Any unexpec ted g rade 3-4 tox ic i ty w i l l be repo r ted to the IBR fo r rev iew . Fu r the rmo re , in the even t o f a tox ic dea th du r ing the 4-cyc le t rea tmen t , the acc rua l w i l l be pu t on ho ld un t i l a tho rough rev iew o f the even t take p lace and a de l ibe ra te dec is ion can be made rega rd ing resum ing acc rua l . 13 .3Exp lo ra to ry Ob jec t ives 13 .3 .1 To exp lo re fac to rs assoc ia ted w i th response in pa t ien ts t rea ted w i th ave lumab a f te r recu r ren t o r p rog ress ive os teosa rcoma (e .g . tumo r PD-L1 exp ress ion ) . Respons ib le inves t iga to rs : M ichae l B ishop , A lbe r to Pappo Respons ib le B ios ta t is t ic ians : J ian rong Wu Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 3/31/2023 Log is t ic reg ress ion ana lys is w i l l be conduc ted to exp lo re fac to rs wh ich may assoc ia te w i th response . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
72,page_72,"OSTPDL1 Page 66 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 13 .3 .2 To measu re pa rame te rs o f immune ac t iva t ion inc lud ing subse ts o f pe r iphe ra l b lood mononuc lea r ce l ls (PBMCs ) and se rum ma rke rs o f immune ac t iva t ion . Respons ib le inves t iga to rs : M ichae l B ishop , Ben jam in Youngb lood , Pau l Thomas Respons ib le B ios ta t is t ic ians : J ian rong Wu , Guo l ian Kang Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 3/31/2023 Desc r ip t ive s ta t is t ics (mean+/- SE o r med ian , m in and max ) w i l l be p rov ided fo r the pa rame te rs o f immune ac t iva t ion inc lud ing subse ts o f PBMCs and se rum ma rke rs o f immune ac t iva t ion fo r each t ime po in t sepa ra te ly and changes be tween two t ime po in ts . Box-p lo t w i l l be p rov ided fo r each t ime po in t to v isua l ly look a t the t rend o f the pa rame te rs o f immune ac t iva t ion ove r t ime o f the rapy . 13 .3 .3 To eva lua te the ro le o f T-ce l ls in immune checkpo in t b lockade v ia measu res o f ce l l p ro l i fe ra t ion , co- inh ib i to ry recep to r exp ress ion on CD8 T ce l ls , T ce l l repe r to i re , and ep igene t ic p rog ramm ing . Respons ib le inves t iga to rs : M ichae l B ishop , Ben jam in Youngb lood , Pau l Thomas Respons ib le B ios ta t is t ic ians : J ian rong Wu , Guo l ian Kang Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 3/31/2023 Fo r the ana lys is o f T ce l l repe r to i re , we w i l l compu te s ta t is t ics (such as d ive rs i ty , en t ropy , r ichness ) and cha rac te r ize known recep to r spec i f ic i t ies o f the immune repe r to i re fo r each t ime-po in t a t wh ich these s tud ies a re pe r fo rmed . Compa r isons among PD1+ and PD1- and o the r inh ib i to ry recep to r-exp ress ing subse ts w i l l be assessed fo r changes in repe r to i re assoc ia ted w i th t rea tmen t . To assess the p ro l i fe ra t ion and ac t iva t ion pheno types o f memo ry CD8 T ce l l subse ts w i l l measu re the pe rcen tage o f na ïve , cen t ra l-memo ry (Tcm ) , e f fec to r-memo ry (Tem ) , and s tem-ce l l (Tscm ) memo ry CD8 T ce l l popu la t ions in the PBMC o f t rea ted ind iv idua ls . The pe rcen tage o f CD8 T ce l l subse ts w i l l be measu red p r io r to t rea tmen t and fo l low ing the s ta r t o f the rapy . Add i t iona l ly , we w i l l pu r i fy the pheno typ ica l ly de f ined memo ry CD8 T ce l l subse ts and measu re subse t- spec i f ic DNA me thy la t ion p rog rams to de te rm ine i f the rapy resu l ts in ep igene t ic changes among the poo l o f na ïve and memo ry T ce l l subse ts . Ove ra l l , desc r ip t ive s ta t is t ics (mean +/- SE o r med ian , m in and max ) w i l l be compu ted fo r the un iva r ia te da ta fo r each t ime po in t sepa ra te ly and changes be tween two t ime po in ts and g raph ic p resen ta t ions w i l l be g iven fo r the long i tud ina l obse rva t ions to demons t ra te the changes ac ross the cou rses o f the rapy (p r io r the rapy and du r ing the rapy ) . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
73,page_73,"OSTPDL1 Page 67 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 13 .3 .4 To assess the qua l i ty o f l i fe o f pa t ien ts w i th recu r ren t o r p rog ress ive os teosa rcoma unde rgo ing t rea tmen t w i th ave lumab , and to exp lo re re la t ionsh ips be tween c l in ica l fac to rs and pa t ien t- repo r ted HRQOL ou tcomes . Respons ib le inves t iga to rs : M ichae l B ishop Respons ib le B ios ta t is t ic ians : J ian rong Wu , Zhaohua Lu Es t ima ted da te fo r comp le t ion o f da ta co l lec t ion : 3/31/2023 Pa t ien ts w i l l comp le te the PROM IS Ped ia t r ic o r Adu l t P ro f i le (based on the i r age a t t ime o f adm in is t ra t ion ) a t fou r t ime po in ts du r ing the s tudy : p r io r to the s ta r t o f t rea tmen t , a t the end o f cyc le 2 (8 weeks ± 1 week ) , a t the end o f cyc le 4 (16 weeks ± 1 week ) , and a t the end o f ave lumab t rea tmen t . Pa t ien ts less than 18 yea rs o ld w i l l comp le ted the PROM IS-37 P ro f i le v .1 .1 ; pa t ien ts age 18 yea rs and o lde r w i l l comp le te the PROM IS- 43 P ro f i le v .2 .0 . M ixed e f fec t mode ls w i l l be used to s tudy the change pa t te rns o f the T-sco res in each qua l i ty o f l i fe doma in ove r t ime , and the assoc ia t ion be tween c l in ica l fac to rs and the T-sco res in each qua l i ty o f l i fe doma in . M iss ing da ta po in ts w i l l be add ressed by mu l t ip le impu ta t ion o r fu l l in fo rma t ion max imum l ike l ihood me thods . 13 .4 An t ic ipa ted Comp le t ion Da tes An t ic ipa ted p r ima ry comp le t ion da te : Decembe r 2020 An t ic ipa ted s tudy comp le t ion da te : Decembe r 2023 14 .0 OBTA IN ING INFORMED CONSENT 14 .1 Consen t P r io r to Resea rch In te rven t ions In i t ia l ly , in fo rmed consen t fo r pa t ien ts en ro l l ing a t S t . Jude w i l l be sough t fo r the ins t i tu t iona l bank ing p ro toco l (TBANK resea rch s tudy ) , and fo r o the r p rocedu res as necessa ry fo r s tanda rd med ica l ca re . Du r ing the sc reen ing p rocess fo r e l ig ib i l i ty , in fo rmed consen t fo r the S t . Jude p re- sc reen ing p ro toco l (SCREEN ) o r fo r OSTPDL1 is requ i red be fo re any resea rch tes ts a re pe r fo rmed . Co l labo ra t ing s i tes w i l l fo l low loca l po l ic ies fo r sc reen ing and consen t/assen t . 14 .2 Consen t a t En ro l lmen t The p rocess o f in fo rmed consen t fo r OSTPDL1 w i l l fo l low loca l ins t i tu t iona l po l icy . The in fo rmed consen t p rocess is an ongo ing one tha t beg ins a t the t ime o f d iagnos is and ends a f te r the comp le t ion o f the rapy . In fo rmed consen t shou ld be ob ta ined by the a t tend ing phys ic ian o r h is/he r des ignee , in the p resence o f a t leas t one non-phys ic ian w i tness . In i t ia l ly , in fo rmed consen t w i l l be sough t fo r the ins t i tu t iona l bank ing p ro toco l ( resea rch s tudy ) , b lood t rans fus ion and o the r p rocedu res as S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
74,page_74,"OSTPDL1 Page 68 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 necessa ry . A f te r the d iagnos is o f re lapsed o r re f rac to ry so l id tumo r is es tab l ished , we w i l l inv i te the pa t ien t to pa r t ic ipa te in the OSTPDL1 p ro toco l . Th roughou t the en t i re t rea tmen t pe r iod , pa r t ic ipan ts and the i r pa ren ts rece ive cons tan t educa t ion f rom hea l th p ro fess iona ls a t S t . Jude and co l labo ra t ing s i tes , and a re encou raged to ask ques t ions rega rd ing a l te rna t ives and the rapy . A l l fam i l ies have ready access to chap la ins , psycho log is ts , soc ia l wo rke rs , and the S t . Jude ombudspe rson fo r suppo r t , in add i t ion to tha t p rov ided by the p r ima ry phys ic ian and o the r c l in ic ians invo lved in the i r ca re . We w i l l a lso ob ta in ve rba l assen t f rom ch i ld ren 12 to 14 yea rs o ld and w r i t ten assen t fo r a l l pa r t ic ipan ts >14 yea rs o f age a t S t . Jude . Co l labo ra t ing s i tes w i l l fo l low ins t i tu t iona l gu ide l ines fo r assen t . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
75,page_75,"OSTPDL1 Page 69 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 14 .3 Consen t a t Age o f Ma jo r i ty Pa r t ic ipan ts who reach the age o f ma jo r i ty wh i le on s tudy w i l l be re- consen ted fo r con t inued pa r t ic ipa t ion on OSTPDL1 a t the t ime o f the i r nex t c l in ic v is i t a f te r tu rn ing 18 yea r acco rd ing to Cance r Cen te r and loca l ins t i tu t iona l po l icy . 14 .4 Consen t When Eng l ish is No t the P r ima ry Language Ob ta in ing consen t fo r non-Eng l ish speak ing pa r t ic ipan ts w i l l fo l low loca l ins t i tu t iona l po l icy . A t S t . Jude , when Eng l ish is no t the pa r t ic ipan t , pa ren t , o r lega l ly au tho r ized rep resen ta t ive ’s p r ima ry language , the inves t iga to r o r the Soc ia l Wo rk depa r tmen t w i l l de te rm ine the need fo r an in te rp re te r . Th is in fo rma t ion w i l l be documen ted in the pa r t ic ipan t ’s med ica l reco rd . E i the r a ce r t i f ied in te rp re te r o r the te lephone in te rp re te r ’s se rv ice w i l l be used to t rans la te the consen t in fo rma t ion . I f the sho r t fo rm consen t is ava i lab le in the p r ima ry language o f the pa r t ic ipan t , pa ren t o r lega l ly au tho r ized rep resen ta t ive , th is may be u t i l ized to s ign consen t and jo ined w i th a fu l l Eng l ish consen t s igned by the resea rch team . The p rocess fo r ob ta in ing an in te rp re te r and fo r the app rop r ia te use o f an in te rp re te r is ou t l ined on the S JCRH In te rp re te r Se rv ices webs i te , as we l l as OHSP and CPDMO webs i tes . 14 .5 Co l lec t ion o f Co l labo ra t ing Ins t i tu t ion Consen t Fo rms S igned co l labo ra t ing ins t i tu t ion ’s consen t fo rms w i l l be faxed to the S t . Jude CPDMO E l ig ib i l i ty O f f ice a t 901-595-6265 . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
76,page_76,"OSTPDL1 Page 70 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 15 .0REFERENCES 1 . M i rabe l lo L , T ro is i R J , Savage SA : Os teosa rcoma inc idence and su rv iva l ra tes f rom 1973 to 2004 : da ta f rom the Su rve i l lance , Ep idem io logy , and End Resu l ts P rog ram . Cance r 115 :1531-43 , 2009 2 . Meye rs PA , Schwa r tz CL , K ra i lo M , e t a l : Os teosa rcoma : a random ized , p rospec t ive t r ia l o f the add i t ion o f i fos fam ide and/o r mu ramy l t r ipep t ide to c isp la t in , doxo rub ic in , and h igh-dose me tho t rexa te . Jou rna l o f c l in ica l onco logy : o f f ic ia l jou rna l o f the Ame r ican Soc ie ty o f C l in ica l Onco logy 23 :2004-11 , 2005 3 . Kemp f-B ie lack B , B ie lack SS , Ju rgens H , e t a l : Os teosa rcoma re lapse a f te r comb ined moda l i ty the rapy : an ana lys is o f unse lec ted pa t ien ts in the Coope ra t ive Os teosa rcoma S tudy G roup (COSS ) . J C l in Onco l 23 :559-68 , 2005 4 . Kage r L , Zoubek A , Po tschge r U , e t a l : P r ima ry me tas ta t ic os teosa rcoma : p resen ta t ion and ou tcome o f pa t ien ts t rea ted on neoad juvan t Coope ra t ive Os teosa rcoma S tudy G roup p ro toco ls . J C l in Onco l 21 :2011-8 , 2003 5 . Ebb D , Meye rs P , G r ie r H , e t a l : Phase I I t r ia l o f t ras tuzumab in comb ina t ion w i th cy to tox ic chemo the rapy fo r t rea tmen t o f me tas ta t ic os teosa rcoma w i th human ep ide rma l g row th fac to r recep to r 2 ove rexp ress ion : a repo r t f rom the ch i ld ren 's onco logy g roup . J C l in Onco l 30 :2545-51 , 2012 6 . B r icco l i A , Rocca M , Sa lone M , e t a l : H igh g rade os teosa rcoma o f the ex t rem i t ies me tas ta t ic to the lung : long- te rm resu l ts in 323 pa t ien ts t rea ted comb in ing su rge ry and chemo the rapy , 1985-2005 . Su rg Onco l 19 :193-9 , 2010 7 . B ie lack SS , Kemp f-B ie lack B , B ransche id D , e t a l : Second and subsequen t recu r rences o f os teosa rcoma : p resen ta t ion , t rea tmen t , and ou tcomes o f 249 consecu t ive coope ra t ive os teosa rcoma s tudy g roup pa t ien ts . J C l in Onco l 27 :557-65 , 2009 8 . Bacc i G , B r icco l i A , Longh i A , e t a l : T rea tmen t and ou tcome o f recu r ren t os teosa rcoma : expe r ience a t R izzo l i in 235 pa t ien ts in i t ia l ly t rea ted w i th neoad juvan t chemo the rapy . Ac ta Onco l 44 :748-55 , 2005 9 . A rnd t CA , Koshk ina NV , Inwa rds CY , e t a l : Inha led g ranu locy te- mac rophage co lony s t imu la t ing fac to r fo r f i rs t pu lmona ry recu r rence o f os teosa rcoma : e f fec ts on d isease- f ree su rv iva l and immunomodu la t ion . a repo r t f rom the Ch i ld ren 's Onco logy G roup . C l in Cance r Res 16 :4024-30 , 2010 10 . Pappo AS , Vassa l G , C row ley J J , e t a l : A phase 2 t r ia l o f R1507 , a monoc lona l an t ibody to the insu l in- l ike g row th fac to r-1 recep to r ( IGF-1R ) , in pa t ien ts w i th recu r ren t o r re f rac to ry rhabdomyosa rcoma , os teosa rcoma , synov ia l sa rcoma , and o the r so f t t issue sa rcomas : resu l ts o f a Sa rcoma A l l iance fo r Resea rch Th rough Co l labo ra t ion s tudy . Cance r 120 :2448-56 , 2014 11 . Lagmay JP KM , Dang H , K im A , Hawk ins DS , Bea t ty O , W idemann B , Zwe rd l ig T , Bomgaa rs L , Langev in A , G r ie r HE , B laney S , Go r l ick R , Janeway K : Ou tcome o f recu r ren t os teosa rcoma pa t ien ts en ro l led in seven phase I I t r ia ls th rough COG , POG and COG :Lea rn ing and mov ing fo rwa rd . P resen ted a t the Ame r ican Soc ie ty o f C l in ica l Onco logy , Ch icago , I l l , 2015 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
77,page_77,"OSTPDL1 Page 71 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 12 . Ko lb EA , Go r l ick R , Reyno lds CP , e t a l : In i t ia l tes t ing (s tage 1 ) o f e r ibu l in , a nove l tubu l in b ind ing agen t , by the ped ia t r ic p rec l in ica l tes t ing p rog ram . Ped ia t r B lood Cance r 60 :1325-32 , 2013 13 . B ie lack SS , Sme land S , Whe lan JS , e t a l : Me tho t rexa te , Doxo rub ic in , and C isp la t in (MAP ) P lus Ma in tenance Pegy la ted In te r fe ron A l fa-2b Ve rsus MAP A lone in Pa t ien ts W i th Resec tab le H igh-G rade Os teosa rcoma and Good H is to log ic Response to P reope ra t ive MAP : F i rs t Resu l ts o f the EURAMOS-1 Good Response Random ized Con t ro l led T r ia l . J C l in Onco l 33 :2279-87 , 2015 14 . Ma r ina N , Sme land S , B ie lack SS , e t a l : MAP IE vs . MAP in pa t ien ts w i th a poo r resopnse to p re-ope ra t ive chemo the rapy fo r new ly d iagnosed os teosa rcoma : resu l ts f rom EURAMOS-1 , Connec t ive T issue Onco logy Soc ie ty . Be r l in , Ge rmany , 2014 15 . Chen X , Bah ram i A , Pappo A , e t a l : Recu r ren t soma t ic s t ruc tu ra l va r ia t ions con t r ibu te to tumo r igenes is in ped ia t r ic os teosa rcoma . Ce l l Rep 7 :104-12 , 2014 16 . Pe r ry JA , K iezun A , Tonz i P , e t a l : Comp lemen ta ry genom ic app roaches h igh l igh t the P I3K/mTOR pa thway as a common vu lne rab i l i ty in os teosa rcoma . P roc Na t l Acad Sc i U S A 111 :E5564-73 , 2014 17 . Pos tow MA , Ca l lahan MK , Wo lchok JD : Immune Checkpo in t B lockade in Cance r The rapy . J C l in Onco l 33 :1974-82 , 2015 18 . Ga ron EB , R izv i NA , Hu i R , e t a l : Pemb ro l izumab fo r the t rea tmen t o f non-sma l l-ce l l lung cance r . N Eng l J Med 372 :2018-28 , 2015 19 . Le DT , U ram JN , Wang H , e t a l : PD-1 B lockade in Tumo rs w i th M isma tch-Repa i r De f ic iency . N Eng l J Med 372 :2509-20 , 2015 20 . Ge t t inge r SN , Ho rn L , Gandh i L , e t a l : Ove ra l l Su rv iva l and Long- Te rm Sa fe ty o f N ivo lumab (An t i-P rog rammed Dea th 1 An t ibody , BMS-936558 , ONO-4538 ) in Pa t ien ts W i th P rev ious ly T rea ted Advanced Non-Sma l l-Ce l l Lung Cance r . J C l in Onco l , 2015 21 . McDe rmo t t DF , D rake CG , Szno l M , e t a l : Su rv iva l , Du rab le Response , and Long-Te rm Sa fe ty in Pa t ien ts W i th P rev ious ly T rea ted Advanced Rena l Ce l l Ca rc inoma Rece iv ing N ivo lumab . J C l in Onco l , 2015 22 . Pos tow MA , Chesney J , Pav l ick AC , e t a l : N ivo lumab and ip i l imumab ve rsus ip i l imumab in un t rea ted me lanoma . N Eng l J Med 372 :2006-17 , 2015 23 . Anse l l SM , Lesokh in AM , Bo r re l lo I , e t a l : PD-1 b lockade w i th n ivo lumab in re lapsed o r re f rac to ry Hodgk in 's lymphoma . N Eng l J Med 372 :311-9 , 2015 24 . La rk in J , Ch ia r ion-S i len i V , Gonza lez R , e t a l : Comb ined N ivo lumab and Ip i l imumab o r Mono the rapy in Un t rea ted Me lanoma . N Eng l J Med , 2015 25 . Tumeh PC , Ha rv iew CL , Yea r ley JH , e t a l : PD-1 b lockade induces responses by inh ib i t ing adap t ive immune res is tance . Na tu re 515 :568-71 , 2014 26 . P la t ten M , O f f r inga R : Cance r immuno the rapy : exp lo i t ing neoep i topes . Ce l l Res , 2015 27 . Snyde r A , Wo lchok JD , Chan TA : Gene t ic bas is fo r c l in ica l response to CTLA-4 b lockade . N Eng l J Med 372 :783 , 2015 28 . Luss ie r DM , O 'Ne i l l L , N ieves LM , e t a l : Enhanced T-ce l l immun i ty to os teosa rcoma th rough an t ibody b lockade o f PD-1/PD-L1 in te rac t ions . J Immuno the r 38 :96-106 , 2015 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
78,page_78,"OSTPDL1 Page 72 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 29 . Luss ie r DM , Johnson JL , H ingo ran i P , e t a l : Comb ina t ion immuno the rapy w i th a lpha-CTLA-4 and a lpha-PD-L1 an t ibody b lockade p reven ts immune escape and leads to comp le te con t ro l o f me tas ta t ic os teosa rcoma . J Immuno the r Cance r 3 :21 , 2015 30 . Shen JK , Co te GM , Choy E , e t a l : P rog rammed ce l l dea th l igand 1 exp ress ion in os teosa rcoma . Cance r Immuno l Res 2 :690-8 , 2014 31 . Tawb i HA-H , Bu rgess MA , C row ley J , e t a l : Sa fe ty and e f f icacy o f PD-1 b lockade us ing pemb ro l izumab in pa t ien ts w i th advanced so f t t issue (STS ) and bone sa rcomas (BS ) : Resu l ts o f SARC028--A mu l t icen te r phase I I s tudy . ASCO Mee t ing Abs t rac ts 34 :11006 , 2016 32 . Ke i r ME , Bu t te M J , F reeman G J , e t a l : PD-1 and i ts l igands in to le rance and immun i ty . Annu Rev Immuno l 26 :677-704 , 2008 33 . Okazak i T , Hon jo T : PD-1 and PD-1 l igands : f rom d iscove ry to c l in ica l app l ica t ion . In t Immuno l 19 :813-24 , 2007 34 . R izv i NA , He l lmann MD , Snyde r A , e t a l : Cance r immuno logy . Mu ta t iona l landscape de te rm ines sens i t iv i ty to PD-1 b lockade in non-sma l l ce l l lung cance r . Sc ience 348 :124-8 , 2015 35 . van Roo i j N , van Buu ren MM , Ph i l ips D , e t a l : Tumo r exome ana lys is revea ls neoan t igen-spec i f ic T-ce l l reac t iv i ty in an ip i l imumab- respons ive me lanoma . J C l in Onco l 31 :e439-42 , 2013 36 . Res t i fo NP , Dud ley ME , Rosenbe rg SA : Adop t ive immuno the rapy fo r cance r : ha rness ing the T ce l l response . Na t Rev Immuno l 12 :269-81 , 2012 37 . Aqu ino d : Cha l lenges and fu tu re pe rspec t ives o f T ce l l immuno the rapy in cance r . Immuno logy le t te rs 166 :117-133 , 2015 38 . Whe r ry E J : T ce l l exhaus t ion . Na t Immuno l 12 :492-9 , 2011 39 . Whe r ry E J , Ha S J , Kaech SM , e t a l : Mo lecu la r s igna tu re o f CD8+ T ce l l exhaus t ion du r ing ch ron ic v i ra l in fec t ion . Immun i ty 27 :670-84 , 2007 40 . Sha rma P , A l l ison JP : The fu tu re o f immune checkpo in t the rapy . Sc ience 348 :56-61 , 2015 41 . B lackbu rn SD , Sh in H , Ha in ing WN , e t a l : Co regu la t ion o f CD8+ T ce l l exhaus t ion by mu l t ip le inh ib i to ry recep to rs du r ing ch ron ic v i ra l in fec t ion . Na t Immuno l 10 :29-37 , 2009 42 . Pe re tz Y , He Z , Sh i Y , e t a l : CD160 and PD-1 co-exp ress ion on H IV- spec i f ic CD8 T ce l ls de f ines a subse t w i th advanced dys func t ion . PLoS Pa thog 8 :e1002840 , 2012 43 . G ros A , Robb ins PF , Yao X , e t a l : PD-1 iden t i f ies the pa t ien t- spec i f ic CD8 (+ ) tumo r- reac t ive repe r to i re in f i l t ra t ing human tumo rs . J C l in Inves t 124 :2246-59 , 2014 44 . Du ra iswamy J , Ibegbu CC , Masopus t D , e t a l : Pheno type , func t ion , and gene exp ress ion p ro f i les o f p rog rammed dea th-1 (h i ) CD8 T ce l ls in hea l thy human adu l ts . J Immuno l 186 :4200-12 , 2011 45 . Twyman-Sa in t V ic to r C , Rech A J , Ma i ty A , e t a l : Rad ia t ion and dua l checkpo in t b lockade ac t iva te non- redundan t immune mechan isms in cance r . Na tu re 520 :373-7 , 2015 46 . La G ru ta NL , Thomas PG : In te r roga t ing the re la t ionsh ip be tween na ive and immune an t iv i ra l T ce l l repe r to i res . Cu r r Op in V i ro l 3 :447-51 , 2013 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
79,page_79,"OSTPDL1 Page 73 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 47 . Wang GC , Dash P , McCu l le rs JA , e t a l : T ce l l recep to r a lphabe ta d ive rs i ty inve rse ly co r re la tes w i th pa thogen-spec i f ic an t ibody leve ls in human cy tomega lov i rus in fec t ion . Sc i T rans l Med 4 :128 ra42 , 2012 48 . K re i te r S , Vo rmeh r M , van de Roeme r N , e t a l : Mu tan t MHC c lass I I ep i topes d r ive the rapeu t ic immune responses to cance r . Na tu re 520 :692-6 , 2015 49 . L innemann C , van Buu ren MM , B ies L , e t a l : H igh- th roughpu t ep i tope d iscove ry revea ls f requen t recogn i t ion o f neo-an t igens by CD4+ T ce l ls in human me lanoma . Na t Med 21 :81-5 , 2015 50 . Youngb lood B , Ha le JS , Ahmed R : T-ce l l memo ry d i f fe ren t ia t ion : ins igh ts f rom t ransc r ip t iona l s igna tu res and ep igene t ics . Immuno logy 139 :277- 84 , 2013 51 . Youngb lood B , No to A , Po r ich is F , e t a l : Cu t t ing edge : P ro longed exposu re to H IV re in fo rces a po ised ep igene t ic p rog ram fo r PD-1 exp ress ion in v i rus-spec i f ic CD8 T ce l ls . J Immuno l 191 :540-4 , 2013 52 . Youngb lood B , Oes t re ich K J , Ha S J , e t a l : Ch ron ic v i rus in fec t ion en fo rces deme thy la t ion o f the locus tha t encodes PD-1 in an t igen-spec i f ic CD8 (+ ) T ce l ls . Immun i ty 35 :400-12 , 2011 53 . Ca rda re l l i C , Ce reda C , Mas ie ro L , e t a l : Eva lua t ion o f hea l th s ta tus and hea l th- re la ted qua l i ty o f l i fe in a coho r t o f I ta l ian ch i ld ren fo l low ing t rea tmen t fo r a p r ima ry b ra in tumo r . Ped ia t r B lood Cance r 46 :637-44 , 2006 54 . Ca rpen t ie r i SC , Meye r EA , De laney BL , e t a l : Psychosoc ia l and behav io ra l func t ion ing among ped ia t r ic b ra in tumo r su rv ivo rs . J Neu roonco l 63 :279-87 , 2003 55 . C rom DB , Cha thaway DK , To l ley EA , e t a l : Hea l th s ta tus and hea l th- re la ted qua l i ty o f l i fe in long- te rm adu l t su rv ivo rs o f ped ia t r ic so l id tumo rs . In t J Cance r Supp l 12 :25-31 , 1999 56 . E ise r C , Vance YH , Ho rne B , e t a l : The va lue o f the PedsQLTM in assess ing qua l i ty o f l i fe in su rv ivo rs o f ch i ldhood cance r . Ch i ld Ca re Hea l th Dev 29 :95-102 , 2003 57 . B rad lyn AS , Ha r r is CV , Sp ie th LE : Qua l i ty o f l i fe assessmen t in ped ia t r ic onco logy : a re t rospec t ive rev iew o f phase I I I repo r ts . Soc Sc i Med 41 :1463-5 , 1995 58 . Va rn i JW , Bu rw ink le TM , Ka tz ER : The PedsQL in ped ia t r ic cance r pa in : a p rospec t ive long i tud ina l ana lys is o f pa in and emo t iona l d is t ress . J Dev Behav Ped ia t r 25 :239-46 , 2004 59 . Kuh l thau KA , Pu ls i fe r MB , Yeap BY , e t a l : P rospec t ive s tudy o f hea l th- re la ted qua l i ty o f l i fe fo r ch i ld ren w i th b ra in tumo rs t rea ted w i th p ro ton rad io the rapy . J C l in Onco l 30 :2079-86 , 2012 60 . Sung L , Yano fsky R , K laassen R J , e t a l : Qua l i ty o f l i fe du r ing ac t ive t rea tmen t fo r ped ia t r ic acu te lymphob las t ic leukem ia . In t J Cance r 128 :1213- 20 , 2011 61 . M i tche l l HR , Lu X , Mye rs RM , e t a l : P rospec t ive , long i tud ina l assessmen t o f qua l i ty o f l i fe in ch i ld ren f rom d iagnos is to 3 mon ths o f f t rea tmen t fo r s tanda rd r isk acu te lymphob las t ic leukem ia : Resu l ts o f Ch i ld ren 's Onco logy G roup s tudy AALL0331 . In t J Cance r 138 :332-9 , 2016 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
80,page_80,"OSTPDL1 Page 74 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 62 . H inds PS , B i l lups CA , Cao X , e t a l : Hea l th- re la ted qua l i ty o f l i fe in ado lescen ts a t the t ime o f d iagnos is w i th os teosa rcoma o r acu te mye lo id leukem ia . Eu r J Onco l Nu rs 13 :156-63 , 2009 63 . H inds PS , Ga t tuso JS , B i l lups CA , e t a l : Agg ress ive t rea tmen t o f non-me tas ta t ic os teosa rcoma imp roves hea l th- re la ted qua l i ty o f l i fe in ch i ld ren and ado lescen ts . Eu r J Cance r 45 :2007-14 , 2009 64 . Ma rchese VG , Og le S , Wome r RB , e t a l : An exam ina t ion o f ou tcome measu res to assess func t iona l mob i l i ty in ch i ldhood su rv ivo rs o f os teosa rcoma . Ped ia t r B lood Cance r 42 :41-5 , 2004 65 . Koopman HM , Koe ts ie r JA , Tam in iau AH , e t a l : Hea l th- re la ted qua l i ty o f l i fe and cop ing s t ra teg ies o f ch i ld ren a f te r t rea tmen t o f a ma l ignan t bone tumo r : a 5-yea r fo l low-up s tudy . Ped ia t r B lood Cance r 45 :694-9 , 2005 66 . Tabone MD , Roda ry C , Obe r l in O , e t a l : Qua l i ty o f l i fe o f pa t ien ts t rea ted du r ing ch i ldhood fo r a bone tumo r : assessmen t by the Ch i ld Hea l th Ques t ionna i re . Ped ia t r B lood Cance r 45 :207-11 , 2005 67 . Ea r le EA , E ise r C , G r ime r R : 'He Neve r L iked Spo r t Anyway ' - Mo the r 's V iews o f Young Peop le Cop ing W i th a Bone Tumou r in the Lowe r L imb . Sa rcoma 9 :7-13 , 2005 68 . F rances JM , Mo r r is CD , A rkade r A , e t a l : Wha t is qua l i ty o f l i fe in ch i ld ren w i th bone sa rcoma ? C l in O r thop Re la t Res 459 :34-9 , 2007 69 . E ise r C , Coo l P , G r ime r R J , e t a l : Qua l i ty o f l i fe in ch i ld ren fo l low ing t rea tmen t fo r a ma l ignan t p r ima ry bone tumou r a round the knee . Sa rcoma 1 :39-45 , 1997 70 . E ise r C , Da r l ing ton AS , S t r ide CB , e t a l : Qua l i ty o f l i fe imp l ica t ions as a consequence o f su rge ry : l imb sa lvage , p r ima ry and seconda ry ampu ta t ion . Sa rcoma 5 :189-95 , 2001 71 . Mank in H J , Gunnoe J , Fa r id Y , e t a l : Long- te rm e f fec ts o f connec t ive t issue cance r t rea tmen t . C l in O r thop Re la t Res :74-86 , 2004 72 . Ho f fmann C , Goshege r G , Gebe r t C , e t a l : Func t iona l resu l ts and qua l i ty o f l i fe a f te r t rea tmen t o f pe lv ic sa rcomas invo lv ing the ace tabu lum . J Bone Jo in t Su rg Am 88 :575-82 , 2006 73 . Naga ra jan R , Neg l ia JP , C loh isy DR , e t a l : Educa t ion , emp loymen t , insu rance , and ma r i ta l s ta tus among 694 su rv ivo rs o f ped ia t r ic lowe r ex t rem i ty bone tumo rs : a repo r t f rom the ch i ldhood cance r su rv ivo r s tudy . Cance r 97 :2554-64 , 2003 74 . Re faa t Y , Gunnoe J , Ho rn icek F J , e t a l : Compa r ison o f qua l i ty o f l i fe a f te r ampu ta t ion o r l imb sa lvage . C l in O r thop Re la t Res :298-305 , 2002 75 . Zah l ten-H ingu ranage A , Be rnd L , Sabo D : [Ampu ta t ion o r l imb sa lvage ? Assess ing qua l i ty o f l i fe a f te r tumo r ope ra t ions o f the lowe r ex t rem i ty ] . O r thopade 32 :1020-7 , 2003 76 . van R ie l CA , Me i je r-van den Be rgh EE , Kemps HL , e t a l : Se l f- pe rcep t ion and qua l i ty o f l i fe in ado lescen ts du r ing t rea tmen t fo r a p r ima ry ma l ignan t bone tumou r . Eu r J Onco l Nu rs 18 :267-72 , 2014 77 . Bekke r ing WP , V l ie t V l ie land TP , Koopman HM , e t a l : Qua l i ty o f l i fe in young pa t ien ts a f te r bone tumo r su rge ry a round the knee jo in t and compa r ison w i th hea l thy con t ro ls . Ped ia t r B lood Cance r 54 :738-45 , 2010 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
81,page_81,"OSTPDL1 Page 75 o f 60 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 78 . S tokke J , Sung L , Gup ta A , e t a l : Sys tema t ic rev iew and me ta- ana lys is o f ob jec t ive and sub jec t ive qua l i ty o f l i fe among ped ia t r ic , ado lescen t , and young adu l t bone tumo r su rv ivo rs . Ped ia t r B lood Cance r 62 :1616-29 , 2015 79 . Whe lan JS , B ie lack SS , Ma r ina N , e t a l : EURAMOS-1 , an in te rna t iona l random ised s tudy fo r os teosa rcoma : resu l ts f rom p re- random isa t ion t rea tmen t . Ann Onco l 26 :407-14 , 2015 80 . E ise r C , Jenney M : Measu r ing qua l i ty o f l i fe . A rch D is Ch i ld 92 :348- 50 , 2007 81 . Va rn i JW , Bu rw ink le TM , Lane MM : Hea l th- re la ted qua l i ty o f l i fe measu remen t in ped ia t r ic c l in ica l p rac t ice : an app ra isa l and p recep t fo r fu tu re resea rch and app l ica t ion . Hea l th Qua l L i fe Ou tcomes 3 :34 , 2005 82 . Va rn i JW , Magnus B , S tucky BD , e t a l : Psychome t r ic p rope r t ies o f the PROM IS (R ) ped ia t r ic sca les : p rec is ion , s tab i l i ty , and compa r ison o f d i f fe ren t sco r ing and adm in is t ra t ion op t ions . Qua l L i fe Res 23 :1233-43 , 2014 83 . H inds PS , Nuss SL , Rucc ione KS , e t a l : PROM IS ped ia t r ic measu res in ped ia t r ic onco logy : va l id and c l in ica l ly feas ib le ind ica to rs o f pa t ien t- repo r ted ou tcomes . Ped ia t r B lood Cance r 60 :402-8 , 2013 84 . Dob rozs i S , Yan K , Ho f fmann R , e t a l : Pa t ien t- repo r ted hea l th s ta tus du r ing ped ia t r ic cance r t rea tmen t . Ped ia t r B lood Cance r , 2016 85 . Janssen S J , Pau l ino Pe re i ra NR , Rask in KA , e t a l : A compa r ison o f ques t ionna i res fo r assess ing phys ica l func t ion in pa t ien ts w i th lowe r ex t rem i ty bone me tas tases . J Su rg Onco l 114 :691-696 , 2016 86 . B rode r ick JE , Schne ide r S , Junghaene l DU , e t a l : Va l id i ty and re l iab i l i ty o f pa t ien t- repo r ted ou tcomes measu remen t in fo rma t ion sys tem ins t rumen ts in os teoa r th r i t is . A r th r i t is Ca re Res (Hoboken ) 65 :1625-33 , 2013 87 . DeWa l t DA , G ross HE , G ipson DS , e t a l : PROM IS ( (R ) ) ped ia t r ic se l f- repo r t sca les d is t ingu ish subg roups o f ch i ld ren w i th in and ac ross s ix common ped ia t r ic ch ron ic hea l th cond i t ions . Qua l L i fe Res 24 :2195-208 , 2015 88 . Th issen D , L iu Y , Magnus B , e t a l : Es t ima t ing m in ima l ly impo r tan t d i f fe rence (M ID ) in PROM IS ped ia t r ic measu res us ing the sca le- judgmen t me thod . Qua l L i fe Res 25 :13-23 , 2016 89 . Schwa r tz G J , Gau th ie r B : A s imp le es t ima te o f g lome ru la r f i l t ra t ion ra te in ado lescen t boys . J Ped ia t r 106 :522-6 , 1985 90 . E isenhaue r EA , The rasse P , Bogae r ts J , e t a l : New response eva lua t ion c r i te r ia in so l id tumou rs : rev ised REC IST gu ide l ine (ve rs ion 1 .1 ) . Eu r J Cance r 45 :228-47 , 2009 91 . Koche rg insky M , Cohen EE , Ka r r ison T : Des ign o f Phase I I cance r t r ia ls fo r eva lua t ion o f cy tos ta t ic/cy to tox ic agen ts . J B iopha rm S ta t 19 :524-9 , 2009 S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
82,page_82,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 APPEND IX I : KARNOFSKY AND LANSKY PERFORMANCE STATUS SCALES/SCORES PERFORMANCE STATUS CR ITER IA Ka rno fsky and Lansky pe r fo rmance sco res a re in tended to be mu l t ip les o f 10 ECOG (Zub rod ) Ka rno fsky Lansky Sco r eDesc r ip t ion Sco r eDesc r ip t ion Sco r eDesc r ip t ion 100 No rma l , no comp la in ts , no ev idence o f d isease 100 Fu l ly ac t ive , no rma l 0Fu l ly ac t ive , ab le to ca r ry on a l l p re-d isease pe r fo rmance w i thou t res t r ic t ion 90 Ab le to ca r ry on no rma l ac t iv i ty , m ino r s igns o r symp toms o f d isease 90 M ino r res t r ic t ions in phys ica l ly s t renuous ac t iv i ty 80 No rma l ac t iv i ty w i th e f fo r t ; some s igns o r symp toms o f d isease 80 Ac t ive , bu t t i res mo re qu ick ly 1Res t r ic ted in phys ica l ly s t renuous ac t iv i ty by ambu la to ry and ab le to ca r ry ou t wo rk o f a l igh t o r seden ta ry na tu re , e .g . , l igh t housewo rk , o f f ice wo rk 70 Ca res fo r se l f ; unab le to ca r ry on no rma l ac t iv i ty o r do ac t ive wo rk 70 Bo th g rea te r res t r ic t ion o f and less t ime spen t in p lay ac t iv i ty 60 Requ i res occas iona l ass is tance , bu t is ab le to ca re fo r mos t o f h is/he r needs 60 Up and a round , bu t m in ima l ac t ive p lay ; keeps busy w i th qu ie te r ac t iv i t ies 2Ambu la to ry and capab le o f se l f- ca re bu t unab le to ca r ry ou t any wo rk ac t iv i t ies ; up and abou t mo re than 50% o f wak ing hou rs 50 Requ i res cons ide rab le ass is tance and f requen t med ica l ca re 50 Ge ts d ressed , bu t l ies a round much o f the day ; no ac t ive p lay , ab le to pa r t ic ipa te in a l l qu ie t p lay and ac t iv i t ies 40 D isab led , requ i res spec ia l ca re and ass is tance 40 Mos t ly in bed ; pa r t ic ipa tes in qu ie t ac t iv i t ies 3Capab le o f on ly l im i ted se l f-ca re , con f ined to bed o r cha i r mo re than 50% o f wak ing hou rs 30 Seve re ly d isab led , hosp i ta l iza t ion ind ica ted ; dea th 30 In bed ; needs ass is tance even fo r qu ie t p lay S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
83,page_83,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 no t imm inen t 20 Ve ry s ick , hosp i ta l iza t ion ind ica ted . Dea th no t imm inen t 20 O f ten s leep ing ; p lay en t i re ly l im i ted to ve ry pass ive ac t iv i t ies 4Comp le te ly d isab led ; canno t ca r ry on any se l f-ca re ; to ta l ly con f ined to bed o r cha i r 10 Mo r ibund , fa ta l p rocesses p rog ress ing rap id ly 10 No p lay ; does no t ge t ou t o f bed S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
84,page_84,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 APPEND IX I I : NEW YORK HEART ASSOC IAT ION FUNCT IONAL CLASS IF ICAT ION NYHA C lass Symp toms ICa rd iac d isease , bu t no symp toms and no l im i ta t ion in o rd ina ry phys ica l ac t iv i ty , e .g . no sho r tness o f b rea th when wa lk ing , c l imb ing s ta i rs e tc . I I M i ld symp toms (m i ld sho r tness o f b rea th and/o r ang ina ) and s l igh t l im i ta t ion du r ing o rd ina ry ac t iv i ty . I I I Ma rked l im i ta t ion in ac t iv i ty due to symp toms , even du r ing less- than-o rd ina ry ac t iv i ty , e .g . wa lk ing sho r t d is tances (20 –100 m ) . Com fo r tab le on ly a t res t . IV Seve re l im i ta t ions . Expe r iences symp toms even wh i le a t res t . Mos t ly bedbound pa t ien ts . The C r i te r ia Comm i t tee o f the New Yo rk Hea r t Assoc ia t ion . (1994 ) . Nomenc la tu re and C r i te r ia fo r D iagnos is o f D iseases o f the Hea r t and G rea t Vesse ls . (9 th ed . ) . Bos ton : L i t t le , B rown & Co . pp . 253 –256 . S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
85,page_85,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 APPEND IX I I I : INSTRUCT IONS FOR COLLECT ION AND SH IPP ING OF RESEARCH BLOOD SAMPLES TO NC I Co l lec t ion : PBMCS : g reen top (Na hepa r in , 10 mL ) tubes , BD Vacu ta ine r Re f #366480 Se rum : red se rum sepa ra to r (8 mL ) tubes , G re ine r B io-One Vacu ta ine r Re f #455071 *B lood is co l lec ted a t the fo l low ing t ime po in ts : P r io r to Cyc les 1 and 3 . Sh ipp ing : PBMCs a re to be sen t on the day o f d raw ; se rum is to be f rozen and ba tch- sh ipped a t in te rva ls . * *P lease no te , PBMCs canno t be sh ipped w i th in 72 hou rs a f te r a bone scan in jec t ion due to the Techne t ium-99 rad io iso tope . I f a bone scan is schedu led , PBMCs mus t be d rawn p r io r to bone scan in jec t ion . Ma te r ia ls : ·Pack b lood v ia ls in the EXAKT-PAK sh ipp ing k i ts desc r ibed be low o r equ iva len t sh ipp ing ma te r ia ls : Fo r amb ien t PBMCs : EXAKT-PAK fo r V ia ls Ca tego ry B D-Pak MD8702V06 (Accommoda tes 6 v ia ls ) Inc ludes Inne r pack (Amb ien t ) and Insu la ted Coo le r W i th 2 coo l packs pe r coo le r , pa r t #CP1003 , room tempe ra tu re o r s l igh t ly coo led (no t f rozen ) to keep samp les be tween 18 and 30oC . Fo r f rozen se rum : EXAKT-PAK F rozen Ca tego ry B D-Pak MD8703V06 D ry ice requ i red (no t inc luded ) EXAKT-PAK k i ts ava i lab le a t : h t tps ://www .exak tpak .com/s to re/ EXAKT Techno log ies , Inc . Home o f f ice : 7002 N . B roadway Ex tens ion Ok lahoma C i ty , OK 73116-9006 405-848-5800 Sh ipp ing Add ress : ·Fo r Resea rch B lood Samp les , p lease FED-EX Ove rn igh t to the sh ipp ing add ress be low : Le idos B iomed ica l Resea rch A t tn : Ludm i la K rymskaya/The resa Bu rks 1050 Boy les S t ree t S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
86,page_86,"OSTPDL1 Rev is ion 1 .1 , da ted : 01-19-2018 IRB app roved : 01-26-2018 P ro toco l documen t da ted : 01-19-2018 B ldg . 469/Room 121 F rede r ick , MD 21702 Phone 301-846-5125 , o r 301-846-1707 ·P lease no t i fy the F rede r ick labo ra to ry when spec imens a re be ing sh ipped . P lease ema i l F rede r ick p r io r to sh ipp ing to no t i fy the lab . ·Ema i ls shou ld be sen t to the fo l low ing ind iv idua ls : Ludm i la K rymskaya , ludm i la .k rymskaya@n ih .gov The resa Bu rks , bu rks t@ma i l .n ih .gov Ca ro l ine Jochems , jochemscm@ma i l .n ih .gov ·Add i t iona l ly , NO spec imens shou ld be sh ipped on F r idays o r the day be fo re a Fede ra l ho l iday . Labe l ing o f B lood Samp les : ·P lease labe l resea rch tubes w i th a cod ing mechan ism . The fo l low ing in fo rma t ion shou ld be con ta ined on the labe l : oS i te oPa t ien t en ro l lmen t numbe r and in i t ia ls o Dose leve l o r a rm oP ro toco l numbe r o Da te d rawn o T ime po in t – such as ‘base l ine ’ o r ‘p r io r to cyc le 3 ’ S t . Jude IRB NUMBER : P ro00006856 IRB APPROVAL DATE : 06/26/2019"
